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Calcium and magnesium: chemistry, physics and biology
Calcium (Ca2+) and magnesium (Mg2+) are of vital importance for many 
physiological functions, which include muscle contraction, neuronal excitability, 
bone formation, and enzymatic activity. Therefore, it is essential that their 
concentration throughout the body is tightly regulated. There are many 
similarities in the homeostatic regulation of Ca2+ and Mg2+ with respect to the 
involved organs, the hormones modulating their transport and mobilization, as 
well as the sensing mechanisms monitoring their concentration [1, 2]. However, 
despite the similarities in their homeostasis, there are also some important 
chemical and physical differences between both elements, which have great 
biological and physiological consequences.
Chemical and physical properties
Both Ca2+ and Mg2+ belong to the Group 2 elements within the periodic table. This 
group consists of the alkaline earth metals; a number of elements with similar 
chemical properties. Basic chemistry rules teach us that the atomic number of an 
element is identical to the number of protons in its core, meaning that Ca2+ and 
Mg2+ consist of 20 and 12 protons, respectively [3]. Since atoms have no overall 
electrical charge, the number of negatively charged electrons always equals the 
number of positively charged protons. The 20 electrons of Ca are divided over 4 
shells surrounding the core, for Mg the 12 electrons are divided over 3 shells (Figure 
1A) [3]. Ions are formed when electrons are lost from the relatively unstable 
outermost electron shell in order to reveal the, chemically more stable, full shell of 
electrons underneath. When ionized, both Ca and Mg will lose the 2 negatively 
charged electrons in their outer shell, turning them into positively charged 
divalent cations; Ca2+ and Mg2+ [4]. The size of these ionized atoms is represented 
by their ionic radius. For Mg2+, the ionic radius (0.65 Å) is among the smallest of all 
cations, and it is approximately 30% smaller than the ionic radius of Ca2+ (0.99 Å) 
[5]. When ions are dissolved, water molecules form a sphere around the ion due to 
the electro-negative charge of the oxygen in the water molecule, which directs 
towards the positively charged ion. Because the attraction of water molecules 
around an ion depends on the ion’s density of charge, smaller ions attract more 
water molecules. The hydrated radius of Mg2+ (4.76 Å) is, therefore, much bigger 
than that of Ca2+ (2.95 Å) (Figure 1B) [5]. These differences become even more 
prominent in the actual three-dimensional environment, meaning hydrated 
Mg2+ is approximately 400 times larger than its ionic form. In contrast, the 
hydrated volume of Ca2+ is only ±25 times bigger than its ionic volume [5].
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Figure 1 A. Ca and Mg atoms with protons and electrons B. When passing a 
transporter, Ca2+ is able to easily shed its single hydration shell so the dehydrated 
ion will fit through the pore. Mg2+ on the other hand, first has to shed two layers, 
which is highly energy consuming (simplified model, adapted from [4]).
Magnesium
12 p
Calcium
20 p
Ca2+ Mg2+
Ca2+ Mg2+
A
B
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This bulky hydrated volume of Mg2+ has serious consequences for its biological 
function. Most transport proteins for example, require complete dehydration of 
an ion before it can to pass through the pore of the protein [6]. Mg2+ poses two 
problems in this situation. First, a transporter needs to be able to recognize and 
interact with the hydrated ion, which is harder when the hydration shell around 
a cation is bigger. Second, when the cation has been recognized, all water 
molecules surrounding it need to be removed before it can pass through the 
membrane via the pore of a transport protein. The relative strength of the 
interaction between the surrounding water molecules and the cation makes it 
harder to strip the hydration shell from the Mg2+ ion compared to for example a 
Ca2+ ion [6]. These differences in hydration between Ca2+ and Mg2+ explain a lot of 
the peculiarities in the biological characteristics of Mg2+, including its often 
antagonistic behavior to Ca2+, despite their similarities in chemical reactivity and 
charge.
Biological functions
The roles of Ca2+ in biology range widely. As a major component of our bones, Ca2+ 
helps to support and protect our body. Ca2+ is also extremely important in cellular 
function, as it is one of the most important second messengers involved in many 
intracellular signaling cascades. There are many biological processes that depend 
on Ca2+, including muscle contraction, neuronal transmission, cellular motility 
and fertilization. Other biochemical roles of Ca2+ include the regulation of enzyme 
activity, permeability of ion channels and activity of pumps [7]. Mg2+ has been 
suggested to play a role in nearly every physiological system, due to its activity as 
a Ca2+ antagonist, it role in energy transfer and its function in membrane stability 
[8]. In addition, over 300 enzymes require the presence of Mg2+ as a cofactor for 
their catalytic action [6]. When interacting with enzymes or substrates, Mg2+ 
either takes part in the chemistry of the catalytic reaction or alters the 
conformation of the enzyme or substrate thereby allowing a reaction to take 
place. Mg2+ frequently acts as a natural Ca2+ antagonist, mostly due to its ability to 
block Ca2+ channels [9]. In addition, Mg2+ plays a role in the stability of 
polyphosphate compounds in the cell [10]. Adenosine triphosphate (ATP), the 
most important source of energy for many cellular processes, must be bound to a 
Mg2+ ion in order to be biologically active [11]. Since ATP is required to fuel glucose 
utilization, synthesis of proteins and nucleic acids, and many other processes, 
Mg2+ is of vital importance for maintenance of normal cellular function. 
Metabolism 
Our body contains about 1,260 gram of Ca2+, 99% of which is stored in bone 
together with phosphate in the form of calcium-hydroxylapatite (Ca10(PO4)6(OH)2) 
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[12]. The remaining 1% resides intracellularly and in the extracellular fluid (ECF), 
which includes the blood compartment. Plasma Ca2+ levels are tightly controlled 
within a narrow range, usually between 2.2 and 2.6 mmol/L [13]. It should be 
noted, however, that only 50% of plasma Ca2+ is present in its biologically active, 
ionized form. The remainder is bound to proteins such as albumin (40%) or 
complexed to anions such as bicarbonate, citrate and phosphate (10%) [13]. Within 
the cell, less than 1% of the total intracellular Ca2+ exists in a free ionized form, 
resulting in a low intracellular concentration of 0.1 µmol/L [14]. These low 
concentrations of free intracellular Ca2+ are necessary to avoid the formation of 
precipitates with phosphate. In addition, the low intracellular concentration is 
essential to enable Ca2+ to function as a second messenger. To maintain a low 
intracellular Ca2+ concentration, Ca2+ is actively pumped out of the cytosol and 
into the extracellular space, endoplasmic reticulum (ER), and mitochondria. In 
addition, Ca2+ can be bound to proteins such as calbindins, which act as Ca2+-buffers 
keeping intracellular Ca2+ concentrations low [15]. The entry of Ca2+ into the cell 
via plasma membrane channels and the release of Ca2+ from intracellular stores 
can trigger a rapid and local increase in the cytoplasmic Ca2+ level up to 0.5–1.0 
µmol/L, which is important in Ca2+ signaling [14].
The total amount of Mg2+ in our body is approximately 24 gram, which is much 
lower than that of Ca2+ [16]. Approximately 53% of the total amount of Mg2+ in the 
body is stored in bone, 46% is located in tissues such as muscle and the remaining 
1% is located in the extracellular fluid [12]. The plasma Mg2+ concentration is 
tightly regulated, in healthy individuals plasma Mg2+ levels should range between 
0.7 and 1.1 mmol/L. Like Ca2+, total plasma Mg2+ consists of three fractions. 
Generally, 55-70% is present in the biologically active, free ionized form, 20-30% is 
bound to intracellular proteins, and 5-15% is complexed to anions [13]. The total 
intracellular concentrations of Mg2+ can vary between 5 and 20 mmol/L, 
depending on the type of tissue [16]. Most of the intracellular Mg2+, however, is 
bound to organic molecules such as ATP or localized within organelles such as the 
mitochondria or the ER. The free intracellular Mg2+ concentration is maintained 
between 0.5 and 1 mmol/L, and shows little fluctuations despite large variations 
in the concentration of total intracellular or extracellular Mg2+ [16]. This means, 
the concentration gradient driving transport between the extracellular and 
intracellular compartments is low. 
Since dietary intake is the only source of Ca2+ and Mg2+ for the body, intestinal 
absorption is of key importance to avoid depletion and keep our bodily stores 
filled. The Recommended Dietary Allowance (RDA) is the daily dietary intake 
level of a nutrient considered sufficient by the US Food and Nutrition Board, as it 
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should meet the daily requirements of 97.5% of healthy individuals. For Ca2+, the 
RDA is 1,000 mg/day [17]. Ca2+ can be found milk and dairy products, but also in 
nuts and seeds, in tofu and in certain vegetables. From the daily intake of 1,000 
mg of Ca2+, around 400 mg is absorbed by the intestine (Figure 2). Approximately 
200 mg is excreted into the intestine, resulting in a fecal excretion of 800 mg of 
Ca2+ per day and a net absorption of 200 mg [17]. Approximately 500 mg of all the 
Ca2+ which is stored in our bones is freely and quickly exchangeable with the ECF 
[14]. In the kidneys, 10,000 mg of Ca2+ is filtered on a daily basis, 9,800 mg is, 
however, reabsorbed from the pro-urine along the nephrons, resulting in a final 
urinary excretion of 200 mg Ca2+ per day.  The RDA for Mg2+, which is 360 mg/day, 
is considerably lower compared to that of Ca2+ [6]. Foods with a particularly high 
Mg2+ content include green leafy vegetables, legumes, nuts, seeds and unrefined 
Figure 2 Homeostasis of Ca2+ and Mg2+ metabolism is maintained by the concerted 
action of the intestine, the bone and the kidneys.
Dietary intake:
Ca2+ 1,000 mg/day
Mg2+ 360 mg/day
Fecal excretion:
Ca2+ 800 mg/day
Mg2+ 260 mg/day
Urinary excretion:
Ca2+ 200 mg/day
Mg2+ 100 mg/day
Filtration:
Ca2+ 10,000 mg/day
Mg2+ 2,400 mg/day
Reabsorption:
Ca2+ 9,800 mg/day
Mg2+ 2,300 mg/day
Intestinal absorption:
Ca2+ 400 mg/day
Mg2+ 120 mg/day
Intestinal secretion:
Ca2+ 200 mg/day
Mg2+ 20 mg/day
Bone accretion:
Ca2+ 500 mg/day
Bone resorption:
Ca2+ 500 mg/day
Extracellular ﬂuid 
and plasma
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grains. From the 360 mg of Mg2+ that is ingested on a daily basis, approximately 
120 mg is absorbed (Figure 2). However, 20 mg is secreted into the intestinal 
lumen, resulting in a net absorption of 100 mg and a fecal excretion of 260 mg 
Mg2+. In the kidneys, 2,400 mg of Mg2+ is filtered from the blood on a daily basis. 
2,300 mg is, however, reabsorbed along the nephron, resulting in a final urinary 
excretion of 100 mg per day [12].
The balance between the absorption of Ca2+ and Mg2+ via the intestine, their 
exchange with bone and their excretion via the kidneys should be neutral in 
normal, healthy individuals, meaning that the total bodily content remains 
stable. Disturbances of Ca2+ and Mg2+ homeostasis can have serious biological 
consequences. In order to maintain a neutral balance, the transport of Ca2+ and 
Mg2+ across epithelial layers in various organs is tightly regulated by the interplay 
of various transport mechanisms and hormones.
Epithelial transport of Ca2+ and Mg2+ 
Epithelial cell layers separate compartments of different compositions such as the 
intestinal lumen or the lumen of the nephron and the interstitial space or blood 
compartment. The movement of solutes, ions, and water across these epithelia 
can take place via either a transcellular route, involving the passage of the apical 
and basolateral plasma membranes, or via a paracellular route, directly connecting 
the luminal compartment with the interstitial space. The absorption of Ca2+ and 
Mg2+ via the transcellular pathway is saturable, takes place via specialized 
transporters and can be regulated by several calciotropic and magnesiotropic 
hormones [18]. Transport via the paracellular pathway is non-saturable, 
concentration depended, and mainly driven by electrochemical gradients. 
Together, these two routes determine the distinct transport properties of a certain 
tissue. 
Transcellular transport
Transcellular transport generally requires three consecutive steps. First, ions 
enter the epithelial cell from the luminal compartment via specific influx proteins 
on the apical side of the cell. Second, ions are bound to specialized intracellular 
carrier proteins that facilitate the diffusion across the cytoplasm from the apical 
area towards to the basolateral membrane. Third, the ions are extruded out of the 
cell and into the interstitial fluid via ion exchangers and/or pumps on the 
basolateral side of the epithelial cell [19, 20]. Transport of Ca2+ and Mg2+ across the 
apical membrane of epithelial cells is considered to be the rate-limiting factor in 
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the transcellular transport pathway [18]. Therefore, members of the transient 
receptor potential channel (TRP) superfamily are essential for the maintenance of 
Ca2+ and Mg2+ balance as they facilitate the entry of these cations from the 
intestinal and renal lumina into the cell [18].
Ca2+ entry across the apical membrane of the renal and intestinal epithelial cells 
is facilitated by TRP Vanilloid 5 and 6 channels (TRPV5 and TRPV6), respectively 
[21]. Once transported into the cell, Ca2+ is bound to calbindin proteins, which 
function as a buffer and facilitate diffusion of the Ca2+ ions towards the basolateral 
membrane [22]. In the intestine, calbindin-D9K is responsible for this process 
whereas in the kidney calbindin-D28K is predominant [20]. By buffering 
intracellular Ca2+ levels, calbindins maintain the low intracellular Ca2+ levels that 
facilitate a continuous chemical inward driving force at the apical membrane [15]. 
At physiological intracellular Ca2+ concentrations, calbindins are saturated with 
Ca2+ [23]. Consequently, Ca2+ signaling can occur during and independently of 
transcellular Ca2+ movement [24]. At the basolateral side of the cell, efflux of Ca2+ 
takes place against a considerable electrochemical gradient. In the intestine, 
extrusion of Ca2+ across the basolateral membrane takes place via a plasma 
membrane Ca2+-ATPase named PMCA1b. In the kidney, a Na+/Ca2+ exchanger 
(NCX1) uses the electrochemical gradient of Na+ to extrude Ca2+ [20].
The key players involved in transcellular transport of Mg2+ are less well defined 
than those responsible for transcellular transport of Ca2+. TRP Melastatin 6 and 7 
cation channels (TRPM6 and TRPM7) are thought to be responsible for Mg2+ 
transport across the apical membrane into the cell [25]. TRPM6 is most abundantly 
expressed in the intestine, kidney and lung, whereas TRPM7 is ubiquitously 
expressed [26]. Transport of Mg2+ from the tubular or intestinal lumen into the 
cell is, therefore, considered to be mediated predominantly via TRPM6, whereas 
TRPM7 seems responsible for cellular Mg2+ homeostasis. A role for TRPM7, and 
even of TRPM6/TRPM7 heterotetrameric complexes in the apical influx of Mg2+ 
has, however, also been suggested [27, 28]. Specific Mg2+-binding proteins involved 
in cytosolic diffusion have not been identified to date. The calbindin proteins, 
primarily responsible for cytosolic Ca2+ transport, have been shown to also bind 
Mg2+, but the physiological relevance of this observation remains to be determined 
[29]. The molecular identity of the basolateral extrusion mechanism for Mg2+ 
remains to be defined as well [30]. Since extrusion of Mg2+ must occur against an 
electrochemical gradient, the process most likely depends on a primary or 
secondary active form of transport, implicating a role for a Mg2+ pump and/or a 
Na+/Mg2+ exchanger [31, 32].
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Paracellular transport
Over the last decade, the scientific view on paracellular transport has been 
changed to a great extent with the identification of various proteins that 
contribute to the sealing of epithelial cell layers as a part of tight junction 
structures. These tight junctions have two basic functions. First, they form a 
fence, which prevents diffusion of membrane proteins from the basolateral to the 
apical side and vice versa, thus ensuring cell polarity [33]. Second, the tight 
junctions represent a transepithelial barrier, which determines the permeability 
of the paracellular pathway to ions and water [33]. Depending on the functional 
requirements of an epithelium, there may be small or large amounts of water and 
small solutes flowing passively through the paracellular junctions. Tight junctions 
consist of several types of integral transmembrane proteins, including occludin, 
tricellulin, and members of the claudin family [34]. The claudin family consists of 
a family with at least 26 members ranging in molecular mass from 20–28 kD. All 
claudins have a similar membrane topology of four transmembrane domains, 
with cytosolic amino- and carboxy-termini [35]. The first extracellular loop of 
each claudin is longer and more hydrophobic than the second extracellular loop 
and is considered to be responsible for determination of the paracellular charge 
selectivity [36]. The extracellular loops of claudin molecules make homophilic 
and heterophilic interactions with the extracellular loops of other claudin 
molecules in adjacent cells [35]. These interactions create either barriers against, 
or pores for, the passage of selective molecules in the paracellular pathways. The 
different claudin family members exhibit distinct tissue-, cell-, developmental 
stage-, and disease-specific expression patterns [33, 37]. 
So far, the involvement of claudins in Ca2+ and/or Mg2+ homeostasis in the kidney 
has been clearly demonstrated for three specific claudins. Patients with mutations 
in CLDN16, the gene encoding claudin 16, suffer from familial hypomagnesemia 
with hypercalciuria and nephrocalcinosis (FHHNC, OMIM 248250) [38]. Patients 
with mutations in CLDN19, encoding claudin 19, have similar clinical features as 
patients with FHHNC, with additional of occular abnormalities (OMIM 248190) 
[39]. Expression of both claudin 16 and claudin 19 is restricted to a part of the 
nephron named the thick ascending limb (TAL) [38, 40]. Here they form a highly 
cation-specific paracellular channel together, able to transport Mg2+ as well as 
Ca2+ [41]. The third claudin family member that is associated with Ca2+ and/or 
Mg2+ homeostasis is claudin 14. A recent genome-wide association study has 
identified CLDN14 as a major risk gene for the development of hypercalciuric 
nephrolithiasis [42]. Like claudin 16 and 19, claudin 14 is localized in the TAL, 
where its expression level seems to vary depending on dietary Ca2+ content [43]. 
This suggests a regulatory role for claudin 14 in renal Ca2+ handling. Interestingly, 
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claudin 14 seems to block the paracellular cation channel formed by claudin 16 
and 19, thereby reducing Ca2+ reabsorption in the TAL [43]. It was shown that high 
dietary Ca2+ intake down regulates the expression level of specific microRNAs 
(miR’s) in the TAL, miR-9 and miR-374, which in turn cause an increase in CLDN14 
expression level [43]. This process takes place under the direct regulation of the 
calcium sensing receptor (CaSR), which monitors the circulating Ca2+ levels and 
subsequently adjusts urinary excretion rates [43]. These findings nicely correspond 
with previous studies, which have demonstrated that paracellular Ca2+ 
reabsorption in the TAL can be inhibited by CaSR activation during hypercalcemia 
[44, 45].
To date, not much is known about the role of claudins in the intestinal absorption 
of Ca2+. In vitro studies have shown that vitamin D induces an increase in 
paracellular Ca2+ transport in Caco-2 cells, a cell-line derived from intestinal 
epithelia cells [46]. In addition, in vivo studies have demonstrated that intestinal 
expression of claudin 2 and claudin 12 may be vitamin D-dependent [46]. Further 
studies are required to confirm these findings and investigate the role of these 
and other claudins in intestinal Ca2+ absorption. Literature does not provide any 
information on the involvement of claudins in paracellular intestinal Mg2+ 
absorption, therefore, their role in intestinal Mg2+ absorption remains to be 
determined.
Intestine
The fraction of dietary Ca2+ which is absorbed in the intestine depends on many 
factors, including bioavailability and bodily needs. As described before, intestinal 
absorption is the sum of two components: transcellular and paracellular 
absorption (Figure 3A) [47, 48]. When dietary Ca2+ supply is high, paracellular 
fluxes in the duodenum, jejunum and ileum are responsible for the main fraction 
(80-90%) of the intestinal Ca2+ absorption [49]. Under normal circumstances, the 
contribution of the transcellular pathway to total intestinal Ca2+ absorption is, 
therefore, relatively low. Transcellular absorption, which mainly takes place in 
the duodenum, is highly sensitive to 1,25-dihydroxyvitamin D3 [50, 51]. Under 
certain circumstances, intestinal absorption via the transcellular pathway can 
be increased up to a level where it accounts for 50% of the total intestinal Ca2+ 
(Figure 3B). This occurs in cases of low dietary load or under circumstances of high 
Ca2+ requirements and prevents depletion of the bodily Ca2+ stores. The caecum 
and colon account for less than 10% of total Ca2+ uptake, presumably in both a 
paracellular and transcellular manner [49].
Chapter 1
18
Between 25-75% of the Mg2+ from dietary sources is absorbed in the intestine, 
depending on the dietary availability as well as the needs of the body. When Mg2+ 
intake is normal the transcellular pathway, involving TRPM6, is responsible for 
approximately 30% of total absorption, a fraction that increases when dietary 
intake is low (Figure 3) [52]. The importance of TRPM6 in intestinal Mg2+ absorption 
is demonstrated in patients suffering from a condition named hypomagnesemia 
with secondary hypocalcemia (HSH). Schlingmann et al. have demonstrated that 
this autosomal-recessive disorder, which is characterized by low plasma Mg2+ 
levels due to diminished intestinal Mg2+ absorption and increased renal Mg2+ 
Figure 3  Total intestinal Ca2+ and Mg2+ absorption is the sum of transport via the 
paracellular pathway and the transcellular pathway. A. Transport via the 
paracellular pathway increases linearly, depending on the luminal concentration. 
Transport via the transcellular pathway is saturable, and predominant when 
luminal concentrations are low (adapted from [52]). B. Key players in intestinal 
absorption of Ca2+ and Mg2+.
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excretion, is caused by mutations in the TRPM6 gene [53]. It was shown that 
transcellular intestinal Mg2+ absorption in these patients was greatly diminished, 
whereas paracellular absorption remained unchanged. As dietary Mg2+ is 
absorbed across the intestine by passive paracellular transport even with loss-of-
function TRPM6 mutations, the treatment of HSH patients consists of high oral 
Mg2+ supplementation, which adequately corrects the hypomagnesemia. 
Intestinal paracellular transport depends on the transepithelial voltage, which is 
around 5 mV lumen positive with respect to the blood [32]. Luminal Mg2+ 
concentrations range from 1-40 mmol/L depending on dietary contents, generally 
providing a transepithelial chemical concentration gradient sufficient to further 
enhance absorption [32]. Paracellular transport is responsible for approximately 
70% of Mg2+ absorption when luminal concentrations are high [52]. However, 
Mg2+-specific intestinal paracellular channels have not yet been identified. 
Kidney
In the kidney, the majority of the filtered Ca2+ is absorbed through paracellular 
reabsorption in the proximal tubule (50-60%) and to a lesser extent in the TAL 
(20-25%) (Figure 4) [20]. The absorption of Na+ and water in the proximal tubule 
(PT) creates a chemical gradient across the epithelium, increasing the luminal 
concentration of Ca2+, which allows it’s paracellular absorption. At the apical side, 
Na+ is reabsorbed from the pro-urine by the Na+/H+ exchanger 3 (NHE3), and 
subsequently extruded on the basolateral side via a Na+-K+-ATPase [18]. Water 
follows via aquaporin 1 (AQP1) waterchannels at both the apical and basolateral 
side of the PT cells. In the TAL, Na+, K+, and Cl- are reabsorbed from the pro-urine 
via the Na+-K+-2Cl- co-transporter (NKCC2). A Na+-K+-ATPase at the basolateral side 
provides the driving force for this process. The absorbed Cl- exits via the basolateral 
membrane via ClC-Kb channels, whereas the renal outer medullary K+ channel 2 
(ROMK2) allows for apical recycling of K+ to the tubular lumen. This generates a 
lumen-positive electrochemical gradient, which drives the reabsorption of Ca2+ 
via the paracellular pathway in this segment [54]. The fine-tuning of the net 
urinary Ca2+ excretion takes place in the late distal convoluted (DCT) and 
connecting tubule (CNT), where a final 3-7% of Ca2+ is reabsorbed via a transcellular 
pathway involving TRPV5, calbindin-D28K, and NCX1 [55]. This process is tightly 
regulated by a variety of mechanisms, including hormonal regulation. In the end, 
only 1-2% of the Ca2+ that was filtered from the blood into the pro-urine in the 
glomerulus is excreted via the urine [55].
Approximately 95% of the filtered Mg2+ load is reabsorbed along the different 
parts of the nephron via both paracellular and transcellular processes [56]. In the 
PT 10-30% of the filtered Mg2+ is reabsorbed via paracellular transport depending 
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on Na+-driven water transport (Figure 4) [57-61].  Paracellular Mg2+ transport in 
the nephron predominates in the TAL, where 40-70% of the filtered Mg2+ is 
reabsorbed [62]. Here, Mg2+ reabsorption is mainly driven by the lumen-positive 
transepithelial voltage and is facilitated by claudin-16 and -19, that operate 
together to form a cation-permeable channel [63]. At the basolateral side, the CaSR 
modulates transport in response to changes in concentration of extracellular 
cations, reducing transport upon stimulation [44]. In the final 5-10% of Mg2+ is 
reabsorbed in an active transcellular manner in the DCT [64]. The tubular 
epithelium in this part of the nephron consists of a high-resistance epithelium 
with a lumen-negative voltage of approximately -5 mV. This is generated by the 
basolaterally localized Na+-K+-ATPase, which also provides a Na+ gradient for the 
Na+-Cl--cotransporter (NCC) to facilitate transport of Na+ from the lumen into the 
cytoplasm. Cl- and K+ are extruded on the basolateral side of the cell via ClC-Kb and 
Kir4.1 respectively. Apical entry of Mg2+ occurs via TRPM6, which can be stimulated 
via the basolateral epidermal growth factor receptor (EGFR) [65]. Mg2+ reabsorption 
Figure 4  Key players in the reabsorption of Ca2+ and Mg2+ along different segments 
of the nephron. In the PT and TAL, Ca2+ and Mg2+ are mainly reabsorbed via the 
paracellular pathway. Reabsorption of Ca2+ and Mg2+ via the transcellular pathway 
mainly takes place in the CNT and DCT, respectively.
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in the DCT defines the final urinary Mg2+ excretion, as there is no significant 
reabsorption of Mg2+ beyond the DCT.
Bone
The maintenance of mineral stores in bone depends on the balance between bone 
mineralization by osteoblasts and bone resorption by osteoclasts. Various TRP 
channels, including TRPV4, TRPV5, and TRPV6, have been shown to be involved in 
Ca2+ homeostasis in the bone [66-68]. At the ruffled border membrane of 
osteoclasts, TRPV5 is involved in the removal of Ca2+ from the bone matrix, 
whereas TRPV4 regulates intracellular Ca2+ concentrations both in the osteoclast 
and osteoblast [66, 68]. TRPV6 is also expressed mainly at the luminal side of the 
osteoclast and osteoblasts, however, it does not seem crucial for bone 
mineralization in mice [67]. Expression studies in bone have also reported CaSR 
transcripts in osteoblasts as well as in osteoclasts [69]. The role of the osteoblast 
CaSR in bone development, mineralization, and resorption, was demonstrated 
using a mouse model with an osteoblast specific ablation of CaSR. These mice 
display severe bone defects, which are independent of systemic calciotropic 
hormones and rely only on local regulatory events involving the CaSR in bone 
tissue [70]. So far, it remains unknown if and how the CaSR in bone affects the 
expressed TRP channels. To date, our understanding of the molecular mechanisms 
underlying Mg2+􏰄handeling in bone is limited. Several studies have demonstrated
a positive correlation between dietary Mg2+ intake and bone density. Dietary 
depletion leads to reduced bone Mg2+ contents without affecting plasma Mg2+ 
levels, indicating that bone acts as a storage from which Mg2+ is released in the 
situation of low Mg2+ supply. TRPM6 and TRPM7 are expressed in various osteoblast 
cell lines [71]. Extracellular Mg2+ concentrations have been demonstrated to 
stimulate osteoblast differentiation via TRPM7 in vitro [72]. The physiological 
relevance of this observation for Mg2+ transport in bone is not yet clear. The role of 
other Mg2+ transporters and sensors in this process remains to be determined as 
well.
Hormonal regulation of Ca2+ and Mg2+ transport
Calciotropic hormones
Ca2+ balance is tightly regulated by a number of hormones. The two predominant 
hormones involved in Ca2+ homeostasis are parathyroid hormone (PTH) and 
vitamin D [73, 74].  Other hormones, such as calcitonin, adrenal corticosteroids, 
estrogens, thyroxine, somatotropin, and glucagon may, however, also contribute 
to the maintenance of Ca2+ homeostasis [7, 20]. 
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The secretion of PTH from the parathyroid glands in response to hypocalcemia is 
controlled by the CaSR, which senses the plasma Ca2+ levels [75]. PTH helps to 
maintain Ca2+ homeostasis via three routes (Figure 5) [12, 14]. First, it stimulates 
bone resorption, releasing Ca2+ from the bone into the blood. Second, it stimulates 
the kidney to reabsorb Ca2+ from the pro-urine. Third, it stimulates the synthesis 
of active vitamin D by the kidney, which in turn leads to an increase in intestinal 
Ca2+ absorption. Once released into the circulation PTH can bind to PTH receptors, 
which are located amongst others in the intestine, bone and kidney [20].
Figure 5  Effects of PTH and vitamin D on Ca2+ homeostasis. PTH, released from the 
parathyroid glands, stimulates the production of active vitamin D3 by the kidney, 
which in turn stimulates intestinal Ca2+ absorption. It also increases bone 
resorption and renal Ca2+ reabsorption, increasing plasma Ca2+ levels.
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Ca2+ absorption
Increased plasma Ca2+
Increased 1,25(OH)2D3 formation
Increased plasma Ca2+
Increased plasma Ca2+
Increased  renal Ca2+ reabsorption
Increased PTH secretion
Increased bone resorption
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Our body can obtain vitamin D from two sources: it can be synthesized in the skin 
under the influence of ultraviolet light, or it can be absorbed from our diet [76]. 
Unless fortified, few foods contain vitamin D; therefore dermal synthesis is the 
major natural source of this vitamin. Previtamin D3 (cholecalciferol) is synthesized 
non-enzymatically in skin from 7-dehydrocholesterol during exposure to the 
ultraviolet rays in sunlight  (Figure 6). In the liver, it undergoes a hydroxylation 
process by an enzyme called 25-hydroxylase, turning it into 25-hydroxyvitamin 
D3 (calcidiol) [14]. Further hydroxylation of 25-hydroxyvitamin D3 into the physio-
logically active vitamin D metabolite 1,25-dihydroxyvitamin D3 (calcitriol) occurs 
in the kidney by an enzyme named 1-alpha-hydroxylase, which is encoded by the 
CYP27B1 gene. The kidney also plays a role in the breakdown of active vitamin D 
into inactive metabolites. With the help of an enzyme named 24-hydroxylase, 
encoded by CYP24A1, 1,25-dihydroxyvitamin D3 is broken down to 24,25-dihy-
droxyvitamin D, which is biologically inactive. CYP24A1 is down-regulated by 
PTH and upregulated by 1,25-dihydroxyvitamin D3 in a regulatory feedback loop 
ensuring proper plasma 1,25-dihydroxyvitamin D3 levels. The major functions of 
1,25-dihydroxyvitamin D3 are carried out in the intestine, where it stimulates the 
Figure 6 Overview of vitamin D metabolites and enzymes involved in their 
synthesis. The active vitamin D metabolite, 1,25 dihydroxyvitamin D3, is 
synthesized from precursors by various enzymes including 1-alpha-hydroxylase. 
The enzyme 24-hydroxylase is responsible for the breakdown of active vitamin D 
to 24,25-dihydroxyvitamin D3, an inactive metabolite.
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absorption of Ca2+, and in the parathyroid glands, where it inhibits the synthesis 
of PTH at the transcriptional level [12]. 1,25-dihydroxyvitamin D3 can bind to the 
vitamin D receptor (VDR), which is a transcription factor. Upon binding to 
1,25- dihydroxyvitamin D3 the VDR heterodimerizes with other nuclear hormone 
receptors, in particular the family of retinoid X receptors. This complex 
subsequently binds to special DNA sequences called vitamin D responsive 
elements (VDRE) in the promoters of genes. These include TRPV5, TRPV6, 
calbindin-D9k, and PMCA1b, which are strongly regulated by 1,25-dihydroxyvitamin 
D3. The expression of renal transporters involved in Ca2+ transport is also regulated 
by 1,25-dihydroxyvitamin D3, albeit to a lesser extent than the intestinal 
transporters [76, 77].
Magnesiotropic hormones
Like Ca2+, Mg2+ has been suggested to be regulated by PTH and vitamin D. However, 
reports on their effects are conflicting and the exact role of these hormones in 
Mg2+ homeostasis remains unclear. The same holds true for many other hormones 
that have been proposed to have a regulatory role in Mg2+ homeostasis, such as 
vasopressin, aldosterone, estrogen and testosterone. Although the hormonal 
regulation of Mg2+ is not as well-defined as that of Ca2+, several findings during 
the last decade have helped us to better understand how Mg2+ homeostasis is 
regulated. 
In 2007, two Dutch sisters with isolated autosomal recessive hypomagnesmia 
(IRH) were diagnosed to have a mutation in the gene encoding the EGF precursor 
protein pro-EGF. It was shown that EGF, via activation of the EGF receptor (EGFR), 
stimulates Mg2+ transport via TRPM6 [78]. Supporting these findings, patients 
treated with the anticancer agent cetuximab, an EGFR antagonist, were also 
found to develop hypomagnesemia [79].  Taken together, these recent studies 
highlight an important role for EGFR signaling in the maintenance of Mg2+ 
homeostasis.
Recently, two common TRPM6 genetic variants (I1393V and K1584E polymorphisms) 
were associated with an increased risk of type 2 diabetes (DM2) in women with 
low Mg2+ intake [80]. Furthermore, it was shown that insulin activates TRPM6, 
and that when the described polymorphisms were introduced in TRPM6, this 
stimulatory effect was lost. In addition, patients with these polymorphisms were 
more likely to develop gestational diabetes mellitus (GDM), demonstrating the 
clinical relevance of these findings [81]. In the future, genetic variants of TRPM6 
could potentially be used as biomarkers to identify individuals at risk for 
developing GDM/DM2-induced hypomagnesemia.
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Clinical relevance
Under certain circumstances, the balance between absorption, storage and 
excretion of Ca2+ or Mg2+ can become disturbed. These disturbances can have 
various reasons. Sometimes, genetic defects in a gene encoding for one of the key 
players involved in Ca2+ or Mg2+ homeostasis cause abnormalities. In addition, the 
use of certain drugs can affect the balance of these divalents. The homeostatic 
disturbances may be relatively harmless when the body is able correct for them, 
however if Ca2+ or Mg2+ homeostasis are significantly disturbed, this may have 
serious clinical implications. 
Hypocalcemia
Hypocalcemia can lead to various clinical manifestations, ranging from no 
symptoms at all or only a few symptoms if the hypocalcemia is mild, to life-threat-
ening seizures and heart failure if it is severe. The rate of development of 
hypocalcemia and the duration of its presence will also influence the clinical 
manifestations. Muscle spasms, tetany, seizures and cardiac arrhythmia may 
occur in patients who develop hypocalcemia acutely, whereas cataracts, 
ectodermal changes and dental changes are features of chronic hypocalcemia 
[82].
The treatment of hypocalcemia varies with its severity and also depends on the 
underlying cause. Non-symptomatic patients, or patients with mild clinical 
manifestations should preferably be treated with oral supplements. Loop diuretics 
such as furosemide, inhibit NKCC2 consequently leading to reduced Ca2+ 
reabsorption in the TAL [82]. It is, therefore, advised to change hypocalcemic 
patients requiring diuretic treatment to a thiazide-type diuretic to prevent further 
renal Ca2+ loss. Intravenous administration of Ca2+ is only advised in severe cases 
where there is a need for acute treatment. 
Hypercalcemia
Under normal circumstances, the body is able to dispose of an overload of Ca2+ by 
increasing the amount of Ca2+ storage in the bone and by increasing urinary Ca2+ 
excretion. Prolonged periods of hypercalciuria however can lead to nephrolithia-
sis as well as nephrocalcinosis. The severity of symptoms resulting from 
hypercalcemia depend on the degree of hypercalcemia as well as the rate at which 
it has developed. Hypercalcemia can lead to gastrointestinal symptoms, such as 
nausea, vomiting and constipation. In addition, it may lead to lethargy, muscle 
weakness, hypertension and shortening of the QT interval of the heart [12].
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Selecting the right therapy to treat hypercalcemia requires a good differential 
diagnosis to determine the underlying cause. In some cases, however, immediate 
action is required. The safest, and most effective, way of treating hy’percalcemia 
in patients with normal cardiac and renal function is the intravenous 
administration of saline. The resulting volume expansion will reduce the 
reabsorption of Na+, Cl- and water in the PT, and will consequently also reduce 
paracellular Ca2+ absorption. Other possibilities include the use of loop diuretics 
like furosemide, the administration of biphosphonates (which reduced the release 
of Ca2+ from the bone by inhibiting osteoclast activity), calcitonin (which inhibits 
bone reabsorption and enhances renal Ca2+ excretion), glucocorticoids (which 
inhibit production of active vitamin D) and cinacalcet (which activates the CaSR, 
leading to reduced PTH release) [82].
Hypomagnesemia
Hypomagnesemia is defined as a plasma Mg2+ concentration below 0.70 mmol/L. 
Muscle cramps, tetany and muscular weakness are the main complaints of 
hypomagnesemic patients [83]. Cardiovascular abnormalities such as 
arrhythmias and convulsions have also been described. Hypomagnesemia is, 
however, often associated with multiple biochemical abnormalities such as 
hypokalemia and hypocalcemia. It is, therefore, difficult to ascribe specific clinical 
manifestations solely to hypomagnesemia. Chronic depletion of Mg2+ generally 
becomes clinically evident in patients at plasma Mg2+ concentrations of <0.40 
mmol/L. Hypocalcemia (muscle cramps, tetany) and hypokalemia (muscle 
weakness), will contribute to the clinical phenotype when occurring secondary 
to hypomagnesemia. Hypokalemia associated with hypomagnesemia is often 
refractory to treatment by K+, and can only be properly corrected when Mg2+ is 
co-administered. The decreased intracellular Mg2+ concentration resulting from 
Mg2+ deficiency, releases the Mg2+-mediated inhibition of ROMK channels, thereby 
increasing K+ excretion via the kidney, eventually resulting in hypokalemia [84]. 
Hypocalcemia secondary to hypomagnesemia has been hypothesized to originate 
from inappropriately low PTH secretion, the release of which depends on an 
intracellular signalling cascade that requires Mg2+.  Also the responsiveness of 
target organs to PTH stimulation seems to be reduced [85, 86]. Hypocalcemia 
secondary to hypomagnesemia with low parathyroid hormone secretion is 
frequently observed when plasma Mg2+ levels are extremely low [87].  Treatment 
is only successful when hypomagnesemia is addressed together with the 
hypocalcemia as Ca2+ supplementation by itself will not suffice [86].
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Hypomagnesemic patients can be repleted in various ways. Depending on the 
severity of the clinical symptoms and the origin of the hypomagnesemia patients 
may be treated with oral supplements, with intramuscular injections or by 
intravenous infusions [88]. Intravenous administration is the most effective in 
restoring plasma Mg2+ to normal levels, and is, therefore, the best treatment in 
case of severe hypomagnesemia. The disadvantage is that patients have to visit 
the hospital on a regular basis if frequent treatment is required. Oral supplements 
do not require hospital visits, however, not all patients tolerate these Mg2+ 
supplements of due to their cathartic effect at higher dosages. Solubility and bio-
availability vary greatly between various Mg2+ supplements. Organic Mg2+ salts 
have a higher solubility and bioavailability compared to inorganic Mg2+ salts, 
making them more suitable for oral Mg2+ replacement therapy. It should be noted 
that in case of severe hypomagnesemia or Mg2+ deficiency due to intestinal 
malabsorption, oral Mg2+ supplements may not be sufficient to restore plasma 
Mg2+ levels to normal. 
Hypermagnesemia
Hypermagnesemia causes a broad variety of symptoms depending on plasma 
Mg2+ levels (Table 1) [83, 89, 90]. In case of a relatively mild degree of hypermagne-
semia, patients may suffer from nausea, vomiting and flushing. Within the 
asymptomatic and mildly symptomatic stages of hypermagnesemia (between 1.1 
and 3.0 mmol/L) there is also the therapeutic range in which hypermagnesemia 
can be used to control convulsions [91]. When the plasma Mg2+ levels increase 
further, however, symptoms become increasingly dangerous, eventually leading 
to a comatose state and/or asystole. Since the renal response to high Mg2+ levels is 
extremely efficient, hypermagnesemia is relatively rare and primarily observed 
in patients with renal insufficiency. However, in rare cases hypermagnesemia is 
found in individuals with normal renal function, mostly as a result of exogenous 
administration of high doses of Mg2+ via oral, intravenous or rectal routes [92].
Treatment of hypermagnesemia should primarily be aimed at lowering plasma 
Mg2+ levels. However, when serious complications of Mg2+ intoxication are present, 
intravenous administration of low doses of Ca2+ may quickly reduce severity of 
symptoms due to the antagonistic effect of Ca2+ to Mg2+. It is, therefore, the advised 
initial treatment in case of life-threatening situations. Also, haemodialysis may 
be used to quickly reduce plasma Mg2+ levels in severe cases [93, 94]. Next, oral 
intake and/or intravenous administration of Mg2+ salts should be discontinued 
immediately to avoid further intoxication. Subsequently, renal Mg2+ excretion 
could be stimulated by intravenous administration of diuretics and saline to 
ensure high urine output and prevent volume depletion [95]. 
Chapter 1
28
Intestinal absorption studies
Reports of scientists studying the absorption of nutrients in the intestine date 
back to the 18th century. Various experimental techniques were applied during 
that time, ranging from small perforated metal tubes filled with grass which 
were fed to sheep in order to determine of the contents would be digested, to linen 
bags filled with bread and meat which were ingested by researchers themselves 
and later collected from the feces. Approximately 250 years after these first 
experiments, a broad range of well established in vivo, ex vivo, in situ and in vitro 
methods to study intestinal absorption are available, which have contributed 
greatly to our understanding of transport processes in the gastrointestinal tract. 
The following paragraphs provide a summary of various methods that are 
presently available to study the intestinal absorption of ions in an in vivo or ex 
vivo setting.
Ussing chamber technique
The Ussing chamber method was developed in 1951 by Ussing and Zerahn as a tool 
to investigate active Na+ transport by frog skin [96]. To date, Ussing chambers are 
still used to study transport across the intestinal epithelium. To this end, small 
sections of intestinal mucosa are clamped between two chambers, which are 
filled with bathing solutions on the mucosal and serosal sides. In addition, the 
experimental set-up of the Ussing chamber offers the possibility to monitor and 
regulate the transepithelial electrical resistance. Fluxes from the mucosal to 
serosal side and from serosal to mucosal side can be measured depending on the 
Table 1  Symptoms of hypermagnesemia.
Plasma Mg2+ level 
(mmol/L)
Symptoms
0.7-1.1 None, normal plasma level
1.1-2.0 Asymptomatic
2.0-3.0 Nausea, vomiting, cutaneous vasodilation, headaches, 
hyporeflexia, lethargy
3.0-5.0 Unresponsiveness, loss of deep tendon reflexes, hypotension, 
electrocardiographic changes, bradycardia
>5.0 Complete heart block, respiratory paralysis, coma, shock
>8.0 Asystole, death
Adapted from [83, 89, 90]
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content of the buffers that are used. This way, it is possible to distinguish between 
passive, paracellular transport and active, transcellular transport. A major 
advantage of the Ussing chamber technique is that it allows scientists to measure 
and compare transport in specific intestinal segments within and between 
different species. The limitations of this technique include the difficulty of 
maintaining tissue viability, the lack of an intact blood flow and the potential 
presence of residues of muscle- and serosal layers, which may disturb accurate 
measurements. 
Everted gut sac technique
The everted gut sac technique was first described by Wilson and Wiseman in the 
1950’s [97]. For this ex vivo technique intestinal segments are isolated from an 
animal. The segment is then everted, filled with buffer, and tied on both sides to 
create a closed compartment. They are then suspended in an oxygenated buffer. 
With (radioactive) probes and non-absorbable markers transport from the outer, 
mucosal, side to the inner, serosal, side of the sac are measured. Paracellular and 
transcellular transport cannot be characterized by studying the bidirectional 
movement of solutes, as transport is measured in a unidirectional, mucosal to 
serosal way only. By determining whether the transport is saturable or 
non-saturable, sensitive to certain modifiers and metabolic inhibitors, and by 
studying competition it is nevertheless possible to distinguish between the 
different transport processes. There are, however, some disadvantages to the 
everted gut sac methods. First, the underlying musculature is not removed from 
the sample, which may act as a barrier and can therefore lead to an underestima-
tion of the actual transport that would take place in vivo. Second, the volume of 
the serosal compartment is small; meaning concentrations of compounds within 
the sac can quickly rise, negatively influencing the reliability of the measurement. 
Similar to the Ussing chamber technique, tissue samples in the everted gut sac 
methods do not have blood supply and tissue viability should be carefully 
monitored.
Perfusion studies
Perfusion experiments are based on an in situ technique in which an intestinal 
loop is isolated in an anesthetized animal by cannulating the proximal and distal 
end of an intestinal segment. This method closely resembles the in vivo situation 
as the blood and lymph supply as well as the innervation remains intact. The 
contents of the perfusion solution (containing a non-absorbable marker) can be 
determined before and after passing the intestinal loop, in order to determine the 
amount of absorption by the intestinal segment. The sensitivity is a limiting 
factor in the applicability of this method; if less than 20% of the compound of 
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interest is absorbed, perfusion techniques are not considered to be accurate. This 
problem may be solved by measuring the concentration of the substance of 
interest in blood samples drawn from the portal vein. Anesthesia and surgical 
manipulation may influence intestinal motility and blood flow, thereby inducing 
changes in intestinal permeability reducing reliability. 
Balance studies
In balance studies, intake and excretion of an ion are analyzed in order to 
determine, amongst others, intestinal absorption. By housing animals in 
metabolic cages it is possible to carefully monitor the individual intake of food 
and water, in addition it allows for separation of urinary and fecal samples. By 
calculating the difference between the intake of an ion via food and water and its 
excretion via the feces an estimation can be made of intestinal absorption. As this 
method does not take into account the excretion of ions from the blood back into 
the intestinal lumen it may lead to an underestimation of absorption. Also, it does 
not distinguish between paracellular and transcellular transport, nor does it 
provide information about the absorption in a specific intestinal segment. 
Absorption studies
Intestinal absorption studies are traditionally performed using radioactive 
isotopes. After oral administration, the rate of absorption from the intestine into 
the blood is measured, providing accurate information on the rate and kinetics of 
absorption. For intestinal Ca2+ absorption studies in animals the radioactive 45Ca 
isotope is frequently used. It emits a low energy beta radiation, which is completely 
absorbed by a layer of matter less than 1 mm thick, meaning its use is relatively 
safe. In addition, its long half-life of 163 days makes it easy to work with, whereas 
it still emits enough radiation to allow for accurate and easy quantification using 
a scintillation counter. There are 19 radioactive Mg2+ isotopes, with half-lives 
varying from 170 nanoseconds to approximately 21 hours. The short half-life and 
the resulting problems involving their availability, costs and applicability, makes 
the radioactive Mg2+ isotopes unsuitable for absorption-studies. Non-radioactive, 
stable isotopes of Mg2+ such as 25Mg and 26Mg can be distinguished from 24Mg 
based on their weight using mass spectrometry techniques. The first report of the 
use of stable isotopes to study Mg2+ absorption dates back to 1975 [98]. However, 
they were mainly used in balance studies, teaching us little about the kinetics of 
intestinal Mg2+ absorption.
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Outline of this thesis
The general aim of this thesis is to generate more insight in the physiological, 
pathophysiological and pharmacological regulation of intestinal Ca2+ and Mg2+ 
transport. TRPV6 is considered the primary protein responsible for transcellular 
intestinal Ca2+ absorption. In vitro studies have demonstrated that a negatively 
charged aspartic acid within the putative pore region of mouse TRPV6 (position 
541) is critical for Ca2+ permeation of the channel. In chapter 2 the in vivo role of 
this amino acid in TRPV6 mediated Ca2+ transport is determined by the functional 
characterization of Ca2+ homeostasis in a TRPV6D541A/D541A knock-in mouse model. 
An increasing number of case-reports is published concerning patients suffering 
from hypomagnesemia due to the use of proton pump inhibitors. In chapter 3, the 
molecular the molecular mechanism underlying proton pump inhibitor induced 
hypomagnesemia is investigated in mice. The effect of the proton pump inhibitor 
omeprazole on Mg2+ homeostasis and expression levels of the colonic H+,K+-ATPase 
as well as magnesiotropic genes is addressed. Chapter 4 describes a method to 
measure intestinal Mg2+ absorption in an in vivo setting using stable isotopes. In 
addition, an innovative technique is described, with which local absorption of 
ions in the colon in mice can be measured using intestinal cannulas. In chapter 5 
a unique set of human gastrointestinal biopsies is used to determine details 
expression patterns of a broad range of claudins. Also, the expression of claudins 
in patients suffering from inflammatory bowel disease is studied. Chapter 6 
describes the clinical and biochemical characteristics of three patients with 
idiopathic infantile hypercalcemia. The potential role of CLDN3 and CLDN4 in the 
intestinal hyperabsorption of Ca2+ found in patients with this rare disease is 
investigated. In chapter 7 a young patient suffering from Williams-Beuren 
syndrome with infantile hypercalcemia is described and recent advances 
concerning the etiology of infantile hypercalcemia are discussed. Finally, the 
studies described in the chapters of this thesis are summarized in chapter 8, 
which also provides a detailed discussion placing the findings in the context of 
the current knowledge regarding intestinal transport of Ca2+ and Mg2+.
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Abstract
TRPV6 is considered the primary protein responsible for transcellular Ca2+ 
absorption. In vitro studies demonstrate that a negatively charged amino acid (D) 
within the putative pore region of mouse TRPV6 (position 541) is critical for Ca2+ 
permeation of the channel. To elucidate the role of TRPV6 in transepithelial Ca2+ 
transport in vivo, we functionally analyzed a TRPV6D541A/D541A knock-in mouse 
model. After weaning, mice were fed a regular (1% wt/wt) or Ca2+-deficient (0.02% 
wt/wt) diet and housed in metabolic cages. Blood was sampled for Ca2+ 
measurements, and the expression of Ca2+ transport proteins was analyzed in 
kidney, duodenum and colon. Intestinal 45Ca2+ uptake was measured in vivo by an 
absorption assay. Challenging the mice with the Ca2+-deficient diet resulted in 
hypocalcemia in wild-type and TRPV6D541A/D541A mice. On a low-Ca2+ diet both 
mouse strains displayed increased expression of intestinal TRPV6, calbindin-D9K, 
and renal TRPV5. TRPV6D541A/D541A mice showed significantly impaired intestinal 
Ca2+ uptake compared with wild-type mice, and duodenal TRPV5 expression was 
increased in TRPV6D541A/D541A mice. On a normal diet, serum Ca2+ concentrations 
normalized in both mouse strains. Under these conditions, intestinal Ca2+ uptake 
was similar, and the expression levels of renal and intestinal Ca2+ transport 
proteins were not affected. We demonstrate that TRPV6D541A/D541A mice exhibit 
impaired transcellular Ca2+ absorption. Duodenal TRPV5 expression was increased 
in TRPV6D541A/D541A mice, albeit insufficient to correct for the diminished Ca2+ 
absorption. Under normal conditions, when passive Ca2+ transport is predominant, 
no differences between wild-type and TRPV6D541A/D541A mice were observed. Our 
results demonstrate a specific role for TRPV6 in transepithelial Ca2+ absorption.
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Introduction 
Two pathways of intestinal Ca2+ absorption exist, and the preferred route depends 
on dietary availability of Ca2+. When dietary Ca2+ levels are high, the paracellular, 
passive pathway is the predominant absorption mechanism, while active, 
transcellular transport occurs if Ca2+ supply is restricted (5; 12).  Transcellular Ca2+ 
absorption requires entry at the luminal side of the intestinal epithelium. The 
epithelial Ca2+ channel transient receptor potential vanilloid 6 (TRPV6) is 
hypothesized to be responsible for this luminal Ca2+ uptake. Active Ca2+ absorption 
occurs at the proximal part of the small intestine, while the concentration- 
dependent paracellular pathway arises gradually throughout the intestine (5; 15). 
Within the gastrointestinal tract of human, rat and mouse, high levels of TRPV6 are 
observed in the duodenum and colon (14; 20; 24), which is in line with its proposed 
function in intestinal Ca2+ entry. Inside the cell, Ca2+ binds to a Ca2+-binding protein, 
calbindin-D9K, enabling diffusion towards the basolateral side of the cell, where Ca2+ is 
extruded into the blood via the plasma membrane Ca2+-ATPase (PMCA1b) (10). 
Despite the absence of known activity in the kidney, TRPV6 expression has been 
reported in human and mouse kidney epithelia (20; 23; 24; 26; 35) as well.
 Previous in vivo experiments revealed a role for TRPV6 in placental Ca2+ 
transport (27). Consistent with this hypothesis is the finding that calbindin-D9K 
gene expression is significantly reduced in placenta of TRPV6-/- mice, while TRPV5 
levels are unaffected, suggesting an association of TRPV6 and calbindin-D9k in 
placental Ca2+ transport. Since a considerable amount of Ca2+ transport still occurs 
in TRPV6-/- mice, it is implied that other channels contribute significantly to this 
process (27). Recently, gain-of-function polymorphisms of the TRPV6 gene have 
been found in Ca2+-stone forming patients, which might contribute to absorptive 
hypercalciuria (28). These findings suggest that TRPV6 is one of the key players in 
intestinal Ca2+ absorption in humans, although further studies are required to 
elucidate its precise role. 
 Structural analysis of TRPV6 channels suggested the presence of a pore region 
between transmembrane domains 5 and 6, in which three negatively charged 
amino acids are situated (3; 4). An aspartate at position 542 in human TRPV6 (541 
in mouse) was hypothesized to determine Ca2+ conductance. In mouse TRPV6, 
replacement of D541 with an alanine residue abrogated Ca2+ permeation and Mg2+ 
block in in vitro experiments, and similar results were obtained in vitro with 
rabbit TRPV5 (21; 34; 36). Expression of human TRPV6 D542A resulted in 
non-functional channels, despite equivalent cell surface expression as for wild- 
type TRPV6 (4; 34). This suggests that D542 or D541 is critical for Ca2+ permeation 
and/or channel activity. To address the specific role of TRPV6 in transepithelial 
Ca2+ permeation in vivo, we analyzed a mouse model with a specific mutation in 
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the pore region; the TRPV6D541A/D541A knock-in mouse (36). This mouse model is 
unique, compared to TRPV6-/- mice, since the mutation creates a non-functional 
TRPV6 channel with no effect on the channel’s structure., rather than a complete 
knock-down of the channel, which might affect other proteins as well. The 
TRPV6D541A/D541A knock-in mice show a marked reduction of Ca2+ uptake by 
epididymal epithelial cells and consequently, the mobility and fertility of sperm 
are significantly reduced (36). Bone microarchitecture and bone matrix 
mineralization were not affected in these mice (29), suggesting a minor role of 
TRPV6 in bone metabolism. In the present study, we determined serum Ca2+ 
concentrations and urinary Ca2+ excretion, and measured intestinal Ca2+ 
absorption in TRPV6D541A/D541A mice in comparison to wild-type littermates under 
both normal dietary circumstances and severe nutritional Ca2+ restriction to 
specifically study the role of TRPV6 in transepithelial transport.
Materials and methods
Animal studies
Generation of TRPV6D541A/D541A knock-in mice is described in (36). TRPV6 littermates 
were housed in a temperature- and light-controlled room with standard pellet 
chow (1% wt/wt Ca2+, SSNIFF Spezialdiäten GmbH, Soest, Germany) or a 
Ca2+-deficient diet (0.02% wt/wt Ca2+, SSNIFF) and filter sterilized drinking water 
available ad libitum.  They were fed their respective diets from weaning (age 3 
weeks) until the experiment date. TRPV6 mice on the normal and Ca2+-deficient 
diet, n=14 per group, were housed in metabolic cages and 24-hr urine was collected. 
Fresh urine was used for the pH determination. The animals were sacrificed at an 
age of 12-14 weeks. Blood samples were taken and kidney and duodenum tissues 
were sampled and snap-frozen in liquid nitrogen. All experiments were performed 
in compliance with the animal ethics board of the Radboud University Nijmegen 
(Ethical License number RU-DEC 2008-192, RU-DEC 2008-067).
Genotyping
Genotypes were determined by PCR as described in (36) to identify animals with 
wild-type or TRPV6D541A/D541A genotypes.
Analytical procedures
Serum and urine total Ca2+ concentrations were measured using a colorimetric 
assay kit as described previously (11). Serum albumin concentrations were 
measured using an ELISA kit according to the manufacturer’s protocol (GenWay 
Biotech Inc. San Diego, CA, USA). Urine Mg2+ concentrations were determined 
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using a colorimetric assay kit, according to the manufacturer’s protocol (Roche 
Diagnostics, Woerden, The Netherlands). Urine phosphate and Na+ concentrations 
were analyzed on a Hitachi autoanalyzer (Hitachi, Laval, Quebec, Canada).
In vivo 45Ca2+ absorption assay
Ca2+ absorption was determined by measuring serum 45Ca2+ levels at early time 
points after oral gavage as described in (33). In summary, mice were fasted over 
night. At time-point 0, mice were administered a solution containing 0.1 mM CaCl2, 
125 mM NaCl, 17 mM Tris pH 7.5, 1.8 g/l fructose, enriched with 20 mCi 45CaCl2/ml 
(New England Nuclear, Newton, Massachusetts, USA); in a volume of 15 mL/g of body 
weight. Blood samples were obtained via orbital puncture at 1, 2, 3 and 4 minutes 
after oral gavage, and serum was analyzed by liquid scintillation counting.  
Quantitative real-time PCR analysis
Total RNA was isolated from kidney, duodenum (proximal part) and colon using 
TriZol Total RNA Isolation Reagent (Gibco BRL, Breda, The Netherlands) as described 
previously (9). cDNA was subsequently used to determine TRPV5, TRPV6, 
calbindin-D9K, calbindin-D28K, Na+/Ca2+ exchanger 1 (NCX1), PMCA1b, and  1αOHAse 
mRNA expression levels. mRNA expression of the housekeeping gene hypoxan-
thine-guanine phosphorybosyl transferase (HPRT) was used as endogenous 
control. mRNA levels were quantified by qPCR on an ABI PRISM 7900 HT Sequence 
Detection System (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). 
Primers and fluorescent probes were purchased from Biolegio (Malden, The 
Netherlands), the sequences are listed in (30; 32). 
Statistical analysis
Data are expressed as mean ± SEM. Statistical comparisons were analyzed by 
one-way ANOVA with a Bonferroni correction; p<0.05 was considered statistically 
significant. All analyses were performed using the Statview Statistical Package 
software (Power PC version 4.51) on an Apple iMac computer.
Results
Ca2+ deprivation reduces serum Ca2+ concentrations in wild-type and TRPV6D541A/
D541A mice 
Feeding the mice a Ca2+-deficient diet, from weaning until the experiment 
resulted in a serum Ca2+ concentration of 1.7 ± 0.1 mM for TRPV6D541A/D541A mice and 
1.6 ± 0.1 mM for wild-type  mice   (Figure 1A).  Ca2+  levels   in   both   mouse  strains 
were  significantly  lower 
Chapter 2
42
Figure 1  Effects of a Ca2+-deficient diet in wild-type and TRPV6D541A/D541A pore mutant 
mice. A. Serum Ca2+ concentration, B. serum albumin concentration, C. weight, D. 
diuresis, E. urine pH and F. total urinary excretion of Ca2+ of wild-type and TRPV6D541A/
D541A mice on a regular 1% wt/wt Ca2+ diet (filled bars) or a Ca2+-deficient diet (0.02% 
wt/wt Ca2+, open bars). N=14 for each group. * P<0.05 versus wild-type mice on the 
regular diet. † P<0.05 versus TRPV6D541A/D541A mice on the regular diet.
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compared to the same genotypes fed the normal Ca2+ diet (1.9 ± 0.1 mM and 2.0 ± 
0.1 mM respectively, Figure 1A). Changes in serum Ca2+ concentration were not 
due to changes in the protein levels caused by a different dietary content, since 
serum albumin concentrations were similar for the four groups analyzed (Figure 
1B). Ca2+-deficiency significantly reduced the body weight of TRPV6D541A/D541A mice 
to 27.9 ± 1.0 g compared with the weight of the same genotype on a regular diet of 
31.3 ± 1.0 g (Figure 1C). Although the trend for wild-type mice was the same, the 
body weights were not significantly decreased in mice fed the Ca2+ deficient diet 
(28.2 ± 1.0 versus 30.9 ± 0.9 g, Figure 1C). The volume of urine voided by TRPV6D541A/
Figure 1  continued Effects of a Ca2+-deficient diet in wild-type and TRPV6D541A/D541A 
pore mutant mice. Total urinary excretion of F. Ca2+, G. Mg2+, H. P(i) and I Na+ of 
wild-type and TRPV6D541A/D541A mice on a regular 1% wt/wt Ca2+ diet (filled bars) or a 
Ca2+-deficient diet (0.02% wt/wt Ca2+, open bars). N=14 for each group. * P<0.05 
versus wild-type mice on the regular diet. † P<0.05 versus TRPV6D541A/D541A mice on 
the regular diet.
 
 
G  H  
0
10
20
30
40
M
g2
+  e
xc
re
tio
n (
m
m
ol/
24
h)
 
0
100
200
300
400
P(
i) 
ex
cr
et
io
n 
(m
m
ol
/2
4h
) 
* 
† 
I 
  
0
100
200
300
N
a+
 e
xc
re
tio
n 
(m
m
ol
/2
4h
) 
TRPV6 wild-type  TRPV6D541A/D541A TRPV6 wild-type TRPV6D541A/D541A
TRPV6 wild-type TRPV6D541A/D541A
Chapter 2
44
D541A and wild-type mice on both diets was not significantly different (Figure 1D), 
and both mice showed comparable urine pH values (Figure 1E). Renal Ca2+ 
excretion varied from 3.9 ± 0.4 - 5.0 ± 0.7 mmol/24h (Figure 1F), and was similar for 
the four groups studied. Urinary Mg2+ excretion (Figure 1G) was slightly increased 
in TRPV6 wild-type mice on the Ca2+-deficient diet, but no significant changes 
could be observed caused by either the genotype or the diet. Ca2+ deprivation 
Figure 2 Intestinal Ca2+ absorption is reduced in TRPV6D541A/D541A mice on a 
Ca2+-deficient diet. A. Serum Ca2+ changes within 4 minutes after 45Ca2+ 
administration by oral gavage in wild-type (squares) and TRPV6D541A/D541A (circles) 
mice (N=12 per group) on a regular diet (1% wt/wt Ca2+, filled symbols) or a diet 
deficient in Ca2+ (0.02% wt/wt Ca2+, open symbols). B. Duodenal mRNA expression 
of TRPV6, C. TRPV5, D. calbindin-D9K and E. PMCA1b  and F. TRPV6 expression in the 
colon (F) were measured and are expressed as a ratio to HPRT1. Data are presented 
as means ± SEM (N=6-8 per group). * P<0.05 versus wild-type mice on the regular 
diet. † P<0.05 versus TRPV6D541A/D541A mice on the regular diet. # P<0.05 versus 
wild-type mice on the Ca2+-deficient diet. 
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significantly enhanced urinary P(i) excretion 9.5-times in TRPV6 wild-type mice, 
and 11.2-fold change in TRPV6D541A/D541A mice (Figure 1H). Renal Na+ excretion was 
comparable for the four groups analyzed (Figure 1I).
Ca2+-deficient TRPV6D541A/D541A mice show impaired intestinal Ca2+ absorption
To study the functional consequences of the Ca2+-impermeable pore mutant on 
intestinal absorption, an in vivo 45Ca2+ absorption assay was performed. A low Ca2+ 
diet resulted in a significantly increased Ca2+ absorption in TRPV6D541A/D541A and 
wild-type mice compared to mice on a regular diet (Figure 2A). At all time-points 
studied, TRPV6D541A/D541A mice displayed significantly reduced Ca2+ absorption 
compared with their wild-type littermates (Figure 2A, open symbols). On the 
regular diet, uptake of Ca2+ from the intestinal lumen was similar for TRPV6D541A/
D541A and wild-type mice (Figure 2A). 
Next, the gene expression of the Ca2+ transporters in the duodenum of these mice 
was examined by qPCR analysis. Ca2+ deprivation resulted in a 20-25-fold induction 
of TRPV6 expression (Figure 2B) in wild-type and TRPV6D541A/D541A mice. 
Interestingly, duodenal TRPV5 expression was significantly increased 6-times in 
TRPV6D541A/D541A mice on the Ca2+-deficient diet (Figure 2C), while a 3-fold change 
was induced by Ca2+-deficiency in wild-type mice (Figure 2C). Calbindin-D9K 
mRNA levels were 2.3 and 3.5 times up-regulated in wild-type and TRPV6D541A/D541A 
mice, respectively (Figure 2D). PMCA1b gene expression was not changed by the 
diet in either genotype (Figure 2E). Intestinal mRNA levels of TRPV6, TRPV5, 
calbindin-D9K and PMCA1b were similar for TRPV6D541A/D541A and wild-type mice on 
the regular diet (Figure 2B-E). Next, we analyzed TRPV6 mRNA levels in the colon, 
to study differences in expression in the large intestine. Ca2+-deficiency 
Figure 2 continued.
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significantly increased TRPV6 expression in TRPV6D541A/D541A and wild-type mice 
(23000 and 18000 fold, respectively, Figure 2F). 
Regulation of the renal Ca2+ transporters by Ca2+ deprivation
Expression of renal Ca2+ transport proteins was then investigated. Ca2+-deficiency 
resulted in a 2-fold up-regulation of TRPV5 mRNA levels (Figure 3A) in both 
TRPV6D541A/D541A and wild-type mice. Renal TRPV6 expression, which is quite low, 
was not increased compared with the mice on the regular diet (Figure 3B). 
Calbindin-D28K mRNA levels were significantly reduced in wild-type mice (Figure 3C), 
Figure 3  mRNA expression of renal Ca2+ transport proteins in TRPV6D541A/D541A pore 
mutant mice is comparable to wild-type mice. A. Renal mRNA expression of TRPV5, 
B. TRPV6, C. calbindin-D28K, D. NCX1, E. PMCA1b, and F. 1αOHase of wild-type and 
TRPV6D541A/D541A mice on a regular 1% wt/wt Ca2+ diet (filled bars) or on a Ca2+-deficient 
diet (0.02% wt/wt Ca2+, open bars) were measured and are presented as ratio to 
HPRT1. Data are shown as means ± SEM. N=6-8 per group. * P<0.05 versus wild-type 
mice on the regular diet. † P<0.05 versus TRPV6D541A/D541A mice on the regular diet.
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while the trend was the same for TRPV6D541A/D541A knock-in mice, no significant 
effect was detected in the kidneys of TRPV6D541A/D541A mice. NCX1 expression was 
decreased by almost 50% in both TRPV6D541A/D541A and wild-type mice (Figure 3D), 
but the levels of PMCA1b were not reduced compared with the mice on the regular 
diet (Figure 3E). Besides the different regulation of calbindin-D28K mRNA levels 
(Figure 3C), gene expression of renal Ca2+ transporters was identical in TRPV6D541A/
D541A and wild-type mice (Figure 3A-E). On a regular diet, renal mRNA levels of 
TRPV5, TRPV6, calbindin-D28K, NCX1 and PMCA1b were equal in TRPV6D541A/D541A and 
wild-type mice (Figure 3A-E). Expression of renal 1αOHase was studied to indicate 
changes in vitamin D homeostasis. In both TRPV6D541A/D541A and wild-type mice, 
1αOHase expression was significantly increased by Ca2+ deprivation (Figure 3F), 
however no changes in expression between TRPV6D541A/D541A and wild-type mice 
could be observed (Figure 3F).  
Discussion
This is the first study characterizing Ca2+ homeostasis in a mouse model in which 
TRPV6 channels are functionally inactivated by mutating the channel pore. Our 
results show that TRPV6 is specifically involved in transepithelial small intestinal 
Ca2+ transport. TRPV6D541A/D541A mice exhibit decreased duodenal Ca2+ uptake and 
increased intestinal TRPV5 gene expression compared to wild-type mice. 
Functional consequences on serum Ca2+ and the net urinary Ca2+ excretion were 
not observed, and the expression of Ca2+ transporters in the kidney was not 
affected. 
 The mice were challenged by a Ca2+-deficient diet to address the specific 
function of TRPV6 in transcellular Ca2+ transport. This resulted in a failure-to-
thrive, emphasizing the importance of in vivo absorption assays to study 
functional consequences. Dietary Ca2+ restriction reduced intestinal absorption in 
TRPV6D541A/D541A knock-in mice, while the homeostasis of other electrolytes, 
measured by urinary excretion, was not significantly affected in TRPV6D541A/D541A 
knock-in mice. This implies a critical role for TRPV6 in transcellular Ca2+ transport 
specifically. This conclusion is supported by a gain-of-function haplotype in 
TRPV6, which is suggested to contribute to absorptive hypercalciuria in patients 
(28). Parallel to our study, Benn et al. (1) described a down-regulation of intracellular 
Ca2+ transport proteins in TRPV6-/- mice on a 0.02% wt/wt Ca2+-deficient diet but 
no differences in the same mice on a regular diet. However, impaired intestinal 
Ca2+ uptake for TPRV6-/- mice on a normal diet has been reported as well (2). This 
model is different from ours in that Bianco et al. (2) studied knock-out mice, while 
we analyzed knock-in mice with inactivated Ca2+ permeation, achieved by a 
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single amino acid replacement in the pore region of TRPV6. This latter study 
described TRPV6-/- mice by a reduction in body weight, polyuria and hypercalciuria 
(2), while we showed that the phenotype of the TRPV6D541A/D541A mice on a regular 
diet is indistinguishable from wild-type mice. This is supported by the study of 
Benn et al. (1), who described the TRPV6-/- mouse on a regular diet as normocalcemic 
with Ca2+ absorption comparable to wild-type mice. Both studies confirm the 
specific role of TRPV6 in transepithelial Ca2+ transport. 
 Ca2+ uptake was not completely absent in TRPV6D541A/D541A mice, implying that 
other mechanisms are critically involved. Vitamin D was found to regulate 
paracellular transport in vitro via direct effects on the expression of the tight 
junction complexes claudin-2 and claudin-12, and on the cell adhesion molecules 
claudin-3 and cadherin 17 (6; 7; 16). In the duodenum of TRPV6-/- mice, vitamin D 
administration slightly increased expression of claudin-12, reduced levels of 
cadherin 17, while no changes in claudin-2 expression were detected.  This suggests 
some stimulation of paracellular absorption, but in vivo proof is still not definite 
(1; 17). Therefore, other yet unidentified transport mechanisms might be 
compensating for the inactivation of TRPV6 in these TRPV6D541A/D541A mice, such as 
the L-type calcium channel Cav1.3. Cav1.3 is highly expressed in the apical 
membrane in jejunum and ileum of rat (19), and is supposed to function in glu-
cose-mediated transcellular Ca2+ absorption under normal dietary conditions (18). 
It is interesting to study the effects of Ca2+-deprivation on Cav1.3-mediated 
transport. 
 Changes in the expression of renal and intestinal Ca2+ transporters mediated 
by Ca2+-deficiency in the TRPV6D541A/D541A and wild-type mice has been described 
before (1; 8). Remarkably, intestinal TRPV5 expression, which is generally low 
compared to TRPV6 expression in the duodenum of rodents (9; 13; 22; 32), was 
significantly enhanced in TRPV6D541A/D541A mice on the Ca2+-deficient diet, and a 
minor, but not significant, increase was observed in wild-type mice. TRPV6 
expression in the colon was not significantly changed in TRPV6D541A/D541A mice 
compared to wild-type mice. The changes in TRPV5 expression suggest the 
existence of a compensatory mechanism in TRPV6D541A/D541A mice, albeit insufficient 
to fully compensate for the loss of TRPV6 activity, as illustrated by the 45Ca2+ 
absorption assay.  Since these mice partially compensate for the reduced Ca2+ 
absorption in their duodenum, this confirms the involvement of TRPV6 in 
transcellular Ca2+ transport in the intestine.
 Furthermore, on a Ca2+-deficient diet both wild-type and TRPV6D541A/D541A 
display  inappropriately high urinary Ca2+ excretion levels; e.g. within the normal 
range, despite being hypocalcemic. This phenomenon has been observed in knock 
out models associated with secondary hypervitaminosis D (25).  TRPV5 expression 
is upregulated in the kidneys in an attempt to reabsorb more Ca2+, but this is not 
2Functional TRPV6 channels are crucial for transepithelial Ca2+ absorption
49
sufficient to correct the hypocalcemia. In addition, calbindin-D28K and NCX1 
expression are also decreased in the kidneys of these mice. This supports the 
theory of the renal dysfunction in wild-type and TRPV6D541A/D541A mice. Indeed, for 
wild-type mice on a Ca2+-deficient diet  this has been described before (8). 
Furthermore, it is known that the expression of these renal Ca2+ transport proteins 
is down-regulated as a consequence of disturbed Ca2+ reabsorption via TRPV5 (31). 
In summary, our results demonstrate that TRPV6 specifically contributes to tran-
sepithelial Ca2+ transport, as demonstrated by the significantly impaired 
intestinal 45Ca2+ uptake in the TRPV6D541A/D541A knock-in mouse. Ca2+ absorption still 
occurs to some extent in these mice, suggesting a role for other transport 
mechanisms, either paracellular or yet unidentified transcellular transport 
mechanisms, and explains why the significantly diminished absorption is not 
reflected by a reduction in serum Ca2+ and/or urinary Ca2+ excretion. 
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Abstract
Proton pump inhibitors (PPIs) are potent blockers of gastric acid secretion, used by 
millions of patients suffering from gastric acid-related complaints. Although PPIs 
have an excellent safety profile, an increasing number of case reports describe 
patients with severe hypomagnesemia due to long-term PPI use. As there is no 
evidence of a renal Mg2+ leak, PPI-induced hypomagnesemia is hypothesized to 
result from intestinal malabsorption of Mg2+. The aim of this study was to 
investigate the effect of PPIs on Mg2+ homeostasis in an in vivo mouse model. To 
this end, C57BL/6J mice were treated with omeprazole, under normal and low 
dietary Mg2+ availability. Omeprazole did not induce changes in serum Mg2+ levels 
(1.48  ± 0.05 mmol/L and 1.54 ± 0.05 mmol/L in omeprazole-treated and control 
mice, respectively), urinary Mg2+ excretion (35 ± 3 µmol/24 h and 30 ± 4 µmol/24 h 
in omeprazole-treated and control mice, respectively) or fecal Mg2+ excretion (84 ± 
4 µmol/24 h and 76 ± 4 µmol/24 h in omeprazole-treated and control mice, 
respectively) under any of the tested experimental conditions. However, 
omeprazole treatment did increase the mRNA expression level of the transient 
receptor potential melastatin 6 (TRPM6), the predominant intestinal Mg2+ 
channel, in the colon (167 ± 15% and 100 ± 7% in omeprazole-treated and control 
mice, respectively, P < 0.05). In addition, the expression of the colonic H+,K+-ATPase 
(cHK-α), a homolog of the gastric H+,K+-ATPase that is the primary target of 
omeprazole, was also significantly increased (354 ± 43% and 100 ± 24% in omepra-
zole-treated and control mice, respectively, P < 0.05). The expression levels of other 
magnesiotropic genes remained unchanged. Based on these findings, we 
hypothesize that omeprazole inhibits cHK-α activity, resulting in reduced 
extrusion of protons into the large intestine. Since TRPM6-mediated Mg2+ 
absorption is stimulated by extracellular protons, this would diminish the rate of 
intestinal Mg2+ absorption. The increase of TRPM6 expression in colon may 
compensate for the reduced TRPM6 currents, thereby normalizing intestinal Mg2+ 
absorption during omeprazole treatment in C57BL/6J mice, explaining unchanged 
serum, urine, and fecal Mg2+ levels.  
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Introduction
Proton pump inhibitors (PPIs) are indicated for gastric acid-related diseases like 
gastroesophageal reflux disease, Zollinger-Ellison syndrome, Barrett’s esophagus, 
duodenal peptic ulcers, and gastritis [1]. All PPIs have a similar chemical structure 
and an identical mode of action. They are administered in the form of lipophilic, 
membrane-permeable, inactive pro-drugs [2]. PPIs are absorbed from the small 
intestine into the blood, after which they accumulate in the highly acidic 
canaliculi of the parietal cells of the stomach. Here, PPIs are protonated, which 
induces covalent binding between the PPI and specific cysteine residues of the 
gastric H+,K+-ATPase (gHK-α), resulting in potent inhibition of acid secretion [2]. 
Although PPIs are generally considered to have an excellent safety profile, over 65 
cases of PPI-induced hypomagnesemia (PPIH) have been reported since 2006 
[3-15]. In addition to these case reports, reduced serum Mg2+ levels associated with 
the use of PPI’s were reported in a cohort of hospitalized patients [16]. A recently 
published study, based on reports submitted to the Adverse Event Reporting 
System of the US Food and Drug Administration, suggests that PPIH might 
concern several hundreds of patients since 2004 [17]. 
PPIH typically manifests after years of chronic PPI use, and patients present with 
symptoms common to severe Mg2+ depletion such as tetany, seizures, convulsions, 
and cardiac arrhythmia, often coinciding with secondary hypocalcemia. The 
causal link between the use of PPIs and the development of hypomagnesemia 
was shown in PPIH patients by a classical challenge-dechallenge-rechallenge 
protocol, leading to fast recovery from hypomagnesemia during dechallenge and 
fast reappearance of hypomagnesemia after rechallenge [3, 7, 14]. Intravenous 
Mg2+ loading tests indicate that PPIH patients are severely Mg2+ depleted, and 
determination of fractional Mg2+ excretion shows appropriate renal retention of 
Mg2+ [3, 4, 12, 14]. These findings implicate that intestinal malabsorption of Mg2+ 
plays a central role in the etiology of PPIH. This sets PPIH apart from many other 
forms of drug-induced hypomagnesemia which most frequently result from 
renal Mg2+ losses [18]. However, the exact molecular mechanisms underlying PPIH 
remain unknown. 
Some authors speculate that PPIH might result from genetic variants in the 
epithelial Mg2+ channel transient receptor potential melastatin 6 (TRPM6) [3, 4, 
12]. The vital role of TRPM6 in the maintenance of Mg2+ homeostasis has been well 
established [19]. The Mg2+ channel is expressed at the apical membrane of 
epithelial cells in the distal convoluted tubules of the kidney and at the luminal 
side of the gastrointestinal epithelium [20]. Recently, several magnesiotropic 
Chapter 3
56
hormones including epidermal growth factor, estrogen, and insulin have been 
described to influence Mg2+ absorption via TRPM6 [21-23]. In addition to the 
hormonal regulation, it is known that the presence of extracellular protons 
enhances inward currents via TRPM6, meaning that Mg2+ influx via this channel 
is strongly dependent on the extracellular pH [24].
The primary target of omeprazole, gHK-α, has a homologue named the colonic 
H+,K+-ATPase (cHK-α), which extrudes protons into the lumen of the intestine in 
exchange for potassium ions [25]. In vitro studies using guinea pig colonic crypts 
or colon tissue in Ussing chambers indicate that PPIs do not only reduce the 
activity of the gHK-α, but also that of the colonic H+,K+-ATPase (cHK-α) [26, 27]. 
Based on these observations, we hypothesize that omeprazole inhibits cHK-α 
activity, resulting in a lower amount of protons being extruded into the large 
intestine, subsequently leading to a reduced rate of intestinal Mg2+ absorption via 
TRPM6.
The aim of our study was, therefore, to create a mouse model of PPIH to test our 
hypothesis that omeprazole reduces TRPM6-mediated colonic Mg2+ absorption. To 
this end, we investigated the effect of omeprazole treatment on Mg2+ homeostasis 
in vivo by means of serum, urine, and fecal Mg2+ measurements and by 
determination of mRNA expression patterns of TRPM6 and cHK-α in the intestine 
and kidney.
Materials and methods
Animal studies
C57BL/6J mice (8 weeks old) were purchased from Charles River, the Netherlands. 
Animals were housed in a temperature- and light-controlled room with pelleted 
chow (SSNIFF Spezialdiäten GmbH, Germany) and drinking water available ad 
libitum. Omeprazole (Fagron, the Netherlands) was dispersed in a solution 
containing 0.5% (w/v) methylcellulose and 0.2% (w/v) NaHCO3 (pH 9.0). Mice 
received a daily dose of 20 mg omeprazole per kilogram bodyweight, which was 
administered via oral gavage. For urine and feces collection, animals were 
individually housed in metabolic cages for 24 h. Blood was sampled from the 
submandibular facial vein at the end of the stay in the metabolic cages, and sera 
were collected for Mg2+ measurements. All experiments were performed in 
compliance with the animal ethics board of the Radboud University Nijmegen.
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For the first experiment, animals were randomly divided into an omeprazole 
group (n=10) and a control group (n=10), receiving vehicle only. They were fed a 
standard chow with normal Mg2+ content (0.2% w/w Mg2+, SSNIFF Spezialdiäten 
GmbH, Germany) during 28 days. A second experiment was performed, in which 
both groups of mice were fed a Mg2+-deficient diet (0.02% w/w Mg2+, SSNIFF 
Spezialdiäten GmbH, Germany) for 22 days followed by a recovery period of 2 days 
in which the mice were reintroduced to a diet with normal Mg2+ content. 
Tissue collection and pH measurements
At the end of each experiment, blood was collected and animals were sacrificed 
via cervical dislocation under isoflurane anesthesia. Kidneys, duodenum, and 
colon segments were extracted, cleaned, and snap frozen in liquid nitrogen. In 
addition, stomach pH was analyzed using diagnostic test strips (Merck, Germany).
Analytical procedures
Before analysis, fecal samples were homogenized and digested in 65% nitric acid 
(Sigma-Aldrich, USA) for 2 h at 70 °C, followed by an overnight incubation at room 
temperature. Serum, urinary, and fecal Mg2+ concentrations were determined by 
a colorimetric xylidyl-II blue method (Cobas Roche Diagnostics, UK) on a Nanodrop 
2000c spectrophotometer (Thermo Fisher Scientific, USA) at 600 nm wavelength 
and were verified using a commercial serum standard (Precinorm U, Roche, 
Switzerland). 
Quantitative real-time PCR
Total RNA was extracted from tissues using TRIzolÒ reagent (Invitrogen, UK) 
according to the manufacturer’s protocol. The obtained RNA was subjected to 
DNase treatment (Promega, USA) to prevent genomic DNA contamination. 
Subsequently, RNA was reverse transcribed with murine leukemia virus reverse 
transcriptase. The obtained cDNA was used to determine mRNA expression levels 
of various magnesiotropic genes and H+,K+-ATPases, as well as mRNA levels of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an endogenous control. 
The mRNA expression levels were quantified by real-time PCR on a CFX69 
real-time detection system (BioRad, USA) using SYBR Green (BioRad, USA). Primers 
(Biolegio, the Netherlands) were designed with Primer 3 software (Whitehead 
Institute for Biomedical Research, USA) and are listed in Table I.
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Statistics
Values are expressed as means ± SEM. Differences between single groups of ome-
prazole-treated mice and controls were tested using a two-tailed, unpaired 
Student’s t test. Comparison of multiple groups was performed by a one-way 
ANOVA with a Bonferroni correction. Differences between groups were considered 
to be statistically significant when P < 0.05. Analysis of the datasets was performed 
using GraphPad Prism (Macintosh version, 4.51).
Results 
Effect of omeprazole on serum Mg2+ levels as well as 24-h urinary and fecal Mg2+ 
excretion under normal and low dietary Mg2+ availability
To study the effect of omeprazole on serum Mg2+ levels as well as 24-h urinary and 
fecal excretion of Mg2+, mice were treated with 20 mg/kg body weight omeprazole 
(or vehicle) via oral gavage once a day. Serum Mg2+ levels, 24-h urinary Mg2+ 
excretion as well as 24-h fecal Mg2+ excretion were determined at the start of the 
experiment and after 28 days of treatment.  There were no significant differences 
in body weight, food and water intake, diuresis, and fecal weight between the 
omeprazole-treated mice and vehicle-treated controls (P > 0.2 for all parameters) 
during their stay in the metabolic cages (Table 2). Serum Mg2+ levels (Figure 1A) 
were unaltered in omeprazole-treated mice compared to the vehicle-treated 
controls (1.48  ± 0.05 mmol/L and 1.54 ± 0.05 mmol/L in omeprazole-treated versus 
vehicle-treated mice, respectively, P > 0.2). The urinary excretion of Mg2+ (Figure 
Table 1  Primer sequences used for real-time PCR. 
Gene NCBI ref. Forward primer Reverse primer
GAPDH NM_008084.2 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
TRPM6 NM_153417.1 5’-AAAGCCATGCGAGTTATCAGC-3’ 5’-CTTCACAATGAAAACCTGCCC-3’
cHK-α NM_138652.2 5’-GCTAAGGCAACGCGCGTCCT-3’ 5’-CTGTTTTCCGGCGCATACTGTGA-3’
TRPM7 NM_021450.2 5’-GGTTCCTCCTGTGGTGCCTT -3’ 5’-CCCCATGTCGTCTCTGTCGT-3’
EGF NM_010113.3 5’-GAGTTGCCCTGACTCTACCG-3’ 5’-CCACCATTGAGGCAGTATCC-3’
EGFR NM_207655.2 5’-CAGAACTGGGCTTAGGGAAC-3’ 5’-GGACGATGTCCCTCCACTG-3’
Kv1.1 NM_010595.3 5’-CTGTGACAATTGGAGGCAAGATC-3’ 5’-GAGCAACTGAGCCTGCTCTTC-3’
CNNM2 NM_033569.3 5’-GGAGGATACGAACGACGTG-3’ 5’-TTGATGTTCTGCCCGTACAC-3’
HNF1B NM_009330.2 5’-CAAGATGTCAGGAGTGCGCTAC-3’ 5’-CTGGTCACCATGGCACTGTTAC-3’
gHK-α NM_018731.2 5’-TCCAGCAGGGATTCTTCAGGAAC-3’ 5’-AGCCAATGCAGACCTGGAACAC-3’
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1B) did not significantly differ between the omeprazole group and the control 
group (35 ± 3 µmol/24 h and 30 ± 4 µmol/24 h for omeprazole-treated and vehi-
cle-treated mice, respectively, P > 0.2). In addition, fecal Mg2+ excretion (Figure 1C) 
was not significantly different in omeprazole-treated mice compared to the vehi-
cle-treated controls (76 ± 4 µmol/24 h and 84 ± 4 µmol/24 h in omeprazole-treated 
and control mice, respectively, P > 0.2).
 To determine whether the effect of omeprazole on Mg2+ homeostasis is 
influenced by dietary Mg2+ availability, a subsequent experiment was performed 
in which mice were fed a Mg2+-deficient diet in addition to the treatment with 
omeprazole or vehicle. This diet induced a significant decline in serum Mg2+ 
values; however, no differences were observed between omeprazole- and vehi-
cle-treated mice after 8 or 20 days of treatment (Figure 2). After 22 days on the 
Mg2+-deficient diet, the animals were reintroduced to a diet with normal Mg2+ 
Table 2  Characteristics of vehicle-treated controls and omeprazole-treated mice.
Control Omeprazole
Body weight (g) 30.1 ± 0.9 30.2 ± 1.1
Food intake (g/24 h) 3.1 ± 0.2 3.0 ± 0.3
Water intake (mL/24 h) 4.2 ± 0.3 4.2 ± 0.2
Diuresis (mL/24 h) 1.2 ± 0.2 1.4 ± 0.2
Fecal weight (g/24 h) 1.6 ± 0.2 1.5 ± 0.2
Figure 1  Effect of omeprazole treatment on Mg2+ homeostasis in CB57BL/6J mice. 
A. Serum Mg2+ concentration B. 24-h urinary Mg2+ excretion and C. 24-h fecal Mg2+ 
excretion in vehicle-treated controls (white bars) and omeprazole-treated mice 
(black bars) are shown. Data are presented as means ± SEM. 
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content, to investigate the recovery rate between the two groups of mice. Within 
2 days serum Mg2+ levels normalized to baseline values with no differences 
between omeprazole-treated animals and controls (1.42 ± 0.02 mmol/L and 1.44 ± 
0.02 mmol/L for omeprazole-treated and vehicle-treated controls, respectively, P > 
0.2).
Effect of omeprazole treatment on gastric pH
To confirm the effect of omeprazole treatment on gastric acid secretion in our 
mouse model, we measured the pH in the gastric lumen using pH indicator strips 
(Figure 3). Four hours after administration of omeprazole, the intragastric pH 
was pH 6.7 ± 0.2 indicating that gastric acid production was effectively inhibited 
by omeprazole. Twenty-eight hours after the last dose of omeprazole was 
administered, the stomach pH remained significantly elevated with a pH 4.4 ± 0.4 
in omeprazole-treated mice compared to a pH of 2.6 ± 0.3 in vehicle-treated mice 
(P < 0.05). These findings indicate that the omeprazole treatment ensured a 
continuous suppression of gastric acid secretion throughout the experiment.
Co-expression of TRPM6 and colonic H+,K+-ATPase in the colon
To confirm the co-localization of TRPM6 and cHK-α, their mRNA expression levels 
were determined in a murine gastrointestinal tissue panel (Figure 4). TRPM6 
mRNA expression was found predominantly in the caecum and throughout the 
colon, while expression levels in the duodenum were negligible. cHK-α mRNA 
expression was low in the duodenum and caecum whereas in the colon, expression 
increased from the proximal towards the distal end. 
Figure 2  Effects of dietary Mg2+ restriction and omeprazole on serum Mg2+ in 
CB57BL/6J mice. Vehicle-treated controls (white bars) and omeprazole-treated 
mice (black bars) were fed a Mg2+-deficient diet (0.02% w/w Mg2+) for 22 days and 
then switched to a normal diet (0.2% w/w Mg2+) to monitor recovery. * # P < 0.05 
compared to the corresponding group on day 0.
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Omeprazole treatment specifically enhances mRNA expression of TRPM6 and 
cHK-α in the colon
Next, we investigated whether omeprazole affected TRPM6 and cHK-α mRNA 
expression levels in the colon (Figure 5A and B). Since the mRNA expression of 
both genes overlaps in the proximal as well as the distal colon, TRPM6 and cHK-α 
mRNA expression levels were analyzed in both colonic segments, to determine if 
they are affected by omeprazole treatment. The expression of TRPM6 in the 
Figure 3  Effects of omeprazole treatment on gastric acid production. Effect of 
omeprazole treatment on gastric pH, 4 or 28 h (black bars) after administration of 
the last dose. Data are presented as means ± SEM. * P < 0.05 compared to vehi-
cle-treated controls (white bars)
Figure 4  Gastrointestinal expression pattern of TRPM6 and cHK-α mRNA. mRNA 
expression levels of TRPM6 (black bars) and cHK-α (white bars) in the different 
segments of the gastrointestinal tract of CB57BL/6J mice as determined by 
real-time PCR. Expression levels are shown as a percentage of total gastrointesti-
nal expression and were corrected for GAPDH expression. Data are presented as 
means ± SEM.
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proximal segment of the colon was not significantly increased (127 ± 17% and 100 
± 4% in omeprazole-treated and control mice, respectively, P > 0.2). There was, 
however, a significant upregulation of cHK-α in omeprazole-treated mice 
compared to vehicle-treated controls (257 ± 55% and 100 ± 7% in omeprazole-treated 
and control mice, respectively, P < 0.05). 
 In the distal colon, the expression level of TRPM6 mRNA was increased ~1.5 
times in omeprazole-treated mice compared to the vehicle-treated controls (167 ± 
15% and 100 ± 7% for omeprazole-treated and vehicle-treated mice, respectively, P 
< 0.05). Similar to our findings in the proximal colon, cHK-α mRNA expression 
Figure 5  Effects of omeprazole treatment on mRNA expression levels of various 
magnesiotropic genes and H+-K+-ATPases in the colon and kidney. Relative mRNA 
expression levels (corrected for GAPDH) of TRPM6 and cHK-α in vehicle-treated 
controls (white bars) and omeprazole-treated mice (black bars) in A. the proximal 
and B. the distal colon, as well as in C. the kidney. D. Expression levels of various 
magnesiotropic genes and the gHK-α in the distal colon of vehicle-treated controls 
and omeprazole-treated mice. Data are presented as means ± SEM, * P < 0.05 
compared to vehicle-treated controls.
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levels in the distal colon were ~3.5 times higher in omeprazole-treated mice 
compared to controls (354 ± 43% and 100 ± 24% for omeprazole-treated and vehi-
cle-treated mice, respectively, P < 0.05). 
 In the kidney (Figure 5C), TRPM6 mRNA expression was significantly lower in 
omeprazole-treated mice compared to the controls (89 ± 4% and 100 ± 1% for ome-
prazole-treated and vehicle-treated mice, respectively, P < 0.05). The levels of 
cHK-α mRNA were unaltered by the omeprazole treatment (112 ± 22% and 100 ± 3% 
for omeprazole-treated and vehicle-treated mice, respectively, P > 0.2). 
The mRNA expression levels of magnesiotropic genes other than TRPM6 could 
function as important negative controls as they could demonstrate the specificity 
of the upregulation of TRPM6 and cHK-α in the colon in reaction to omeprazole 
treatment. Therefore, we determined the expression levels of the following 
well-known magnesiotropic genes in the distal colon of omeprazole- and vehi-
cle-treated mice: TRPM7, epidermal growth factor (EGF), EGF receptor (EGFR), 
potassium voltage-gated channel subfamily A member 1 (Kv1.1), Cyclin M2 
(CNNM2) and hepatocyte nuclear factor 1 homeobox B (HNF1B) (Figure 5D).  
 The mRNA expression level of TRPM7, the closest homologue of TRPM6 and 
therefore the most important negative control, was unaltered in the distal colon 
of omeprazole-treated mice compared to the expression in vehicle-treated controls 
(104 ± 7% and 100 ± 3% for omeprazole-treated and vehicle-treated mice, 
respectively, P > 0.2). The expression levels of the other tested magnesiotropic 
genes were also not significantly altered by omeprazole treatment. In addition to 
the magnesiotropic genes, we have also analyzed the expression levels of the 
gHK-α. There was a small but significant increase in the expression of gHK-α in 
omeprazole-treated mice versus vehicle-treated controls (148 ± 15% and 100 ± 2% in 
omeprazole-treated and control mice, respectively, P < 0.05). 
Discussion
This study demonstrates for the first time that omeprazole treatment enhances 
the colonic expression levels of both TRPM6 and cHK-α mRNA suggesting that 
omeprazole indeed influences intestinal Mg2+ absorption. However, prolonged 
exposure to omeprazole had no effect on either serum Mg2+ levels, urinary Mg2+ 
excretion, or fecal Mg2+ excretion in C57BL/6J mice under normal or low dietary 
Mg2+ conditions. Moreover, omeprazole did not affect the development of 
hypomagnesemia under dietary Mg2+ restriction, nor the recovery from 
hypomagnesemia under normal dietary Mg2+ conditions. 
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Under conditions of normal dietary Mg2+ availability, the majority of intestinal 
Mg2+ absorption takes place in the small intestine via a passive, paracellular 
pathway. When dietary Mg2+ concentrations are low, or when bodily needs are 
high, active transcellular transport via TRPM6 becomes more important [28]. By 
performing our experiments both under normal and low dietary Mg2+ availability, 
we aimed to distinguish between the effect of omeprazole on the paracellular 
and transcellular absorption pathways. Although there was no effect of 
omeprazole treatment on serum Mg2+ levels nor on urinary and fecal Mg2+ 
excretion, there was a significant increase in both TRPM6 and cHK-α mRNA levels 
in the distal colon of omeprazole-treated mice. The difference in the effect of 
omeprazole on TRPM6 mRNA expression in the proximal and distal colon is most 
likely the result of the lower baseline cHK-α expression in the proximal segment 
(as shown in figure 4), the net increase in cHK-α expression is therefore much 
lower in the proximal colon, consequently resulting in a less robust effect on 
TRPM6. The mRNA expression levels of several other known magnesiotropic 
genes, including the TRPM6 homologue TRPM7, were not affected, indicating that 
the effect of omeprazole treatment on TRPM6 expression in the colon is highly 
specific. 
In addition to the effect in the colon, omeprazole treatment also slightly decreased 
TRPM6 mRNA expression in the kidney; however, the renal expression of cHK-a 
remained unchanged. Importantly, the unaltered urinary Mg2+ excretion of the 
mice indicates that the final renal Mg2+ balance was not compromised by the 
slight decrease of renal TRPM6 expression. 
The increased expression of cHK-α mRNA in the colon upon treatment with 
omeprazole was very distinct. We also found a small, but statistically significant, 
increase in gHK-α mRNA expression in the distal colon of omeprazole-treated 
mice compared to the vehicle-treated controls. The expression levels of gHK-α in 
the colon are, however, very low, so the functional relevance of this small increase 
is disputable. Previous studies have described an increase in mRNA expression 
level of the gHK-α in the stomach induced by omeprazole treatment [29]. Most 
likely, the increased mRNA levels of the H+,K+-ATPases in the colon represent an 
adaptation mechanism to restore acid secretion. There is clear evidence from in 
vivo models that omeprazole can indeed accumulate in the colonic epithelium, 
although this accumulation is not as strong as in the stomach [30, 31]. As described 
before, omeprazole is a lipophilic pro-drug which easily passes the plasma 
membrane. In the presence of protons, the pro-drug is converted into an active 
form, trapping it into the cell. The conversion of the PPI, which causes its 
accumulation in the cell, also enables the binding of the PPI to intracellular 
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cystein residues of the gHK-α, thereby inhibiting the extrusion of protons [32]. The 
fact that omeprazole accumulates in the colon indicates that the colonic cells have 
a sufficiently low pH to allow for omeprazole activation, potentially leading to 
inhibition of cHK-α. The function and pharmacological sensitivity of the various 
HK-αs depends on the species, tissues, and systems in which they are studied [33, 
34]. The inhibitory effect of omeprazole on cHK-α was shown in fractionized 
membranes of guinea pig distal colon, in which omeprazole was found to reduce 
cHK-α activity by 30% [26]. Furthermore, studies in Ussing chambers indicated 
that omeprazole inhibits cHK-α activity in the colon [27]. Inhibition of cHK-α by 
omeprazole would lead to a reduction of proton secretion into the lumen of the 
colon. Importantly, it has been shown that extracellular protons enhance inward 
currents via TRPM6, indicating that Mg2+ influx via TRPM6 is strongly dependent 
on the extracellular pH [24]. We therefore hypothesized that the effect of 
omeprazole on intestinal Mg2+ absorption is the result of an indirect effect of 
omeprazole on TRPM6, elicited via a reduction of cHK-α-mediated proton secretion. 
This hypothesis is in line with findings from previous studies which show that 
fermentable substrates, such as carbohydrates, stimulate intestinal Mg2+ 
absorption [35]. The fermentation of these substrates by bacteria leads to an 
acidification of the caecum and colon, without influencing systemic acid/base 
homeostasis. Interestingly, increasing the amount of fermentable substrate in the 
food results in increased intestinal Mg2+ absorption, whereas the absorption of 
other minerals such as calcium, iron, and zinc remains unchanged. Several 
human studies have confirmed the enhancing effect of fermentable oligo- or pol-
ysaccharides on Mg2+ absorption [35]. These findings are in line with our 
hypothesis that changes in pH can influence Mg2+ absorption in the colon.
A tissue panel of the mouse intestinal tract shows abundant TRPM6 mRNA 
expression in the caecum as well as the colon, which is in line with earlier 
observations from our group [23]. cHK-α mRNA expression was predominantly 
found in the colon, where its expression increases towards the distal end, that is 
in accordance with the fact that active potassium absorption predominantly 
takes place in the distal part of the colon [36]. The co-expression of TRPM6 and 
cHK-α along the entire colon supports our hypothesis. The concurring upregulation 
of TRPM6 and cHK-α mRNA expression could represent a compensatory 
mechanism aiming to maintain sufficient Mg2+ absorption by counteracting the 
inhibitory effects of omeprazole on cHK-α-mediated proton secretion and 
TRPM6-mediated Mg2+ absorption. This would explain the lack of an effect of 
omeprazole on serum Mg2+ levels as well as urinary and fecal Mg2+ excretion in 
our mouse model. 
Chapter 3
66
Recently, a mathematical model simulating intestinal Mg2+ absorption has been 
described, aiming to explain PPIH. According to this model, PPI treatment reduces 
Mg2+ absorption, leading to a 5% decrease of serum Mg2+ [37]. In a study with healthy 
volunteers, administration of omeprazole (40 mg) once a day for 7 days reduced 
Mg2+ absorption by 1% [38]. Bai et al. showed that a 1% reduction of Mg2+ absorption 
could lead to an 80% depletion of Mg2+ stores over the course of 1 year. The minute 
changes described might go undetected in clinical practice or experimental 
conditions but could, over longer periods, result in PPIH. This is in line with the fact 
that most PPIH patients described so far are indeed long-term (>1 year) PPI users [5].
Several questions concerning the development of PPIH in human patients remain 
unanswered. The incidence of PPIH is still unknown, although there are 
indications that the case reports only represent the tip of the iceberg [17]. A simple 
explanation may be found in the dietary intake of Mg2+; as the changes in Mg2+ 
absorption due to omeprazole treatment are small, they are easily corrected by a 
higher intake of Mg2+, which could explain why certain patients develop PPIH 
whereas others do not [37]. The low incidence could, however, also indicate that 
patients will only develop PPIH if they are in some way predisposed. For example, 
a recent study shows a strong correlation between PPIH and the combined use of 
PPIs and diuretics [39]. Another possibility, outlined in case reports, is that the 
presence of mutations or single-nucleotide polymorphisms (SNPs) in 
magnesiotropic genes such as TRPM6 contributes to the development PPIH. In a 
single case of PPIH, TRPM6 was sequenced, but no abnormalities were found in 
exonic regions of TRPM6 [8]. Another study excluded the presence of mutations in 
SLC12A3, which is one of the genes involved in Gitelman syndrome [12]. However, 
these individual cases do not exclude the involvement of SNPs in magnesiotropic 
genes, and larger studies are needed in order to confirm or exclude the involvement 
of predisposing factors in the development of PPIH. 
In conclusion, this study provides new insights in the effect of omeprazole on 
Mg2+ homeostasis in an in vivo setting, which could potentially shed light on the 
molecular aspects of the etiology of PPIH. A significant and specific effect of 
omeprazole treatment on TRPM6 and cHK-α mRNA expression levels in the distal 
colon was found, while the serum Mg2+ levels, 24-h urinary Mg2+ excretion as well 
as 24-h fecal Mg2+ excretion were not affected. The stimulation of mRNA levels 
was distinct in the colon, whereas in the kidney, little or no changes occurred. This 
is in line with the clinical findings indicating that PPIH results from reduced 
intestinal Mg2+ absorption and not from renal Mg2+ wasting. Further research, 
both on a clinical as well as a fundamental level, is needed to fully understand 
and prevent PPIH in the near future.
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Abstract 
Calcium (Ca2+) and magnesium (Mg2+) ions are involved in many vital physiological 
functions. Since dietary intake is the only source of minerals for the body, 
intestinal absorption is essential for normal homeostatic levels. The aim of this 
study was to characterize the absorption of Ca2+ as well as Mg2+ along the gastro-
intestinal tract at a molecular, functional and physiological level. The expression 
patterns of transient receptor potential vanilloïd subtype 6 (TRPV6) and transient 
receptor potential melastatin subtype 6 (TRPM6) along the gastrointestinal tract 
of humans as well as mice was determined. A method was established to measure 
the rate of Mg2+ absorption from the intestine using 25Mg2+ in a time-dependent 
manner. In addition, local absorption in different segments of the intestine was 
determined using surgically implanted intestinal cannulas. With these methods, 
the absorption of Ca2+ and Mg2+ in the proximal and distal segments of the 
intestine was determined at different concentrations. In addition, the effect of 
dietary Mg2+ content and vitamin D on intestinal Mg2+ absorption was 
investigated. In humans, TRPV6 is expressed in the proximal intestinal segments 
and TRPM6 in the distal parts of the intestine. In mice, similar expression patterns 
were observed, although both transporters are also expressed in the caecum. 
Intestinal absorption of Mg2+ is regulated by dietary needs in a vitamin 
D-independent manner. In line with the expression patterns of TRPV6 and TRPM6, 
it was shown that transcellular Ca2+ transport mainly takes place in the proximal 
segments of the intestine. On the other hand, transcellular Mg2+ absorption 
predominantly occurs in the distal part of the gastrointestinal tract. Vitamin D 
treatment of mice increased serum Mg2+ levels and 24-hr urinary Mg2+ excretion, 
but not intestinal absorption of 25Mg2+. Further research is necessary to determine 
the exact role of vitamin D on intestinal Mg2+ absorption. Segmental cannulation 
of the intestine and time-dependent absorption studies using 25Mg2+ provide new 
ways to study intestinal Mg2+ absorption. These methods can be used to address 
longstanding scientific questions with regard to the intestinal absorption of Mg2+, 
such as the effect of magnesiotropic hormones.
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Introduction
Calcium (Ca2+) and magnesium (Mg2+) are essential for many physiological 
functions, such as muscle contraction, neuronal excitability, bone formation, and 
enzymatic activity. It is, therefore, of vital importance that the concentration 
throughout the body is tightly regulated. For Ca2+ as well as Mg2+, this regulation 
takes place by the concerted action of the intestine, where these divalents are 
absorbed from our diet, the bones, where Ca2+ and Mg2+ are stored, and the kidneys, 
where they are filtered from the blood and reabsorbed from the pro-urine [1].
Since our dietary intake is the only source of minerals for the body, intestinal 
absorption is of key importance for the maintenance of normal homeostatic levels. 
Intestinal absorption of Ca2+ and Mg2+ can take place via a paracellular and a 
transcellular pathway [2]. Paracellular transport takes place via tight-junctions and 
is driven by the electrochemical gradient across the epithelium. The tran sepithelial 
electrical potential difference is around 5 mV, lumen positive with respect to the 
interstitial compartment [3]. In addition, the luminal concentrations of Ca2+ and 
Mg2+ depend on their dietary contents and are in general sufficient to provide a 
transepithelial chemical concentration gradient which further enhances absorption 
[3]. Transcellular absorption of Ca2+ and Mg2+ from the intestinal lumen is facilitated 
by members of the transient receptor potential (TRP) ion channel family. Intestinal 
absorption of Ca2+ is mediated via TRP vanilloïd type 6 (TRPV6), whereas absorption 
of Mg2+ takes place via TRP melastatin type 6 (TRPM6) [1].  The relative contribution 
of the paracellular and transcellular pathway to the total amount of Ca2+ and Mg2+ 
that is absorbed from the intestine depends on dietary supply and bodily needs [2]. 
Under normal circumstances paracellular absorption seems predominant [3, 4]. 
When paracellular absorption cannot meet the daily need of the body, transcellular 
absorption becomes essential [2, 5]. Specific transport proteins, located in the 
luminal and basolateral membrane of the epithelial cells, govern this latter process 
[3, 6]. Previous studies in mice have shown that TRPV6 is primarily expressed in 
duodenum, caecum and colon, whereas TRPM6 was only found in caecum and 
colon [7]. This finding suggests that transcellular Ca2+ and Mg2+ absorption takes 
place only in distinct segments of the gastrointestinal tract. Functional data 
supporting this hypothesis is, however, lacking. 
The aim of the present study was, therefore, to characterize the absorption of Ca2+ 
and Mg2+ along the gastrointestinal tract at the molecular, functional and 
physiological level. To this end, the expression patterns of TRPV6 and TRPM6 
along the gastrointestinal tract of humans as well as mice were determined. In 
addition, methods were developed to measure the rate of Mg2+ absorption from 
Chapter 4
74
various segments of intestine in a time-dependent manner. To this end, a 
technique was developed to measure local absorption at different segments of the 
intestine using surgically implanted intestinal cannulas. The intestinal 
absorption of Ca2+ was studied with the use of the radioactive 45Ca2+ isotopes. 45Ca2+ 
emits a low energy beta radiation, meaning its use is relatively safe. In addition, 
its long half-life (more than 5 months) allows for accurate and easy quantification 
using a scintillation counter. Although there are ample radioactive Mg2+ isotopes, 
none of them is particularly suitable for absorption studies due to their short 
half-lives, which range from nanoseconds to hours [8]. In addition to the 
radioactive isotopes, three stable Mg2+ isotopes exist. These stable isotopes, i.e. 
24Mg, 25Mg and 26Mg, have a respective natural abundance of 79, 10 and 11% and 
can be distinguished using inductively coupled plasma mass-spectrometry 
(ICP-MS) [9]. Enriched (±99%) preparations of a 25Mg2+ or 26Mg2+ are commercially 
available. The stable isotope technique is based on the measurement of a change 
in the ratio between the three isotopes in a sample of interest, such as urine, blood 
or feces. Absorption of the enriched Mg2+ isotope will change the isotopic ratio 
compared to the normal natural abundance [10]. Both 25Mg2+ and 26Mg2+ have been 
used to study Mg2+ homeostasis in humans as well as in animal models [11, 12]. The 
most commonly used and well-established method to determine Mg2+ absorption 
by stable isotopes techniques is via fecal monitoring [12, 13]. After oral 
administration, excretion of the isotope via the feces is monitored over a certain 
period of time, subsequently, the difference between the amount of isotope that 
was administered and the amount that was excreted via the feces can be used to 
determine how much Mg2+ was absorbed. However, this technique will 
underestimate intestinal absorption since part of the absorbed Mg2+ is secreted 
into the intestinal lumen via for example bile or pancreatic excretions. To correct 
for intestinal secretion, the double labeling technique has been developed [10]. In 
this latter approach, enriched isotopes are administered via two routes: one 
isotope is given orally, while the other one is injected intravenously. Net absorption 
can then be measured by correcting for fecal excretion of the intravenously 
administered isotope. Both the single- and the double labeling technique are 
laborious and, more importantly, neither of the techniques provides detailed 
information on time-dependent absorption kinetics. Thus, in the present study 
stable 25Mg2+ isotopes were employed to measure intestinal Mg2+ absorption in a 
time- and concentration dependent manner. The effect of dietary Mg2+ content on 
intestinal absorption was determined. In addition, with the use of intestinal 
cannulas the absorption of Ca2+ as well as Mg2+ was analyzed at in the proximal 
and distal regions of the gastrointestinal tract, at several concentrations, to 
determine the location of paracellular and transcellular absorption. Finally, the 
effect of vitamin D on Mg2+ homeostasis was analyzed. 
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Materials and methods
Patient selection, sample collection and ethical considerations
For the expression gradients human mucosal gastrointestinal (GI) biopsies were 
obtained from subjects undergoing gastroscopy and/or colonoscopy in the context 
of indefinite gastric or colonic complaints. In more detail, a mucosal biopsy was 
collected from each site, comprising the esophagus, fundus, antrum, duodenum 
(3-5 centimeter beyond the pylorus), terminal ileum, ascending colon, transverse 
colon, descending colon, sigmoid colon and rectum. The jejunum could not be 
reached for sample collection. All biopsies were taken from healthy mucosa. 
Patients were selected during routine patient care in Finland (Tampere University 
Hospital). Exclusion criteria included active hyperparathyroidism, kidney 
insufficiency (serum creatinine >200 umol/L) and liver insufficiency (INR 
spontaneously >1.5). Gastroscopies and colonoscopies were performed during 
routine patient care when needed by clinical diagnosis. The additional biopsy 
samples taken for the study did not increase the complication risk of patients 
significantly. This study was approved by the ethical committee of Tampere 
University Hospital, Finland. Written informed consent was obtained from each 
subject.
Quantitative real-time PCR
Total RNA was extracted from tissues using TRIzolÒ reagent (Invitrogen, Paisly, 
UK) according to the manufacturer’s protocol. The obtained RNA was subjected to 
DNase treatment (Promega, Leiden, The Netherlands) to prevent genomic DNA 
contamination. Subsequently, RNA was reverse transcribed with murine 
leukemia virus reverse transcriptase. The obtained cDNA was used to determine 
mRNA expression levels of various calciotropic and magnesiotropic genes, as well 
as mRNA levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an 
endogenous control. The mRNA expression levels were quantified by real-time 
PCR on a CFX69 real-time detection system (BioRad, Veenendaal, The Netherlands) 
using SYBR Green (BioRad, Veenendaal, The Netherlands). Primers (Biolegio, 
Nijmegen, the Netherlands) were designed with Primer 3 software (Whitehead 
Institute for Biomedical Research, Cambridge, USA) and are listed in Table I.
Animal studies
C57BL/6J mice (8 weeks old) were purchased from Harlan, the Netherlands. For the 
tissue panels, animals were sacrificed by cervical dislocation. Subsequently, 
intestinal segments were isolated, cleaned and snap frozen in liquid nitrogen. For 
all other studies mice were housed in a temperature- and light-controlled room 
with pelleted chow and drinking water available ad libitum. For the diet studies, 
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mice were fed a low Mg2+-deficient diet (0.02% w/w Mg2+) a high Mg2+ diet (0.48% 
w/w Mg2+) or a normal diet (0.25% w/w Mg2+). All diets were purchased from 
SSNIFF Spezialdiäten (SSNIFF Spezialdiäten GmbH, Soest, Germany). For urine 
and feces collection, animals were individually housed in metabolic cages for 24 
h. Blood was sampled from the submandibular facial vein at the end of the stay in 
the metabolic cages, and sera were collected for Mg2+ measurements. For studies 
on vitamin D, animals received daily intraperitoneal injections with 1,25-dihy-
droxyvitamin D3 (100 pg/g bodyweight (BW)/day) or vehicle. All experiments 
were performed in compliance with the animal ethics board of the Radboud 
University Nijmegen (Ethical License number RU-DEC 2010-143, RU-DEC 2010-204, 
RU-DEC 2011-165).
Placement of intestinal cannulas
Cannulas were made using PE50 polyethylene tubing (Instech laboratories, 
Plymouth Meeting, USA), with an inner diameter 0.58 mm and outer diameter of 
0.97 mm. Suture bulbs with a diameter of approximately 2 mm were created on 
the end of pieces of PE tubing using Dow Corning 723 flowable sealant silicone 
elastant (Dow Corning, Midland, USA). Mice were anesthetized using 1 µg/g BW 
medetomidine-hydrochloride (Sedastart, ASTfarma, Oudewater, The Netherlands) 
and 0.08 mg/g body weight (BW) ketamine (Nimatek, Eurovet, Bladel, The 
Netherlands), both administered via subcutaneous injection. The abdominal skin 
Table 1  Primer sequences used for real-time PCR.
Gene Species Forward primer Reverse primer
GAPDH Homo Sapiens 5’-GGAGTCAACGGATTTGGTCGTA-3’ 5’-GGCAACAATATCCACTTTACCAGAGT-3’
TRPV6 Homo Sapiens 5’-GCTTTGCTTCAGCCTTCTATATCAT-3’ 5’-TGGTAAGGAACAGCTCGAAGGT-3’
TRPM6 Homo Sapiens 5’-GCGGACATGGCATAAAATCTTC-3’ 5’-TTGAGCAGCTCTTTGTTGTTGAA-3’
GAPDH Mus musculus 5’-TAACATCAAATGGGGTGAGG-3’ 5’-GGTTCACACCCATCACAAAC-3’
TRPV6 Mus musculus 5’-CTTTGCTTCAGCCTTCTATATCAT-3’ 5’-TGGTAAGGAACAGCTCGAAGGT-3’
TRPM6 Mus musculus 5’-AAAGCCATGCGAGTTATCAGC-3’ 5’-CTTCACAATGAAAACCTGCCC-3’
TRPV5 Mus musculus 5’-CCACAGTGATGCTGGAGAGG-3’ 5’-GGATTCTGCTCCTGGTGGTG-3’
1αOHase Mus musculus 5’-CGGATTGCTAACGGCGGA-3’ 5’-GGCGCCTTAGTCGTCGCA-3’
CLDN2 Mus musculus 5’-TGGTGGGCATGAGATGCA-3’ 5’-CTCCACCCACTACAGCCACTCT-3’
CLDN12 Mus musculus 5’-TCACATTCAACAGAAACGAGAAGAA-3’ 5’-CCATCATACCGGGCACACTT-3’
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TRPV6, transient receptor potential vanilloïd 
type 6; TRPM6, transient receptor potential melastatin type 6; TRPV5, transient receptor potential 
vanilloïd subtype 5, 1αOHase, 1-alpha-hydroxylase; CLDN2, claudin 2, CLDN12, claudin 12. 
4Segmental transport of Ca2+ and Mg2+ along the gastrointestinal tract
77
was opened via a lateral incision, after which the muscle layer was cut along the 
linea alba (Figure 1A). Next, the caecum or stomach was localized, a small hole 
was created, a pouch suture was placed around the hole after which the tip of the 
cannula was inserted into the lumen (Figure 1B-F). The suture was closed around 
the cannula, in-between the suture bulbs, fixing the canule in place. The tubing 
was passed through the muscular layer of the intestinal wall on the lateral side, 
after which the abdominal cavity was closed with a running stitch using Vicryl 
Plus 5.0 sutures (Johnson & Johnson Medical, Amersfoort, The Netherlands) 
(Figure 1G-H). A pocket was created between the muscular layers and the skin. A 
SIP22/4 miniature injection port (Instech laboratories, Plymouth Meeting, USA) 
was attached to the cannula and placed in the subcutaneous pocket on the 
vetrolateral side of the animal (Figure 1I-J). The wound was closed using a running 
stitch and covered with wound clips to prevent post-surgical opening of the 
wound. Medetomidine anesthesia was reversed with a subcutaneous injection of 
1 µg/g BW atipamezolhydrochloride (Sedastop, ASTfarma, Oudewater, The 
Netherlands). The cannula was accessible via the skin and was flushed every 
other day with saline to prevent clogging (Figure 1K). During the first 3 days after 
surgery, animals received 0.05 µg/g BW Buprenorphine hydrochloride (Temgesic, 
Reckitt Benckiser, West Ryde, Australia) twice a day via subcutaneous injection to 
prevent post-operative pain. Animals were allowed to recover for a minimum of 7 
days, before absorption experiments were performed. In general, the mice fully 
recover during this period, as indicated by their return to their pre-operative 
weight (Figure 1M). 
Ca2+ and Mg2+ determinations in serum, urine and feces
Serum and urine total Ca2+ concentrations were measured using a colorimetric 
assay as described previously [14]. Serum and urine Mg2+ concentrations were 
determined using a colorimetric assay kit, according to the manufacturer’s 
protocol (Roche Diagnostics, Woerden, The Netherlands). Within-run precision 
and accuracy was controlled by means of an internal control Precinorm U (Roche 
Diagnostics, Almere, The Netherlands).
In vivo 25Mg2+ absorption assay
Intestinal absorption of Mg2+ was measured by analyzing serum 25Mg2+ levels. In 
short, animals were fasted (food, not water) overnight on wire-mesh raised floors 
to prevent coprophagia. At time-point 0, mice were administered a solution 
containing 44, 10 or 1.8 mM 25Mg2+ (MgO, isotopic enrichment of >98%, CortectNet, 
Voisins-Le-Bretonneux, France), 125 mM NaCl, 17 mM Tris-HCl pH 7.5, 1.8 g/L 
fructose. Animals were administered a volume of 15 mL/g BW via oral gavage or 
via the subcutaneously placed injection ports. Subsequently, blood was 
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Figure 1  Surgical procedure to place intestinal cannulas connected to a 
subcutaneously positioned injection port. For a detailed description see “Placement 
of intestinal cannulas” in the materials and methods section. A. Opening of the 
abdominal cavity. B. Localization of the stomach or duodenum. C. Creating of an 
opening for the insertion of the cannula. D. Placement of a pouch suture around 
the opening. E. Insertion of the cannula in the intestine. F. Tightening the 
pouch-suture around the cannula in between the suture bulbs, fixing the cannula 
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withdrawn at serial time-points via orbital puncture or via a small cut in the tail 
and collected in Microvette serum tubes (Sarstedt, Etten-Leur, The Netherlands). 
After collecting the serum from the coagulated blood samples, samples were 
digested in nitric acid (65% concentrated, Sigma, Zwijndrecht, The Netherlands) 
for 1 hour at 70 ˚C followed by an overnight incubation at room temperature. 
Subsequently, samples were diluted in milliQ and subjected to ICP-MS analysis (X1 
series, Thermo Fisher Scientific, Breda, The Netherlands.
Calculations
The three stable isotopes of Mg2+ have the following natural abundance: 24Mg 
78.9%, 25Mg 10.0%, 26Mg 11.1%. The isotopic ratios at baseline are therefore: 25Mg : 
24Mg = 0.1267 and 26Mg : 24Mg = 0.1407. The percentage of isotopic enrichment in 
the serum, urine and fecal samples was calculated using the following equation: 
(measured 25Mg : 24Mg ratio – baseline 25Mg : 24Mg ratio) / (baseline 25Mg : 24Mg 
ratio) * 100.
In vivo 45Ca2+ absorption assay
Mice were fasted (food, not water) overnight on wire-mesh raised floors to prevent 
coprophagia. At time-point 0, mice were administered a solution containing 0.1, 
10 or 44 mM CaCl2, 125 mM NaCl, 17 mM TrisHCl pH 7.5, 1.8 g/L fructose, enriched 
with 20 mCi 45CaCl2/ml (New England Nuclear, Newton, USA); in a volume of 15 
mL/g of body weight. The solution was administered via the subcutaneously 
placed injection-port. Blood samples were obtained via orbital puncture at serial 
time-points after isotope administration via orbital puncture. Blood was collected 
in Microvette tubes, after clotting serum was removed and serum 45Ca2+ levels 
were analyzed by liquid scintillation counting.  
Statistical analysis
Values are expressed as means ± SEM. Statistical comparisons were analyzed by 
one-way ANOVA with a Bonferroni correction, or using an unpaired Student’s t 
test. Differences between groups were considered to be statistically significant at 
P < 0.05. Statistical analysis was performed using GraphPad Prism (Macintosh 
version, 4.51).
in place. G. The cannula is passed through the muscular layer of the abdomen to 
the lateral side of the mouse. H. The abdominal cavity is closed. I/J. The injection 
port is attached to the cannula and placed in a subcutaneous pocket. K. The 
abdominal skin is closed and the cannula is flushed via the injection port. L. 
Cannula with suture bulbs and injection port. M. Weight development of the mice 
throughout experiments (n=81).
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Results
TRPV6 and TRPM6 expression along the gastrointestinal tract in humans  
and mice
In the human gastrointestinal tract, TRPV6 is expressed predominantly in the 
stomach and duodenum (Figure 2A). Along the murine gastrointestinal tract, the 
expression pattern of TRPV6 is slightly different. In addition to the expression in 
the stomach and the duodenum, TRPV6 is also strongly expressed in the caecum 
as well as in the distal regions of the colon (Figure 2B). TRPM6 is expressed in the 
distal regions of the gastrointestinal tract of human subjects and mice (Figure 
2C-D). Interestingly, like TRPV6, TRPM6 in mice is expressed strongly in the 
caecum (Figure 2D). 
Figure 2 Localization of TRPM6 and TRPV6 along the gastrointestinal tract in 
humans and mice. Total gastrointestinal mRNA expression of TRPV6 (A/B) and 
TRPM6 (C/D) corrected for GAPDH expression, in human (A/C) and murine (B/D) 
samples (n=5). Data is expressed as a percentage of total gastrointestinal (GI) 
expression and presented as means ± SEM. ND, not determined.
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Time dependent absorption of 25Mg2+ after administration via oral gavage
To determine the sensitivity of our measurements in various types of samples, 
mice were given 25Mg2+ (0.7 mmol/g BW) via oral gavage and placed in a metabolic 
cage for urine and feces collection, in addition, blood was collected.  After 24 hrs, 
high levels of enrichment of 25Mg2+ were found in both the urine and the feces, 
while in serum the enrichment was lower (Figure 3A). To determine the time 
dependence of 25Mg2+ absorption from the intestine mice were given (0.7 mmol/g 
BW) 25Mg2+ via oral gavage. Subsequently, blood was collected at serial time-points 
(Figure 3B). 25Mg2+ was absorbed in a time-dependent manner, and reached a 
plateau-phase after approximately 2 hrs. 
Proximal intestinal Mg2+ absorption is regulated by bodily needs
To investigate whether Mg2+ absorption, like Ca2+ absorption, is regulated by 
bodily needs, mice were fed a diet with a low (0.02% wt/wt Mg2+), a normal (0.25% 
wt/wt Mg2+) or a high (0.48% wt/wt Mg2+) Mg2+ content for 2 weeks.  After this 
period, the mice on the low Mg2+ diet had significantly lower serum Mg2+ levels 
compared to the group on the normal diet (Figure 4A). In addition, urinary Mg2+ 
excretion was diminished and fecal Mg2+ excretion was decreased  (Figure 4B/C). 
Serum Mg2+ levels in mice receiving the high Mg2+ diet were not significantly 
different from the group on the normal diet (Figure 4A). Urinary and fecal Mg2+ 
excretion, however, were both significantly increased (Figure 4B/C). Interestingly, 
urinary excretion of Ca2+ was significantly decreased in the group receiving the 
Figure 3  Time-dependent absorption of 25Mg2+. A. Measurement of 25Mg2+ in serum, 
urine and feces 24 hrs after administration of 0.7 mmol 25Mg2+/g BW via oral gavage 
(n=2). B. Absorption of 25Mg2+ from the intestine after administration via oral 
gavage (n=5). Data are presented as means ± SEM.
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low Mg2+ diet, and significantly increased in the group receiving the high Mg2+ 
diet (Figure 4E). Serum Ca2+ levels and fecal Ca2+ excretion remained unchanged 
(Figure 4D/F).
Paracellular and transcellular absorption of Mg2+ in intestinal segments
To investigate the mineral absorption specifically in the proximal and distal 
intestinal segments, cannulas were surgically implanted in either the stomach or 
the caecum of mice. Subsequently, absorption of 45Ca2+ or 25Mg2+ was measured as 
a function of the luminal mineral concentration to distinguish between 
paracellular and transcellular transport. The Ca2+ absorption in the proximal 
Figure 4  Effect of dietary Mg2+ on Intestinal Mg2+ absorption. A. Serum Mg2+ values 
of mice two weeks on diet with a low (0.02 % wt/wt Mg2+), a normal (0.25 % wt/
wt Mg2+) or a high (0.48 % wt/wt Mg2+) Mg2+ content (n=5 for each group). B. 
Urinary Mg2+ excretion C. Fecal Mg2+ excretion. D. Serum Ca2+ levels. E. Urinary 
Mg2+ excretion. F. Fecal Mg2+ excretion. G. Intestinal absorption of 25Mg2+, low- 
normal- and high Mg2+ diet groups are represented by dotted, filled and dashed 
lines, respectively. H. Average difference in intestinal absorption of 25Mg2+ during 
four hours after isotope administration. I. TRPM6 mRNA expression levels in the 
colon, corrected for GAPDH expression and normalized to the normal Mg2+ diet 
group J. 1αOHase mRNA expression levels in the kidney, corrected for GAPDH 
expression and normalized to the normal Mg2+ diet group. Data are presented as 
means ± SEM. * P < 0.05 compared to normal Mg2+ diet. Lo
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intestine was significantly higher compared to the more distal part at all luminal 
concentrations of Ca2+ tested (44, 10 and 0.1 mM), (Figure 5B/D/F). The proximal 
Mg2+ absorption was higher compared to the distal intestine at a high luminal 
concentration of Mg2+ (44 mM) (Figure 5A), but not at lower luminal concentrations 
(10 and 1.6 mM Mg2+) (Figure 5C/E). The relationship between the absorption of 
25Mg2+ and the luminal Mg2+ concentration is displayed in figure 5G. In the 
proximal intestine, the absorption of 25Mg2+ is linearly related to the buffer Mg2+ 
concentration, whereas in the distal intestine the absorption of Mg2+ is saturable 
at higher Mg2+ concentrations. The relation between 45Ca2+ absorption and luminal 
Ca2+ concentration is comparable in the proximal and distal intestine, and consists 
of a saturable and a non-saturable, linear component (Figure 5H).
The effect of vitamin D on Mg2+ homeostasis
To determine whether vitamin D has an effect on Mg2+ homeostasis in general 
and more specifically on intestinal Mg2+ absorption, mice were treated with 
1,25-dihydroxyvitamin D3 (100 pg/g BW/day) for 7 days and subsequently the 
intestinal absorption of 25Mg2+ was measured. Vitamin D treatment significantly 
increased serum Mg2+ and Ca2+ levels as well as 24 hr urinary Mg2+ and Ca2+ 
Figure 4 continued.
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Figure 5  Paracellular and transcellular absorption of Mg2+ in intestinal segments. 
Solid lines represent mice with a cannula placed in the stomach, dashed lines 
represent mice with a cannula placed in the caecum. 25Mg2+ absorption using a 
buffer containing A. 44 mM, C. 10 mM, or E. 1.6 mM Mg2+. 45Ca2+ absorption using a 
buffer containing B. 44 mM, D. 10 mM, or F. 0.1 mM. G. Relationship between luminal 
Mg2+ concentration and 25Mg2+ absorption, and H. between luminal Ca2+ concentration 
and 45Ca2+ absorption at t=30 minutes. Data are presented as means ± SEM, n=4-6. * 
P < 0.05 compared to the group with cannula placed in the stomach.
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excretion (Figure 6A-D). Importantly, the Mg2+ absorption in the proximal was not 
significantly different between vehicle and vitamin D-treated mice (Figure 6E).
Figure 6  The effect of vitamin D on Mg2+ homeostasis. Mice were treated with 
vehicle (control) or 1,25-dihydroxyvitamin D3 (100 pg/g BW/day) for 7 days A. 
Serum Ca2+ levels in controls and vitamin D-treated mice B. 24 hr urinary Ca2+ 
excretion C. Serum Mg2+ levels D. 24 hr urinary Mg2+ excretion E. Intestinal 25Mg2+ 
absorption in control (solid line) and vitamin D (dashed line) treated mice. Data 
are presented as means ± SEM, n=5-7. * P < 0.05 compared to vehicle-treated 
controls.
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Figure 7  Expression of calciotropic genes, but not TRPM6, is regulated by vitamin 
D-treatment. mRNA expression levels of various calciotropic and magnesiotropic 
genes were determined in vehicle- treated controls and 1,25-dihydroxyvitamin 
D3-treated mice. All values were corrected for GAPDH expression and were normalized 
to controls. A. TRPV6 and B. TRPM6 mRNA expression in colon. C. TRPV6, D. CLDN2, 
and E. CLDN12 mRNA expression in duodenum. F. 1αOHase, G. TRPV5 and H. TRPM6 
mRNA expression in kidney. Data are presented as means ± SEM n=5-7. * P < 0.05 
compared to vehicle-treated controls.
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Effect of vitamin D on intestinal Mg2+ absorption
The mRNA expression levels of TRPV6 in duodenum (Figure 7C) as well as the 
colon (Figure 7A) of vitamin D-treated mice were significantly increased compared 
to vehicle-treated controls. TRPM6 expression in the colon, however, remained 
unchanged (Figure 7B). The duodenal expression levels of CLDN2 and CLDN12 
were analyzed to determine the effect of vitamin D on paracellular mineral 
transport. No significant differences in the expression levels were observed 
between vitamin D-treated mice and controls (Figure 7 D/E). In kidney, 1aOHase 
expression was significantly decreased in the vitamin D-treated group, indicating 
appropriate suppression of vitamin D synthesis by vitamin D treatment (Figure 
7F). The renal TRPV5 expression of vitamin D-treated mice was significantly 
augmented compared to controls, while no changes were observed in renal TRPM6 
expression between both groups. 
Discussion
Compared to Ca2+, little is known about Mg2+ absorption in the intestine, including 
hormones regulating this process. The aim of this study was, therefore, to 
investigate the absorption of Mg2+ along the gastrointestinal tract on a molecular, 
a functional and a physiological level. Our findings indicate that: i) mRNA 
expression of TRPV6 is predominant in the proximal part of the human gastroin-
testinal tract, whereas TRPM6 is mainly expressed in the distal segments; ii) in 
the murine gastrointestinal tract expression patterns of TRPV6 and TRPM6 are 
similar to those observed in humans. In addition, TRPV6 and TRPM6 are both 
highly expressed in the caecum and TRPV6 is also present in the distal segments; 
iii) Ca2+ is predominantly absorbed in the proximal parts of the intestine, 
irrespective of its luminal concentration; iv) only at high luminal concentrations, 
Mg2+ is predominantly absorbed in the proximal parts of the intestine, compared 
to the distal intestinal segments.
The epithelial divalent channels, TRPV6 and TRPM6, form the gate-keepers of Ca2+ 
and Mg2+ absorption, respectively, along the gastrointestinal tract [15]. In humans, 
TRPV6 is expressed predominantly in the stomach and duodenum, whereas 
TRPM6 is mainly expressed in the ileum and colon. In mice, TRPV6 was also 
expressed in caecum and distal segments of the colon, while TRPM6 was in 
addition to ileum and colon also abundantly detected in caecum. The discrepancy 
between the expression patterns of these TRP’s in human and mice might be 
explained by the morphological and functional differences between their gastro-
intestinal tracts. Mice are non-ruminant herbivores that have a large caecum 
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compared to humans [16]. Their caecum houses many types of micro-organisms, 
which aid in the digestion of plant material by breaking down cellulose [17]. Plant 
material is an important source of Ca2+ and Mg2+, which is only released if cellulose 
is digested. Since the digestion of cellulose takes place in the caecum of mice, 
these nutrients are released from the plant material in the more distal segments 
of the intestine. 
Intestinal absorption of Ca2+ is strictly regulated by bodily need; increased when 
dietary Ca2+ supply is limited and decreased when Ca2+ is abundantly available 
[18]. To determine whether the same holds true in case of Mg2+, the effect of dietary 
Mg2+ supply on intestinal absorption of Mg2+ was investigated. A low Mg2+ diet 
effectively induced a hypomagnesemia and urinary Mg2+ conservation. 
Conversely, enhanced renal Mg2+ excretion indicated that the high Mg2+ diet 
resulted in a surplus of Mg2+ in the body. Absorption of 25Mg2+ was significantly 
increased in mice receiving the low Mg2+ diet, whereas Mg2+ absorption in the 
high Mg2+ diet group was reduced. This indicates that the rate of Mg2+ absorption, 
like for Ca2+, nicely follows the dietary body needs. These alterations in Mg2+ 
absorption were accompanied by a slight, but significant, effect on the expression 
of TRPM6 in the mice on the low Mg2+ diet but not the high Mg2+ diet. This could be 
explained by the fact that the adaptation in Mg2+ was relatively mild. This findings 
contrast mice challenged with a Ca2+ deficient diet who showed a strong increase 
in intestinal Ca2+ transport, which was facilitated by the increased expression of 
proteins involved in Ca2+ transport, including TRPV6 [18, 19]. Renal expression of 
1αOHase, the enzyme responsible for the production of active vitamin D, was 
unchanged during the various dietary Mg2+ regimes. This suggests that the 
process of intestinal Mg2+ absorption is vitamin D-independent. Alternatively, 
new magnesiotropic hormones, including the epidermal growth factor (EGF) and 
insulin, have been identified and shown to regulate Mg2+ reabsorption via TRPM6 
in the kidney [20, 21]. These hormones could potentially play a role in the regulation 
of intestinal Mg2+ absorption. Another possible player is the Ca2+-sensing receptor 
(CaSR), which senses the extracellular concentration of both Ca2+ and Mg2+ to 
control for instance, TRPV5 activity [22]. Interestingly, the dietary Mg2+ content 
also affected renal excretion of Ca2+. The coupling between the Ca2+ and Mg2+ 
balance has previously been observed [7, 23], but the underlying mechanism 
remains under debate [23-26]. 
Paracellular absorption of Ca2+ and Mg2+ mainly takes place in the duodenum and 
jejunum. Based on the expression patterns of TRPV6 and TRPM6 observed in the 
gastrointestinal tracts of humans and mice, we hypothesized that transcellular 
Ca2+ absorption mainly takes place in the proximal parts of the intestine and 
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potentially also in the caecum and distal part of the colon in mice, whereas 
transcellular Mg2+ absorption is restricted to the distal parts of the gastrointesti-
nal tract. To address this hypothesis with functional measurements, intestinal 
cannulas were placed in either the stomach or the caecum of mice, to allow local 
in vivo measurements of mineral absorption. Indeed, Ca2+ absorption in the 
proximal intestine was significantly higher compared to the more distal parts at 
all luminal concentrations of Ca2+ that were tested. Mg2+ absorption on the other 
hand was higher compared to the distal part of the intestine at a high luminal 
concentration of Mg2+, but not at lower luminal concentrations. Absorption of Ca2+ 
in both the proximal and distal intestine consisted of two components; a 
nonsaturable, linear component, representing transport via the paracellular 
route, and a saturable component, corresponding to transport via the transcellular 
pathway. In contrast, absorption of 25Mg2+ in the proximal intestine was linearly 
correlated to the Mg2+ concentration of the uptake-buffer, indicating that the 
absorption takes place solely via the paracellular route. In the distal intestine on 
the other hand, absorption of Mg2+ shows a curve consisting of both a linear and a 
saturable component, suggesting a combination of paracellular and transcellular 
absorption in this location. This is in line with the observed expression patterns of 
TRPV6 and TRPM6. These measurements indicate that transcellular intestinal 
absorption of Ca2+ and Mg2+ takes place at distinct locations along the gastrointes-
tinal tract. Interestingly, at low luminal Ca2+ concentrations, the absorption of 
Ca2+ is approximately twice as high in the proximal intestine as in the distal part 
of the intestine. This is perfectly in line with the expression of TRPV6, which is 
almost twice as high in duodenum as in caecum of mice.
The observed expression patterns of TRPV6 and TRPM6 and the corresponding 
absorption of Ca2+ and Mg2+ is in line with clinical findings in patients that have 
undergone gastrointestinal resections of either the small or the large intestine. 
Patients that have small bowel resections often suffer from Ca2+ deficits due to 
reduced Ca2+ absorption [27]. Similarly, patients with Crohn’s disease, mainly 
affecting the small intestine, are also known to have reduced serum Ca2+ levels 
[28]. Patients that have undergone large bowel resections on the other hand are 
more likely to display reduced serum Mg2+ levels [29-31]. The physiological reason 
for the spatial separation of Ca2+ and Mg2+ absorption remains to be determined. 
The stable isotope technique was successfully applied to measure time-dependent 
absorption of Mg2+ in the intestine. Since the measurements were performed in a 
relatively short time-scale, there was no need to correct for intestinal secretion or 
renal excretion. Double–labeling, which is the most commonly applied technique 
in fecal monitoring studies with isotope tracers, was, therefore, not applied. Thus, 
our method is more easily applicable and less costly [10]. The major limitation of 
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the present analysis is the reduced sensitivity because the relatively high natural 
abundance of 25Mg2+ limits the reliability at low luminal concentrations. 
Due to the similarities between Ca2+ and Mg2+ homeostasis, the calciotropic 
hormone vitamin D has often been suggested to play a role in Mg2+ handling [32]. 
To examine the effect of vitamin D on Mg2+ homeostasis, mice were treated with 
1,25-dihydroxyvitamin D3 for a week [32]. Vitamin D treatment increased serum 
Ca2+ levels as well as urinary Ca2+ excretion. Interestingly, serum Mg2+ levels and 
24-hr urinary Mg2+ excretion were also significantly higher compared to controls, 
suggesting that intestinal absorption of Mg2+ was increased. However, changes in 
intestinal absorption were not detected using the 25Mg2+ absorption assay. In order 
to gain more insight in the underlying molecular processes, mRNA expression 
levels or various genes were determined in duodenum, colon and kidney of the 
vehicle treated controls and vitamin D-treated mice. The expression of TRPV6 and 
TRPV5 in the intestine and kidney, respectively, were elevated in vitamin D-treated 
mice. TRPM6 expression, however, was unchanged both in colon and kidney, 
indicating that vitamin D does not affect transcellular absorption via TRPM6 at 
the transcriptional level. Vitamin D could also have an effect on paracellular 
transport of Ca2+ and Mg2+. CLDN2 and CLDN12 are tight-junction proteins that 
have been suggested to play a role in paracellular absorption of Ca2+ in the 
intestine [33]. Their expression levels in the duodenum were however unchanged 
by vitamin D treatment in our study. Therefore, it is unlikely that they contributed 
to changes in intestinal Mg2+ absorption. So, despite the changes in serum Mg2+ 
levels and urinary Mg2+ excretion, no functional or molecular evidence was found 
that vitamin D affects intestinal Mg2+ absorption. High urinary Ca2+ levels may 
affect renal Mg2+ handling, explaining the hypermagnesiuria but not the 
observed hypermagnesemia [34, 35]. Alternatively, vitamin D induced 
mobilization of Mg2+ from bone could provide an alternative explanation for the 
increased serum Mg2+ levels and urinary Mg2+ excretion in vitamin D-treated 
animals [36]. Although Mg2+ homeostasis can be influenced by vitamin D in phar-
macological doses, which is in line with previous findings, vitamin D seems to 
have no effect on Mg2+ homeostasis in the normal physiological range [32]. Indeed, 
1αOHase knockout mice and klotho knockout mice, which are vitamin D deficient 
or display hypervitaminosis D, respectively, both have normal serum Mg2+ levels, 
urinary Mg2+ excretion and renal TRPM6 expression levels [7, 37]. 
In conclusion, transcellular Ca2+ and Mg2+ absorption in the intestine is spatially 
separated, as shown by 45Ca2+ and 25Mg2+ absorption studies. In addition, absorption 
of Mg2+ from the intestinal lumen is regulated by dietary supply. Further research 
is necessary to clarify the exact role of vitamin D in Mg2+ homeostasis. With the 
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use of 25Mg2+ assays, this and many other scientific questions with regard to the 
absorption of Mg2+ can be addressed.
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Abstract
Claudins, being part of the tight junction protein family, partially determine the 
integrity and paracellular permeability of the intestinal epithelium. The aim of 
this study was twofold. First, we set out to create an overview of claudin mRNA 
expression along the proximal-distal axis of the healthy human intestine.  Second, 
we aimed to analyze expression levels of claudins in patients with active and 
inactive inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) or 
ulcerative colitis (UC).
 Claudins show distinct expression patterns throughout the gastrointestinal 
tract. Some claudins show a proximal expression pattern, such as CLDN18 which 
is solely expressed in the stomach, and CLDN2 and -15 that are predominantly 
expressed in the proximal parts of the gastrointestinal tract. Other claudins such 
as CLDN3, -4, -7 and -8 are predominantly expressed in the distal parts of the gas-
trointestinal tract, or show a ubiquitous expression pattern throughout the entire 
gastrointestinal tract, which is the case for CLDN12. In addition, we show that 
changes in claudin expression in IBD are dependent on gastrointestinal location 
and inflammatory activity.
 This study provides detailed mRNA expression patterns of various claudins 
throughout the human gastrointestinal tract. Analysis of expression levels of 
claudins in patients with CD, active- and inactive UC shows that changes in 
expression are confined to specific intestinal segments, and strongly depend on 
inflammatory activity.
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Introduction
The intestinal epithelium forms the largest surface area and most important 
barrier between the internal and external environment of the body. For its 
integrity, the intestinal epithelium depends on three components: desmosomes, 
adherens junctions and tight junctions [1]. Tight junctions between epithelial 
cells play a dual role. First, they ensure cell polarity by inhibiting diffusion of 
membrane proteins from the apical to the basolateral side and vice versa. Second, 
they function as a gateway, determining the permeability of the epithelial cell 
layer via the paracellular pathway [1]. To this end epithelial cells are connected by 
tight junction strands. To date, several proteins have been identified within these 
tight junction strands, including occludin, claudins, tricellulin and marvel3D [2]. 
Consisting of a large family that comprises more than 24 isoforms, claudins have 
been shown to determine membrane integrity and form pore-like structures, 
which are responsible for size and charge selectivity of paracellular transport via 
tight junctions in a large variety of epithelia [3]. The different isoforms exhibit 
distinct tissue-, cell-, developmental stage-, and disease-specific expression 
patterns [4, 5]. 
 Several studies have set out to determine the expression patterns of claudins 
in the intestine of mice or rats, showing expression of CLDN1, -2, -3, -4, -5, -7, -8, -12, 
-15, and -18. CLDN6, -9, -10, -11, -13, -14, -16, -17, and -19 were not detected in these 
studies [4, 6, 7]. In human intestine, however, expression of various claudins is 
less well established. Experimental data showing expression patterns throughout 
the human gastrointestinal tract is lacking.
 In active inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) or 
ulcerative colitis (UC), a perturbed expression of tight junction proteins is a typical 
feature [8]. In accordance with this, IBD patients with inflamed gut epithelium 
may present with electrolyte disturbances [9]. Here, the pathophysiological 
relevance of claudins comes into play as changes in claudin expression influence 
epithelial integrity, thereby potentially leading to altered electrolyte absorption 
via tight junctions.
 The aim of this study was twofold. First, we set out to create an overview of 
claudin mRNA expression along the proximal-distal axis of the healthy human 
intestine.  Second, we aimed to analyze expression levels of claudin isoforms in 
patients with CD, active- and inactive UC to identify changes in expression that 
might explain the changes in epithelial integrity and electrolyte absorption.
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Materials and Methods
Patient selection, serum and urine biochemistry
Patients were all selected during routine patient care in Finland (Tampere 
University Hospital). Included patients were undergoing coloscopy, gastroscopy 
or pouch/ileoscopy for medical indications. Diagnosis was confirmed based on 
both macro- and microscopical findings. Exclusion criteria included active hyper-
parathyroidism, kidney insufficiency (serum creatinine >200umol/L) and liver 
insufficiency (INR spontaneously >1.5). Biochemical analysis of blood and urine 
was routinely performed using standard techniques at the Laboratory Centre of 
the Pirkanmaa Hospital District, Finland. Three patients with active ulcerating 
colitis were unable to give urine samples because of diarrhea.
 For the expression gradient study seven patients (2 males) with mean age 57 
years (range 44-70) underwent gastroscopy and seven patients (2 males) with 
mean age 58 years (range 45-74) colonoscopy. Indications for gastroscopy were 
anemia, reflux, abdominal pain, Barrett’s esophagus (n=2) and melena (n=2). 
Macroscopic findings included four normal, one Barrett’s esophagus, one small 
ventricular ulcus and one patient had small erosions in duodenal bulbus. Of mac-
roscopically normal gastroscopies two had helicobacter gastritis and one had 
Barrett’s changes. Colonoscopies were done because of diarrhea (n=1), constipation 
(n=2), control of polypectomy (n=3) and control of inactive ulcerating proctitis 
(n=1). Three colonoscopy results were macro- and microscopically normal, 4 
benign polyps were found in three patients, and the patient with previous 
proctitis had no inflammation with slightly atrophic sigmoid colon.
 To investigate claudin expression in various patient groups human sigmoid 
and ileal biopsies were obtained from 27 patients (15 females, 12 males). Mean age 
was 41 years (range 18-73). CD and UC patients had mean disease history of 11 
years (range 0-32). Four patients with CD had ileocolonic and 3 isolated colonic 
disease. Corticosteroid treatment was given to four patients with active UC 
(prednisolone 20 and 40 mg/day or intravenous methylprednisolone 60 mg/day), 
and one patient with inactive UC (prednisolone 20 mg started 6 weeks earlier for 
active disease). Mesalazine was used by 14 (median dose 2400 mg/day, range 
1600-3200 mg), sulfasalazine by 2 (range 1000-1500 mg/day), azathioprine by 7 
(median dose 150 mg/day, range 100-150 mg), and methotrexate by 3 patients 
(median dose 15 mg/week, range 15-20 mg/week). After colonoscopy three patients 
with active CD and six with active UC had their IBD medication increased. 
Sample collection
For the expression gradients human mucosal gastrointestinal (GI) biopsies were 
obtained from subjects undergoing gastroscopy and/or colonoscopy in the context 
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of indefinite gastric or colonic complaints. In more detail, a mucosal biopsy was 
collected from each site, comprising the esophagus, fundus, antrum, duodenum 
(3-5 centimeter beyond the pylorus), terminal ileum, ascending colon, transverse 
colon, descending colon, sigmoid colon and rectum. The jejunum could not be 
reached for sample collection. All biopsies were taken from healthy mucosa. 
 The samples used to determine expression during IBD were taken during 
colonoscopy or pouch/ileoscopy. Biopsies for analyses of claudin expression were 
taken from macroscopically not inflamed terminal ileum and sigmoid colon or if 
inflammation was present from an area least inflamed and not from an area of an 
ulcer or spontaneous bleeding. Biopsies for diagnostic purposes were taken 
according to clinical decision of the gastroenterologist not always coinciding 
with study biopsies. Small bowel biopsy samples were taken in the terminal 
ileum. Colon biopsy samples were taken above the rectosigmoid junction when 
the colonoscope was ~30 centimeters ab ano. In patients with active UC or CD 
additional biopsy samples were taken from any part of colon: approximately 5 cm 
off from macroscopically healthy-inflamed margin to healthy side and to inflamed 
side. Tissue specimens were immediately snap-frozen in liquid nitrogen, to 
prevent mRNA degradation, and subsequently stored at -80°C. 
Macro- and microscopic findings in colonoscopy
Control patients and inactive UC group had no macroscopic or microscopic 
inflammation. Five CD patients had slight macro- and/or microscopic 
inflammation in some part of colon, one macroscopically but not microscopically 
in ileum, and five macroscopically of whom three microscopically in sigmoid 
colon. All patients in active UC group had macro- and/or microscopic inflammation 
in some part of colon, two mild and five moderate to severe; none had inflammation 
in ileum, and in sigmoid colon one had mild and three moderate to severe 
macroscopic inflammation and microscopically two had mild and four had 
moderate to severe inflammation.
Quantitative real-time PCR analysis
Real-time analysis was performed according to MIQE guidelines [10]. In short, 
total RNA was extracted from intestinal mucosal biopsies using Trizol Total RNA 
Isolation Reagent (Life Technologies BRL, Breda, The Netherlands) according to 
manufacturers protocol. Obtained RNA was subjected to DNAse treatment (RQ1 
RNase-free DNase, Promega, Madison, WI, USA) according to manufacturers 
protocol to prevent genomic DNA contamination. Quantity and quality of RNA 
was assessed by spectrophotometry on a Nanodrop 2000c spectrophotometer 
(Thermo Fisher Scientific, USA). Thereafter, 1.5 µg of RNA was reverse transcribed 
by Moloney-murine leukemia virus-reverse transcriptase (Life Technologies BRL), 
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an rt- sample (not containing reverse transcriptase) as well as a no-template 
control (not containing RNA) were included. The obtained cDNA was analyzed to 
determine mRNA levels of CLDN2, -3, -4, -7, -8, -12, -15, -18. The final volume of each 
reaction was 12,5 ul, consisting of 2,5 ul (5ng/ul) cDNA and 10 ul SybrGreen PCR 
master mix (Applied Biosystems, Foster City, CA, USA). Primers were designed 
with Primer 3 software (Whitehead Institute for Biomedical Research), and have a 
95-105% amplification efficiency. Where possible, exon-spanning primers were 
used for amplification (Table 1). Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) mRNA levels served as endogenous control for expression levels. 
Quantitative real-time PCR analysis was performed on an iQ5 iCycler Detection 
System (Bio-rad, Hercules, CA, USA). For figure 1, total GI expression was 
determined in the following way: For each segment the average relative 
expression was determined based on the delta Ct method using GAPDH as a 
reference gene. The total expression level of all segments was set to 100%, and the 
expression level of each segment is expressed as a percentage of this 100%. For 
figure 2 and 3, data is plotted in arbitrary units (AU), representing mRNA 
expression levels after correction with GAPDH and normalization to the control 
group.
Table 1  Primer sequences for SybrGreen real-time PCR
Gene Accession Forward primer (5’-3’) Reverse primer (5’-3’) Product 
size (bp)
GAPDH NM_002046.3 GTCGGAGTCAACGGATTTGG GGCAACAATATCCACTTTACCA-
GAGT
78
CLDN2 NM_020384.3 CTCCTGGGATTCATTCCTGTTG TCAGGCACCAGTGGTGAGTAGA 74
CLDN3 NM_001306.3 CCACGCGAGAAGAAGTACAC GTAGTCCTTGCGGTCGTAGC 102
CLDN4 NM_001305.3 GGCTGCTTTGCTGCAACTG AGAGCGGGCAGCAGAATACTT 71
CLDN7 NM_001307.5 ATCCCTACCAACATTAAGTAT-
GAGTTTG
TGCACCTCCCAGGATGACTAG 84
CLDN8 NM_199328.2 TGCTGACGGCTGGAATCAT ATTGGCAACCCAGCTCACA 71
CLDN12 NM_012129.4 CCTTTCCTTCCTGTGTGGAATC AATTTTCTCCAGTTGGGAAGCA 75
CLDN15 NM_014343.2 TCCACATTCTGGCCGGTATC GAAGTCCCGGGTGATGTTGA 71
CLDN18 NM_016369.3 TCATGTTCATTGTCTCAG-
GTCTTTG
ACATCCAGAAGTTAGTCACCAG-
CAT
81
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Statistical analysis
Data is expressed as either mean ± SEM, or as box-plots. Data were statistically 
analyzed using SPSS statistics software (version 19) for Macintosh computers. A 
Levene test for Equality of Variance was used to assess equality of variance. 
Groups were compared using one-way ANOVA, followed by a Dunnett or a 
Dunnett T3 correction Post-test depending on the outcome of the Levene test.
Ethical considerations
Colonoscopies were performed during routine patient care when needed by 
clinical judgement. The additional biopsy samples taken for the study did not 
increase the complication risk of patients significantly. This study was approved 
by the ethical committee of Tampere University Hospital, Finland. Written 
informed consent was obtained from each subject.
Results
Profiling of claudin mRNA expression throughout the gastrointestinal tract
Real-time PCR analysis was performed to examine the expression patterns of 
claudins along the proximal-distal axis of the human intestine. Individual 
claudin show specific localization patterns in the GI tract, which vary strongly 
between the different isoforms (Figure 1). CLDN2 is mainly expressed in the 
proximal intestine and in the antrum, with less than 10% of total expression 
found beyond the ileum. Expression patterns of CLDN3 and -4 are almost identical, 
with approximately 90% of total mRNA expression located throughout the colon 
and rectum. CLDN7 expression resembles that of CLDN3 and -4, with predominant 
expression in the colon, sigmoid and rectum, and little expression in the 
esophagus, gastric region and proximal parts of the GI tract. CLDN8 shows a 
gradually increasing expression along the colon towards the rectum. CLDN12 is 
evenly expressed in the entire GI tract with exception of the esophagus. CLDN15 
expression is confined predominantly to the duodenum and ileum where over 
75% of its expression was found. CLDN18 was detected solely in the stomach.
Claudin expression in IBD
To evaluate whether claudin abundance is changed by either active or inactive 
IBD, mRNA expression levels of claudin isoforms were determined in several 
intestinal segments in various IBD patient groups and controls. We analyzed the 
expression of CLDN2, CLDN12, CLDN3 and CLDN4 in the ileum and sigmoid colon of 
control subjects compared to patients with CD, active UC, and inactive UC (Figure 2). 
In the ileum, CLDN2 expression was unchanged in IBD patient groups compared 
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Figure 1  mRNA expression patterns of claudins along the human gastrointestinal 
tract. Claudins show specific localization patterns throughout the gastrointestinal 
tracts, varying strongly between the different isoforms. Results, corrected for 
GAPDH mRNA expression levels, are expressed as a percentage of total GI 
expression (mean ± SEM), ND; not determined. 
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Figure 2  Expression of CLDN2, CLDN12, CLDN3 and CLDN4 in the ileum and sigmoid 
colon.  mRNA expression of CLDN2, -12, -3 and -4 in the ileum (A-D) and sigmoid 
colon (E-H) of controls and IBD groups. Data is plotted in arbitrary units (AU), 
representing mRNA expression levels after correction with GAPDH and 
normalization with the control group. Results are expressed as Wiskers plots box 
showing the 5-95 percentile, lower quartile, median and upper quartile, significance 
was accepted at P<0.05. 
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to control subjects (Table 2) although some outliers, in whom expression was 
increased, were observed in the group of CD patients. CLDN12 mRNA expression 
was significantly upregulated in the ileum of CD patients (1.0 ±0.2 vs 1.8 ±0.4 AU, 
p<0.02), no changes were found between controls and UC patients. CDLN3 
expression in the ileum was highly variable between individuals, both in the 
control group and in the IBD groups, consequently no differences in expression 
were observed between the groups. No significant changes were found in CLDN4 
expression in the ileum. Interestingly, variance in the IBD groups compared to 
controls is significantly increased in all groups for both CLDN12 and CLDN4. 
 In the sigmoid colon (Figure 2), CLDN2 expression was significantly reduced 
by 5-fold in CD patients compared to controls (1.0 ±0.4 vs 0.2 ±0.1 AU, p=0.01). In 
addition, there is a trend towards increased expression in patients suffering from 
active UC. CLDN12 expression in the sigmoid colon was slightly decreased in CD 
patients (1.0 ± 0.2 vs 0.6 ± 0.2 AU, p=0.05). In the UC patient groups, no significant 
changes were found. Similar to the ileum, sigmoid colon expression of CLDN3 is 
highly variable, with no significant differences between the control subjects and 
subjects from any of the IBD groups. CLDN4 expression remains unchanged in IBD 
groups versus controls. In the sigmoid, significant differences between controls 
and IBD groups were found for CLD2, -4 and -12. Most notable is the increased 
variance in CLDN2 expression in active UC patients and in CLDN12 in all UC 
patients. 
 In the colon (Figure 3), expression of claudins was determined in biopsies 
taken from unaffected tissue and from inflammatory active areas as judged 
macro scopically. CLDN2 expression remains unchanged in CD, in UC patients 
there is a tendency towards increased expression (1.0 ± 0.4 vs 4.7 ±4.7 AU, p=0.24). 
CLDN12 is significantly downregulated (1.0 ±0.3 vs 0.4 ±0.2 AU, p=0.02) in CD 
patients compared to the nearby macroscopically more quiescent areas, in UC 
patients expression is unchanged. CLDN3 expression in the colon is highly 
variable, similar to expression in the ileum and sigmoid colon. However, a trend 
towards a downregulation in CD patients (1.0 ±0.7 vs 0.3 ±0.3 AU, p=0.08) was 
observed. For CLDN4 a significant downregulation (1.0 ±0.5 vs 0.2 ±0.2 AU, p=0.02) 
by macroscopic inflammation compared to healthy-appearing area is present in 
patients with CD.
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Table 2  Overview of statistical parameters
 N Mean St.Dev. Min. Max. Significance 
compared to 
Control
ILE
UM
CLDN2 Control 6 1.0 0.2 0.8 1.2 /
CD 7 2.2 2.2 0.2 6.7 0.24
Inactive UC 5 1.0 0.6 0.5 1.8 1.00
Active UC 5 1.0 0.5 0.3 1.6 1.00
CLDN12 * Control 6 1.0 0.2 0.9 1.4 /
CD 7 1.8 0.4 1.4 2.7 0.01
Inactive UC 5 1.2 0.4 0.8 1.8 0.75
Active UC 5 1.0 0.6 0.5 1.8 1.00
CLDN3 Control 6 1.0 0.7 0.3 2.2 /
CD 7 1.5 1.1 0.3 3.7 0.69
Inactive UC 5 1.3 0.8 0.4 2.2 0.94
Active UC 5 1.3 1.1 0.3 3.1 0.95
CLDN4  * Control 6 1.0 0.1 0.9 1.1 /
CD 7 1.3 0.7 0.7 2.3 0.80
Inactive UC 5 1.1 0.6 0.5 1.8 1.00
Active UC 5 0.9 0.6 0.2 1.6 1.00
SI
GM
OÏ
D 
CO
LO
N
CLDN2 * Control 6 1.0 0.4 0.6 1.4 /
CD 5 0.2 0.1 0.1 0.4 0.01
Inactive UC 6 1.4 1.8 0.1 4.8 0.98
Active UC 7 5.4 4.3 0.1 11.3 0.23
CLDN12 * Control 6 1.0 0.2 0.8 1.2 /
CD 6 0.6 0.2 0.2 0.8 0.05
Inactive UC 7 1.1 0.7 0.5 2.5 1.00
Active UC 7 1.8 1.1 0.4 3.5 0.42
CLDN3 Control 6 1.0 0.8 0.1 2.4 /
CD 5 0.8 0.3 0.5 1.2 0.96
Inactive UC 7 1.2 0.8 0.2 2.4 0.98
Active UC 7 2.0 1.7 0.4 5.4 0.28
CLDN4 * Control 4 1.0 0.2 0.8 1.2 /
CD 5 0.7 0.4 0.4 1.3 0.51
Inactive UC 7 1.0 0.3 0.6 1.4 1.00
Active UC 7 1.7 0.9 0.6 3.4 0.40
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Discussion
In this study, we set out to analyze the expression patterns of claudins throughout 
the human gastrointestinal tract. The expression gradients observed in our study, 
can function as a standard for future research, showing which claudin isoforms 
are predominantly expressed in a certain region. In addition, we analyzed 
expression levels of claudins in patients with CD, active- and inactive UC to 
identify changes in expression that coincide with the changes in epithelial 
integrity and electrolyte absorption known to occur in IBD.
Based on function, claudins can be divided into three groups: barrier builders, 
pore formers, and claudins of ambiguous function [2]. Barrier builders decrease 
paracellular permeability and are also referred to as tightening claudins. CLDN1, 
-3, -4, -5, -8, -11, -14, and 19 are all considered to be part of this barrier building 
group. Pore formers enhance paracellular permeability in a size and charge 
Table 2  Continued
 N Mean St.Dev. Min. Max. Significance 
compared to 
Control
CO
LO
N
CLDN2 * Unaffected 
IBD
8 1.0 0.4 0.4 1.4 /
Inflamed CD 4 1.0 1.5 0.2 3.3 1.00
Inflamed UC 6 4.7 4.4 0.6 12.5 0.24
CLDN12 Unaffected 
IBD
9 1.0 0.3 0.6 1.4 /
Inflamed CD 5 0.4 0.2 0.3 0.9 0.02
Inflamed UC 5 1.2 0.5 0.7 1.8 0.59
CLDN3 Unaffected 
IBD
8 1.0 0.7 0.0 2.2 /
Inflamed CD 5 0.3 0.3 0.0 0.8 0.08
Inflamed UC 5 0.7 0.5 0.2 1.5 0.51
CLDN4 Unaffected 
IBD
8 1.0 0.5 0.1 1.8 /
Inflamed CD 5 0.2 0.2 0.1 0.5 0.02
Inflamed UC 5 0.6 0.4 0.3 1.4 0.49
* p<0.05 Levene Test for equality of Variance
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selective way and include CLDN2 and -10. Function of the remaining claudins 
such as claudin-7, -12, -15, and -16 is under debate or remains unclear [2]. The 
observed differential expression patterns of claudin isoforms in the human GI 
tract are likely to contribute to local diversity of transepithelial resistance and 
paracellular ion flow. We find an increased expression of the tightening claudin 
isoforms from proximal to distal sections of the GI tract. This is in line with 
previous studies by Markov et al, which showed that the transepithelial resistance 
in the rat intestine slightly decreases from duodenum towards the ileum, after 
which it strongly increases in colon [11]. According to our analysis, CLDN3 and 
CLDN4, both part of the barrier building group, are predominantly expressed in 
Figure 3  Expression of claudins in the colon in macroscopically active areas and 
nearby unaffected tissue of IBD patients. A. mRNA expression of CLDN2, B. CLDN12, 
C. CLDN3 and D. CLDN4 in the colon of IBD patients. Samples were obtained from 
macroscopically healthy (unaffected IBD) or inflamed tissue. Data is plotted in 
arbitrary units (AU), representing mRNA expression levels after correction with 
GAPDH and normalization with the group of macroscopically unaffected samples. 
Results are expressed as Wiskers plots box showing the 5-95 percentile, lower 
quartile, median and upper quartile, significance was accepted at P<0.05.
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the distal parts of the GI tract, but also show some expression in the duodenum. 
This is comparable to earlier findings by Holmes and Markov who found similar 
expression patterns in mice and rats, respectively [4, 11]. CLDN8, another barrier 
builder, gradually increases from proximal to distal GI sections, which is in line 
with the increasing epithelial resistance along this trajectory and previous 
finding indicating CLDN8 prevents backleak of absorbed Na+ [12]. In addition, 
these results strongly resemble the expression pattern in mice, but not those of 
Markov et al. who found a high level of expression in the duodenum [4, 11]. The 
expression of CLDN7 is similar to the expression pattern of CLDN3 and CLDN4. Not 
much is known about its function in the intestine, however, in kidney it has been 
suggested to function as a paracellular Cl- channel in the distal part of the nephron 
[13].  Remarkably, in kidney CLDN7 expression also overlaps with that of CLDN3, 
CLDN4 and CLDN8, similar to our findings in the intestine [13].  CLDN2, part of the 
previously discussed group of paracellular pore-formers, is predominantly 
expressed in the antrum, duodenum and ileum after which expression drops 
dramatically, which is in line with its pore-forming characteristics. Here our 
results are in line with Markov et al. whereas Holmes finds a constant level of 
expression throughout the entire intestinal tract [4, 11]. CLDN12 is ubiquitously 
expressed throughout the GI tract. Previous studies have shown that CLDN2 and 
CLDN12 are involved in vitamin D-mediated intestinal Ca2+ absorption in vitro as 
well as in vivo experiments [14, 15]. Ca2+ absorption is generally assumed to take 
place in the small intestine, an idea that matches perfectly with the expression 
pattern of CLDN2. Correlating these functional observations with the expression 
pattern of CLDN12 found in this study is more difficult. Some studies have 
suggested CLDN12 is part of the group of tightening claudins, responsible for 
decreasing epithelial permeability, deduced from it expression in blood vessels, 
the urine bladder and the brain [16, 17]. Potentially its function is variable, 
depending on interactions with other claudins as previously described for CLDN16 
and CLDN19 [18, 19]. CLDN15 is essential for normal-sized morphogenesis of the 
small intestine, with knockout mice developing a mega-intestinal phenotype 
[20]. Additionally, it seems indispensable for small intestinal Na+ and glucose 
absorption [21]. Based on our data, CLDN15 is mainly expressed in the duodenum 
and ileum, which matches with the previously described morphological, 
functional and pathological effects. CLDN18 expression is restricted to the 
stomach, and has been shown to prevent paracellular H+ leakage [22]. In line with 
this function and the expression pattern we observed that CLDN18 is upregulated 
in Barrett’s oesophagus epithelium during reflux disease, contributing to greater 
acid resistance [23, 24]. Our findings provide a detailed map displaying the 
predominant location of expression of various claudin isoforms in humans. As 
described above, expression patterns are in line with known isoform functions. 
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The expression profiles can thus be used to pinpoint the proper location for 
studying function/expression of claudin isoforms. In addition, human expression 
patterns of claudin seem to be quite similar to those in rodents, indicating that 
extrapolation of these results from animal models to a human setting is valid.
 Since perturbed expression of tight junction proteins, including claudins, is a 
typical feature in IBD, the second aim of this study was to analyze mRNA expression 
levels of claudins in the intestinal tissues of patients with CD [8]. Our predominant 
finding in the ileum was a significant increase in CLDN12 abundance in CD patients 
compared to controls. In addition, variance is significantly increased in IBD groups 
compared to controls for CLDN12, and -4. Especially for CLDN4 the increased variance 
in IBD groups compared to the control group is pronounced. The larger heterogeneity 
in CLDN4 mRNA expression could result from local inflammatory processes, which 
were not macroscopically visible during the collection of the biopsies. CLDN4, but 
also CLDN5 and -8, have previously been shown to be redistributed from the tight 
junction to the subjunctional lateral membrane in CD, possibly adding to the 
observed variability in expression levels [25, 26]. No changes were found in CLDN3 
expression. Notably, variance of CLDN3 expression is relatively high in all groups, 
including controls, compared to that of other genes.
 In the sigmoid colon of the CD patients, CLDN2 is significantly downregulated 
compared to controls and a similar trend is present for CLDN12 expression. In 
sigmoid samples of active UC patients, a trend towards upregulation of CLDN12 
abundance is observed and a clear increase in variance is found. As in the ileum, 
variance of CLDN3 is high, with no significant differences between controls and 
IBD patient groups. The increased variance in CLDN4 expression in sigmoid colon 
is less distinct in the ileum, no significant changes in mRNA expression between 
controls and IBD groups were found.
 In the colon biopsies were taken from macroscopically healthy areas or 
inflamed tissue. No changes in expression of CLDN2 were found between healthy 
and inflamed areas in CD patients. A tendency towards CLDN2 upregulation was 
found in inflamed areas in UC patients, which is in line with findings from 
previous studies [27, 28].  CLDN12 is significantly downregulated in CD patients 
compared to controls, with no changes in UC patients. In the colon of CD patients 
CLDN4 is also significantly downregulated in inflamed tissue areas compared to 
macroscopically healthy areas, a similar trend is present for CLDN3 (p=0.084). 
Expression of CLDN3 and CLDN4 in areas of activity in UC is unchanged compared 
areas with no macroscopic inflammatory activity. These sample sets clearly show 
that major differences in expression are present in the same intestinal location, in 
this case colon, between macroscopically healthy and inflamed tissue. This could 
potentially explain the large variability we find in the samples from IBD patients 
compared to healthy controls.
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 Several studies have shown changes in CLDN expression in the intestinal 
epithelium of both CD and UC patients. CLDN2 expression has been shown to 
correlate positively with inflammatory activity [29]. In accordance with Zeissig et 
al. we observed that the CLDN2 expression in the sigmoid colon of UC patients is 
higher than expression in patients with CD, however, we find a decreased 
expression in CD patients compared to healthy controls which has not been 
described before [26]. Various other studies also show an increase in CLDN2 
expression in cases of CD and UC. These studies have, however, sampled from 
macroscopically inflamed sigmoid colon or rectum [30]. This could explain the 
inconsistencies between their findings and the findings in our study, as we 
sampled locally from macroscopically healthy appearing tissue. 
 Adding to previous studies we also sampled the ileum of CD patients. In 
contrast to the decreased CLDN2 and CLDN12 in the sigmoid we observed an 
increased expression in the ileum not present in the UC patients or controls. None 
of the CD patients had inflammatory activity in the ileum which suggests our 
finding is related to the basic pathophysiology of CD or to be a reactive change in 
the non-inflamed areas in response to disease activity elsewhere. The increased 
expression of the pore-forming CLDN2 in the ileum coinciding with decreased 
expression elsewhere is not readily explained and requires further investigation.
In the sigmoid colon, our study shows a reduced expression of CLDN3 and 
unchanged expression of CLDN4 in the sigmoid of active CD patients, but no 
changes in the inactive CD, which is in line with previous findings by Zeissig et al. 
[26].  In addition, we found a reduced expression of CDLN3 as well as CLDN4 in 
macroscopically inflamed colon tissue of patients with active CD compared to 
macroscopically healthy tissue. Reports on CLDN3 and CLDN4 expression in IBD 
are conflicting, with some groups showing reduced expression of CLDN3 with no 
changes in CLDN4 expression [26], others showing stable CLDN3 expression with 
reduced CLDN4 expression [28, 31], no significant changes at all [25, 30], or changes 
in cellular localization of proteins [25]. These differences may be the consequence 
of variations in sampling protocol, sample handling, and post-analysis corrections. 
In addition, it is not clear at which level the expression of claudins is regulated, 
inconsistencies may, therefore, also arise as some studies have analyzed mRNA 
expression whereas others have studied total protein levels [31] or protein 
localization [25, 27].
 The discrepancy between findings in CD and UC patients can potentially be 
explained by the differences in etiology of these conditions. CD may involve any 
part of the gut including the ileum and the colon, but involvement of the rectum 
is seldom, UC on the other hand does not involve the ileum.  This could explain 
that for UC patients, no significant changes in expression of any of the tested 
claudin isoforms were found in the ileum, as there are no inflammatory processes 
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present in this location.  In addition, inflammation in CD is typically patchy and 
penetrates deep into the tissue, whereas UC is characterized by a more continuous 
area of inflammation, which is more superficially located in the mucosal layers 
[32]. The more superficial character of the inflammation in UC is likely to increase 
variation in expression analysis since the amount of inflamed tissue that is 
biopsied might vary. The increased variance in CLDN4 in the IBD groups compared 
to controls in the ileum is interesting as it indicates that, even in UC in which the 
ileum is supposedly unaffected, changes in expression in healthy area’s can be 
observed. This could potentially be the result of compensatory mechanisms, 
aimed to counteract changes further along the GI tract.
 The heterogeneous findings between the patient groups may be the result of 
local inflammatory processes releasing cytokines that exert a local effect. CD is a 
T-helper 1 inflammation producing interferon gamma and tumor necrosis factor 
alfa, whereas UC is a T-helper 2 inflammation producing interleucin-13 and 
interleucin-4 [33, 34]. In the sigmoid, we find a decrease CLDN2 expression in CD 
patients and an increased expression in active UC patients. This is in line with 
previous findings from Prasad et al. which showed in a series of in vitro experiments 
that interferon gamma decreases CLDN2, whereas interleucin -13 increases CLDN2 
[25]. In addition, they show a significant upregulation of CLDN2 mRNA in the colon 
of UC patients, in the colon of CD patients, however, results were highly variable 
and not significant [25]. Our study shows a tendency towards downregulation of 
CLDN3 and -4 in the sigmoid and colon of CD patients, which was absent in UC 
patients. Again, this is in line with the study by Prasad et al., which found no 
changes in CLDN3 and CLDN4 expression in reaction to interleucin-13, whereas 
exposure to tumor necrosis factor alpha and interferon gamma resulted in altered 
protein distribution patterns of CLDN3 and more particularly CLDN4. 
 In conclusion, this study provides a detailed map with mRNA expression 
patterns of claudins in the human gastrointestinal tract. Additionally, this study 
analyzed mRNA expression of CLDN2, -12, -3, and -4 in several intestinal segments 
in IBD patients compared to healthy controls, indicating that changes in mRNA 
expression of claudins are indeed correlated to IBD.
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Abstract 
Idiopathic infantile hypercalcemia (IIH) is a rare disease that generally resolves 
spontaneously between the age of 1- 3 years. Similar symptoms may occur in 
patients suffering from Williams-Beuren syndrome (WBS), which is caused by a 
microdeletion on chromosome 7. Two of the genes, named CLDN3 and CLDN4, 
located within this region are members of the claudin family that has been shown 
to be involved in paracellular calcium (Ca2+) absorption. Based on the hemizygous 
loss of CLDN3 and CLDN4 in WBS and the function of these genes in paracellular 
Ca2+ transport we hypothesized that mutations in CLDN3 or CLDN4 could also be 
involved in IIH. 
 Biochemical characteristics, including calciotropic hormone levels, were 
obtained from three typical IIH patients. CLDN3 and CLDN4 sequences were also 
analyzed in these patients. The major intestinal Ca2+ transporter TRPV6 was also 
screened for the presence of mutations, since hypercalcemia in IIH and WBS has 
been shown to result from intestinal hyperabsorption. All three patients were 
also analyzed for the presence of deletions or duplications using a single nucleotide 
polymorphism (SNP) array for genomic DNA. 
 The serum Ca2+ levels of patients were 2.9, 3.3 and 3.8 mmol/L (normal <2.7 
mmol/L). Levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 were 
normal, parathyroid hormone (PTH) and PTH-related peptide (PTHrP) levels were 
appropriately low. Sequencing of coding regions and intron-exon boundaries did 
not reveal mutations in CLDN3, CLDN4 and TRPV6. Identified SNPs were not 
correlated with the disease phenotype. A SNP array did not reveal genomic 
deletions or duplications.
 Biochemical analysis did not reveal inappropriate levels of calciotropic 
hormones in IIH patients in this study. Furthermore, based on the lack of mutations 
in CLDN3, CLDN4 and TRPV6, we conclude IIH is neither caused by mutations in 
these candidate genes nor by deletions or duplications in the genome of these 
patients.
6Claudin 3 and 4 in IIH
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Introduction
Idiopathic infantile hypercalcemia (IIH) is a rare disorder of thus far unknown 
etiology with a reported prevalence of 1 in 50000 life births (patients with 
Williams Beuren syndrome, WBS, included) [1]. Children suffering from IIH 
usually present during their first year of life with clinical features of hypercalcemia, 
such as irritability, constipation, vomiting, increased thirst and a failure to thrive. 
Hypercalcemia in IIH patients is the result of intestinal hyperabsorption, which 
was shown by Barr et al. using oral calcium (Ca2+) loading tests, and is emphasized 
by a cellulose phosphate treatment which normalizes the serum Ca2+ levels [2, 3]. 
Hypercalcemia generally resolves between the ages of 1 to 3 years, however 
hypercalciuria may persist up to the age of 12 [4, 5]. If diagnosed and treated in an 
early stage, the prognosis of IIH patients can be improved and the extent of 
nephrocalcinosis limited [5, 6].
 IIH was first described in the United Kingdom in the 1950s by Lightwood and 
Fanconi [7, 8]. Originally, a subdivision of “mild” and “severe” IIH was made in 
order to distinguish between patients suffering solely from hypercalcemia and 
patients that also display additional abnormalities such as distinctive facial 
features [9]. The “severe” form has subsequently been shown to be part of a larger 
group of symptoms common to patients suffering from WBS [10]. WBS is nowadays 
known to result from a hemizygous microdeletion at 7q11.23 which arises from a 
recombination between misaligned repeat sequences flanking the region [11, 12]. 
The WBS deletion region encompasses 24 genes [13]. Among the genes located in 
the deleted region are CLDN3 and CLDN4, which encode tight junction proteins 
claudin 3 and 4, respectively [14, 15]. Members of the claudin protein family have 
been shown to be involved in paracellular Ca2+ absorption [16]. Also, they have 
been described to play an important role in the regulation of ion transport in both 
the intestine and the kidney [16]. The deletion of claudin 3 and 4 increases the 
permeability of the intestinal epithelium [17-20]. Changes in expression of various 
claudins in murine intestine throughout time indicate that the absence of a 
particular claudin can, in time, be compensated for by the maturation of other 
claudins [21]. 
 Similarities in the course of development of hypercalcemia in IIH and WBS 
patients could be explained by a shared underlying mechanism such as a gene 
defect. The hemizygous loss of CLDN3 and -4 in WBS, combined with their function 
in ion transport, makes them good candidate genes underlying the similarities in 
disease phenotype in patients suffering from IIH and WBS. In order to validate 
this hypothesis, three typical IIH patients were analyzed for the presence of 
mutations in CLDN3 and CLDN4. Since the IIH phenotype is the result of intestinal 
hyperabsorption, the major intestinal Ca2+ transporter TRPV6 was also analyzed 
Chapter 6
118
in order to exclude changes in uptake due to mutational changes in this 
transporter. Finally, the presence of deletions and duplications was analyzed in 
all three patients using a single nucleotide polymorphisms (SNP) array.
Materials and methods 
Patient selection and phenotype assignment
Patients 1 and 2 were selected and treated in Australia. They have been described 
in two previous Australian studies as patient III2 and III3 and as patient 1 and 10 
[4, 22]. Observation and treatment of patient 3 took place in the Netherlands and 
this patient has not been previously described. 
Serum and urine biochemistry
Biochemical analysis of blood and urine was routinely performed using standard 
laboratory techniques at the Royal Children’s Hospital and Mater Children’s 
Hospitals in Brisbane Australia (patient 1 and 2) or the Radboud University 
Nijmegen Medical Centre in the Netherlands (patient 3). Parathyroid hormone 
(PTH) measurements in both hospitals were performed using an immunometric 
assay measuring only intact PTH.
DNA extraction
DNA sample collection and storage were carried out according to standard 
methods. In short, 10 ml of peripheral blood was collected into ethylene- diamine-
tetraacetic-acid (EDTA) containing tubes and centrifuged for 10 min at 3000 g to 
separate buffy coats and plasma. Total genomic DNA was isolated from the buffy 
coat using a standard blood and body fluid protocol. Extracted DNA was quantified 
by spectrophotometrical absorbance measurements and stored in aliquots. 
Genotyping
Oligonucleotide primers (Biolegio, Malden, The Netherlands) for the amplification 
of genomic DNA by polymerase chain reaction (PCR) were developed based on 
genomic sequences. Since CLDN3 and CLDN4 both consist of one large exon, 
primers were designed to amplify overlapping parts of the exon and included 
intron-exon boundaries. For TRPV6, a similar approach was used. Because of short 
intron sequences between exons 2 and 3, 7 and 8, as well as 9 and 10, PCR 
amplification of these exons was combined and PCR-products were sequenced as 
single fragments. Primer sequences used for the amplification of CLDN3, CLDN4 
and TRPV6 are listed in Table 1. PCR products were purified using a GenEluteTM PCR 
Clean-up Kit (Sigma, St Louis, MO, USA). DNA sequencing was carried out by 
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standard procedures at the sequence facility of the Radboud University Nijmegen 
Medical Centre. Subsequently, patient sequences were aligned and compared 
with human CLDN3 (NM_001306), CLDN4 (NM_001305), or TRPV6 (NM_018646) 
mRNA sequences, obtained from the NCBI nucleotide database.
Affymetrix NspI SNP array hybridisation and analysis
Microdeletion analyses were carried out on the Affymetrix GeneChip 250k (NspI) 
SNP array platform (Affymetrix, Inc., Santa Clara, CA), which contains 25-mer oli-
gonucleotides representing a total of 262,264 SNPs. Hybridisations were performed 
according to the manufacturer’s protocols. Copy numbers were determined using 
Table 1  Human primer sequences for CLDN3, CLDN4 and TRPV6
Gene Exon_
part 
Forward primer Reverse primer 
CLDN3 1_1 5’-ACTGTCCTTAGGCCCTGGAG -3’ 5’-AGATGTTCTGCGACGTGATG-3’ 
CLDN3 1_2 5’-GGCACCATCGTGTGCTGCG-3’ 5’-CTTGGTGGCCGTGTACTTC-3’ 
CLDN3 1_3 5’-GTCGGCCAACACCATTATCC-3’ 5’-TGAGGTTTCACAGTCCATGC-3’ 
CLDN3 1_4 5’-CTACGACCGCAAGGACTACG-3’ 5’-GCTCAGCTTACAACCCCATC-3’
CLDN4 1_1 5’-AGCATGGGCTTTGAGGAAG-3’ 5’-GCGATGCCCATTACCTGTAG-3’ 
CLDN4 1_2 5’-TGCACTCTGCGAACGTTAAG-3’ 5’-CACCGGCACTATCACCATAAG-3’ 
CLDN4 1_3 5’-AACTGCCTGGAGGATGAAAG-3’ 5’-CTTGGGAAGTTGTCCGAGTG-3’ 
CLDN4 1_4 5’-TGTTCTTCCCTGGACTGAGC-3’ 5’-CTCTAAACCCGTCCATCCAC-3’ 
CLDN4 1_5 5’-ATCACCTCTGGGACTGTGC-3’ 5’-CACCTCCACAGTTGAAATC-3’
TRPV6 1 5’-GCAGGTCTGTGGCTGGCCTG-3’ 5’-CCTGGGAGCACCATCTGTCC-3’
TRPV6 2-3 5’-GCCTCTCCCTCCACAACTAGG-3’ 5’-ACTGACTTGAAATACCCAACC-3’
TRPV6 4 5’-GAGGGACCCCCTGCAGGATCC-3’ 5’-GCTGCCCAACAGATACGGCTG-3’
TRPV6 5 5’-GGAAGATAAGGCTGTCACTTG-3’ 5’-GAAGGTCCCAGCCCCTCTCC-3’
TRPV6 6 5’-GGAGAGGGGCTGGGACCTTC-3’ 5’-CACCTCTGTTTCTCCCAGGGC-3’
TRPV6 7-8 5’-CCTATCCACACTCTGTGACCG-3’ 5’-AGTCTCTGAGGACAGAGAGCC-3’
TRPV6 9-10 5’-CCCTGGGCACCATGGAAATGC-3’ 5’-CAGGAATCCAAGGAGTGGAAC-3’
TRPV6 11 5’-GGAGGCTGAATCTGCATGTGTGG-3’ 5’-CCTGCAATGTCTACTGTTCTGCCC-3’
TRPV6 12 5’-CTGGATGGGGCAATTGCTTGCTTGG-3’ 5’-CTCCTCCCCAAGTTTAGCCAG-3’
TRPV6 13 5’-GGACATGCACGCAGAGCCCGG-3’ 5’-GCAGGTTCCTTGGTAGGAAGG-3’
TRPV6 14 5’-CTCAAGCTCTATCAACTCTCTCCC-3’ 5’-ACACAGGCCTCCACAGGGAACCC-3’
TRPV6 15 5’-CCAGGGGATAACAGACAAGCATCC-3’ 5’-CTGGAGATGAGACCTCTGG-3’
CLDN3, claudin 3; CLDN4, claudin 4; TRPV6, transient receptor potential vanilloid 6
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the 2.0 version of the CNAG (Copy Number Analyzer for Affymetrix GeneChip 
mapping) software package, by comparing SNP intensities from patient DNA 
with those of a sex-matched pooled reference DNA sample (DNA from either ten 
healthy male or ten healthy female individuals) [23]. The average resolution of 
this array platform is 150-200 kb.
Results
Patient phenotype and biochemistry
An overview of selected clinical and biochemical characteristics of all patients 
and the corresponding reference ranges for infants under 12 months of age are 
provided in Table 2. Family background and clinical and biochemical characteris-
tics of patient 1 and patient 2 have been described in previous publications [4, 22, 
24]. In short, patient 1 and 2 both showed elevated serum Ca2+ levels and a urinary 
Ca/Cr ratio above normal reference range. PTH levels were below reference range 
in patient 1 and normal in patient 2. PTH-related peptide (PTHrP) levels were 
normal in both patients, as were 25-hydroxyvitamin D3 levels. 1,25-dihydroxyvita-
min D3 levels were not changed in patient 1 and slightly elevated in patient 3.
Figure 1  Ultrasound of the left kidney of patient 3 at the age of 2 months. Nephro-
calcinosis in the medullar regions is indicated by white arrows.
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 Patient 3 was born at 40 weeks gestational age with normal birth weight of 
3150 g. Both parents were healthy without consanguinity. Ultrasonography 
during pregnancy showed increased echogenicity of both kidneys of the fetus. 
She was first seen at our out-patient clinic at the age of 2 months because of failure 
to thrive and to evaluate the increased echogenicity observed before birth. An 
extensive nephrocalcinosis was observed (Figure 1). Clinical evaluation revealed 
no abnormalities, with blood pressure in the normal range. Biochemical analysis 
showed elevated levels of both total and ionized serum Ca2+. The urinary Ca/Cr 
ratio was approximately four times. PTH levels were low, levels of PTHrP, 25-
hydroxyvitamin D3 and 1,25-dihydroxyvtamin D3 were within normal reference 
range. Additional biochemical characteristics at the age of 2-3 months are shown 
in Table 3. Chromosomal examination showed a normal 46XX karyotype. Williams- 
Beuren syndrome was excluded based on the absence of a microdeletion in 7q11.23. 
As the serum Ca2+ levels decreased spontaneously upon increase of fluid intake no 
other therapy was applied and her growth resumed at a normal rate. Since the age 
of two years she suffered from recurrent urinary tract infections. A cystogram 
Figure 2  Development of serum Ca2+, phosphate and creatinine levels in patient 3 
throughout time. After an initial period of severe hypercalcemia serum Ca2+ levels 
(n) normalize in the upper percentiles of the normal reference range (<2.7 mmol/L). 
Serum phosphate levels (s) are generally within reference range (1.2-2.2 mmol/L), 
but remain in the lower percentiles. Serum creatinine levels (l), right Y-axis) are 
within reference range (20-80 µmol/L) and seem to increase throughout time.
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showed no reflux. Figure 2 depicts the development of Ca2+, phosphate and 
creatinine levels in patient 3 over time. After an initial period of extreme 
hypercalcemia, serum Ca2+ levels normalized at a level within normal range, but 
remained in the upper percentiles (2.6-2.7 mmol/L). At the age of 8 years her serum 
creatinine was 92 umol/l with an estimated creatinine clearance of 76 ml/
min/1.73m2. This slightly decreased clearance rate can be explained by the 
combination of recurrent urinary infections and nephrocalcinosis.
Sequence analysis
Analysis of coding regions and intron-exon boundaries of CLDN3, CLDN4, and 
TRPV6 genomic sequences revealed a number of SNPs in our three patients. Two 
SNPs were identified in CLDN3 of patient 1 and located in the 5’ untranslated 
region (UTR) of the exon. CLDN4 showed five identical SNPs in both patient 2 and 
3. One was located outside the exon near its 5’ e nd, one in the 5’ UTR and three in 
the 3’ UTR. Sequence analysis of TRPV6 revealed one synonymous SNP in the 
coding region of exon 11 in patient 3. Table 4 provides an overview of all SNPs 
identified in our patients in CLDN3, CLDN4 and TRPV6. All SNP’s found in this 
study were previously identified and are listed in single nucleotide polymorphism 
Table 3  Biochemical characteristics patient 3
Source Analyzed compound Patient 3 Normal reference range
Blood Ca2+ 3.41-3.76 mmol/L <2.7 mmol/L
Ionized Ca2+ 1.26-1.34 mmol/L 1.0-1.3 mmol/L
Mg2+ 0.8 mmol/L 0.78-1.04 mmol/L
Phosphate 1.05-1.14 mmol/L 1.20-2.2 mmol/L
Alkaline Phosphatase 278-397 U/L 150-350 U/L
Creatinine 46-62 mmol/L 20-80 mmol/L
Intact PTH 0.3 pmol/L 1.0-6.5 pmol/L
PTHrP <0.3 pmol/L <0.3 pmol/L
25-hydroxy-vitamin D3 51 nmol/L 35-100 nmol/L
1,25-dihydroxy-vitamin D3 132 pmol/L 50-150 pmol/L
Calcitonin 5 pmol/L <3.5 pmol/L
Urine Ca/Cr ratio 8.2-8.7 mmol/mmol 0.09-2.2 mmol/mmol [34]
Phosphate reabsorption 78-82% 78-96% [35]
Ca2+, calcium; Mg2+, magnesium; PTH, parathyroid hormone; PTHrP, PTH related peptide; Ca/Cr, 
calcium/creatinine
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(SNP) databases (http://ncbi.nlm.nih.gov/SNP/). SNP array analysis of genomic 
DNA from the patients did not reveal significant deletions or duplications.
Discussion
To date the diagnosis IIH is still based on exclusion. Only if disorders such as Wil-
liams-Beuren syndrome, benign familial hypocalciuric hypercalcemia, primary 
hyperparathyroidism, thyroid disease, malignancy, excessive vitamin D and A 
intake, diuretic administration, sarcoidosis, and other granulomatous diseases 
are excluded the diagnosis IIH can be made [25]. No genetic defects causing IIH are 
known thus far.
 Certain polymorphisms in TRPV6 have been associated with hypercalcemia 
due to intestinal hyperabsorption [26]. In IIH and WBS correlations between the 
absorptive hypercalcemic phenotype and mutations or polymorphisms in specific 
genes have not been identified thus far. Most studies on Ca2+ homeostasis in IIH and 
WBS patients have focused on abnormalities in Ca2+, Ca2+-regulating hormones 
including PTH and vitamin D. Studies consistently show that infants with IIH and 
WBS suffer from hyperabsorption of Ca2+ in the intestine and evidence for excessive 
vitamin D intake is generally lacking [1, 2, 27]. Although some reports show elevated 
levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3, other studies were 
not able to confirm these findings [5]. We found no increased levels of 25-
hydroxyvitamin D3 in our patients. 1,25-dihydroxyvitamin D3 levels were elevated 
Table 4  Sequence analysis of patients
Gene Region dbSNP allele dbSNP cluster ID Patient
CLDN3 Exon 1 à 5’ UTR C/G rs7084 1
Exon 1 à 5’UTR A/G rs6460054 1
CLDN4 5’ near gene A/G rs4458741 2/3
Exon 1 à 5’UTR C/T rs8629 2/3
Exon 1 à 3’UTR A/G rs1127155 2/3
Exon 1 à 3’UTR C/T rs1127156 2/3
Exon 1 à 3’UTR C/G rs11316 2/3
TRPV6 Exon 11 CàT rs4987704 3
CLDN3, claudin 3; CLDN4, claudin 4; TRPV6, transient receptor potential vanilloid 6; UTR, untranslated 
region
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in one patient, however, in the two patients with the highest Ca2+ levels 1,25-dihy-
droxyvitamin D3 levels were normal. Alternative mechanisms to explain the 
hypercalcemia are an increased sensitivity for vitamin D, deficient suppression of 
PTH by hypercalcemia, or an increased release of PTHrP, which is highly similar to 
PTH in structure and function [5, 28-30]. PTH levels of our patients were below the 
normal reference range indicating an appropriate suppression of PTH in response to 
hypercalcemia. None of the patients described in this study had elevated PTHrP 
levels. PTHrP is, therefore, not likely to be involved in the increased intestinal Ca2+ 
absorption seen in IIH patients. Patient 3 showed slightly decreased serum 
phosphate concentrations and low renal phosphate reabsorption (Table 3). Decreased 
tubular phosphate reabsorption as a result of chronic hypercalcemia is a known 
phenomenon of unspecified etiology [31]. The correlation between serum phosphate 
and Ca2+ levels in patient 3 is also shown in figure 2.
 The leading hypothesis on IIH and WBS pathogenesis is a genetic defect in 
Ca2+ homeostasis resulting in intestinal hyperabsorption of Ca2+, which is 
compensated later in life [32, 33]. As described before CLDN3 and CLDN4, which are 
hemizygously deleted in WBS, are members of a large family of claudin proteins 
that are part of the tight junction complex regulating the paracellular 
permeability. Holmes et al. studied the expression of intestinal claudins in the 
mice of different ages and showed that some claudins are significantly up or 
down regulated throughout life [21]. The transient character of hypercalcemia in 
IIH and WBS patients could therefore potentially be explained by the altered 
expression of claudins that regulate the permeability of the intestinal epithelium. 
The partial loss of claudin 3 or claudin 4 expression would in this case be 
compensated for after a certain period of time, explaining the disappearance of 
hypercalcemia. This way our hypothesis would explain the clinical phenotype as 
observed in our patients on both a genetic and molecular level. 
 Patient DNA was analyzed for the presence of mutations in CLDN3 and CLDN4. 
Alternatively, the major intestinal Ca2+ channel TRPV6 was also analyzed to 
exclude the presence of gain of function mutations and activating polymorphisms 
that could be involved in the development of hypercalcemia. All SNP’s found in 
this study were previously identified and are listed in single nucleotide 
polymorphism (SNP) databases (http://ncbi.nlm.nih.gov/SNP/). None of the 
polymorphisms is known to be related to disease, nor did our study indicate such 
a correlation. A SNP array did not reveal significant deletions or duplications in 
any of the patients. Together these results not only show that mutations in CLDN3 
and CLDN4 are not involved in IIH, they also indicate that the IIH phenotype does 
not result from deletions or duplications in the genome of these patients. 
 In summary, this study showed no aberrant levels of vitamin D, PTH and 
PTHrP in IIH patients thereby invalidating a number of previous proposed 
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hypotheses. Furthermore, no mutations in CLDN3, CLDN4 and TRPV6 were found 
in these patients, who also did not have genomic deletions or duplications. The 
sporadic occurrence and general lack of a clear inheritance pattern in IIH, together 
with the limited number of patients known to suffer from IIH, complicates 
identification of genes involved in the development of transient hypercalcemia. 
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Abstract
Williams-Beuren syndrome is a rare genetic disorder, caused by the deletion of 
26-28 genes on chromosome 7. Fifteen percent of Williams-Beuren syndrome 
patients present with hypercalcaemia during infancy, which is generally mild 
and resolves spontaneously before the age of 4 years. The mechanisms underlying 
the transient hypercalcaemia in Williams-Beuren syndrome are poorly understood. 
 We report a case of severe symptomatic hypercalcaemia in a patient with 
Williams-Beuren syndrome, in which treatment with mild calcium restriction, 
hyperhydration and repeated bisphosphonate administration only resulted in 
short-lasting effects. Long-term lowering of serum calcium was only achieved 
after reducing calcium and vitamin D intake to the bare minimum. 
 This case illustrates the potential severity of hypercalcaemia in WBS, and 
demonstrates that both the cause as well as the solution of this problem may be 
found in the intestinal absorption of calcium. We hypothesize that the 
phenotypical resemblance between Williams-Beuren syndrome and transient 
idiopathic infantile hypercalcaemia can be explained by similarities in the 
underlying genetic defect. Patients suffering from transient infantile 
hypercalcaemia were recently described to have mutations in CYP24A1, the key 
enzyme in 1,25-dihydroxyvitamin D3 degradation. In the light of this new 
development we discuss the role of one of the deleted genes in WBS, Williams 
Syndrome Transcription Factor, in the etiology of hypercalcaemia in Williams- 
Beuren syndrome.
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Introduction
Williams-Beuren syndrome (WBS, OMIM 194050) is a rare genetic disorder, caused 
by a hemizygous deletion at 7q11.23 comprising approximately 26 to 28 genes [1]. 
WBS patients are generally characterized by distinctive facial dysmorphisms, 
mental retardation and cardiovascular abnormalities. In addition, approximately 
15% of WBS patients present with hypercalcaemia during infancy, generally mild 
in nature. It resolves spontaneously before the age of 4 years, but sometimes 
reoccurs briefly during puberty [1]. The mechanisms explaining the transient 
hypercalcaemia are poorly understood. We report a case of severe symptomatic 
hypercalcaemia in a patient with WBS only resolving with a profound reduction 
of calcium and vitamin D intake, and present a potential mechanism for this 
metabolic abnormality.
Case report
An 18-months-old female patient was admitted to a local hospital to start tube 
feeding for treatment of failure to thrive due to feeding difficulties and persistent 
vomiting despite proton-pump inhibition. Three months earlier she was diagnosed 
with WBS with normal serum calcium levels (2.40 mmol/L), and was known 
with low birth weight, a cardiac murmur without a structural anomaly, and a 
developmental delay. 
 During her admission, her condition deteriorated, and she developed a 
hypercalcaemia (Table 1) and hypertension (up to 150/130 mmHg) for which she 
was transferred to the pediatric intensive care unit at the Radboud University 
Nijmegen Medical Centre. Her blood pressure was controlled with an intravenous 
calcium-antagonist, which was successfully switched to oral anti-hypertensive 
agents (amlodipine and labetalol). Extensive evaluation, excluding renal 
angiography, did not show an explanation for the hypertension, other than the 
hypercalcaemia and the underlying WBS. 
The hypercalcaemia was treated with hyperhydration, furosemide and a reduced 
calcium intake. Laboratory tests ruled out other causes than the WBS for the 
hypercalcaemia (Table 1). To prevent nephrocalcinosis due to the subsequent 
hypercalciuria (urine calcium-creatinine ratio up to 3.0 mmol/mmol), potassium 
citrate was administered. 
 As this treatment just led to a small reduction in serum calcium (Figure 1), a 
bisphosphonate was administered, in a low dose to prevent hypocalcaemia. This 
resulted in only a short and mild reduction of the serum calcium, so repeated and 
increased doses of pamidronate were administered, all with only short-lasting 
effects (Figure 1). With every return of hypercalcaemia, the patient also showed 
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an increase in blood pressure and vomiting. Therefore, calcium and vitamin D 
intake (drip-feed containing 588 mg Ca/d and 150 IE/d) was reduced to the bare 
minimum (68 mg/d and 0 IE/d, respectively) while maintaining adequate 
nutritional intake. With this treatment serum calcium was maintained at high- 
normal but stable levels that were clinically well accepted. Phosphate supplemen-
tation was initiated to treat her accompanying hypophosphataemia.
 During follow-up, we found to our surprise a low renal calcium excretion and 
high PTH level during the calcium restriction. We interpreted this to be indicative 
of a more calcium-deficient state, despite the high-normal serum calcium, for 
which the calcium intake was gradually increased. No nephrocalcinosis is present 
at the latest ultrasound, and no hypercalciuria occurred during the gradual 
increase in calcium intake.
Figure 1  Time course of total calcium and ionized calcium levels in serum during 
treatment and follow-up. Grey area’s indicate the normal range total serum 
calcium (2.20-2.70 mmol/L) and ionized calcium (1.10-1.30 mmol/L). The arrows 
indicate interventions. 1-4: i.v. administration of pamidronate, 0.25, 0.50, 1.0, and 
1.0 mg pamidronate /kg bodyweight, respectively. 5: diet changed from drip-feed 
containing 588mg Ca/d and 150 IE 1,25-dihydroxyvitamin D3 /d to a drip-feed with 
68 mg Ca/d and 0 IE 1,25-dihydroxyvitamin D3/d.
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Discussion
In the past, various studies have been performed to try and elucidate the 
mechanism underlying hypercalcaemia in WBS. We hypothesize that increased 
intestinal absorption of calcium is the main factor in the pathogenesis of 
hypercalcaemia in these patients, as has been described in the past [2], potentially 
as a result of reduced break down of vitamin D. Most studies aimed to find changes 
in Vitamin D metabolism, with various degrees of success. Some groups find 
abnormalities in all patients suffering from WBS, whereas others only describe 
changes in vitamin D metabolism in WBS patients with hypercalcaemia, and 
some groups find no changes at all [2].
 Bisphosphonate therapy (pamidronate) is recommended as an additional 
therapy when conventional measures (intravenous fluids, furosemide and dietary 
calcium restriction) fail to normalize serum calcium. However, the course of 
the hypercalcaemia in our patient seems to suggest no sustained effect of 
bisphosphonate treatment and suggests an intestinal cause of hypercalcaemia 
that can only be treated by (extensive) calcium and vitamin D restriction. Of note, 
our patient did not show extensive hypercalciuria at presentation (Table 1), which 
would be expected in hypercalcaemia However, renal function was reduced at 
that time with an estimated glomerular filtration rate of 41 ml/min/1.73m2 and 
hypercalciuria did present after optimizing renal function (urine calcium-creatinine 
ratio up to 3.0 mmol/mmol). The reduced renal function may explain the 
temporary absence of hypercalciuria, and may have contributed to the observed 
hypercalcaemia. The persisting hypercalciuria as well as hypercalcaemia that 
were observed when renal function was restored indicate that the hypercalcaemia 
in our patient is not solely explained by inappropriate renal calcium handling due 
to renal failure. Some of the features of our patient are not easily explained and 
may indicate an additional factor involved in the aetiology of hypercalcaemia in 
this particular patient. The high PTH levels observed after 3-6 months, when 
serum calcium levels are in the high-normal range could also indicate an altered 
set point of serum calcium, which is commonly associated with inactivating 
mutations in the calcium-sensing receptor (CaSR). Hypertension is, in addition to 
the hypercalcaemia, a well known feature in up to 50% of WBS patients and may 
be explained by elastin deficiency, a hallmark feature of WBS [1]. Alternatively, 
renal artery stenosis is described in some patients with WBS, which we did not 
fully exclude in our patient yet. As blood pressure was well controlled with the 
current medical therapy, renal ultrasound showed identical sized and normal 
structured kidneys, and renography showed a normal split renal function, no 
renal angiography was performed. 
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Our case of severe and sustained hypercalcaemia highlights that the underlying 
mechanism in WBS can be found, at least in part, in the uptake of calcium, as the 
long-term lowering of serum calcium was only obtained by a subtotal reduction 
of the calcium and vitamin D intake. Hypercalcaemia in WBS patient and patients 
suffering from idiopathic infantile hypercalcaemia (IIH) without WBS both have 
been shown to result from intestinal hyperabsorption of calcium, the contribution 
of potential changes in renal calcium handling to the observed hypercalcaemia 
remains to be determined [3].
 Similar to our WBS patient, IIH patients were shown to benefit from dietary 
calcium and vitamin D restriction [4]. Patients should however by carefully 
monitored since long-term restriction of dietary calcium and vitamin D may 
induce rickets in these young patients [4, 5].
 Based on these phenotypical similarities between patients with WBS and IIH 
patients we previously suggested there might be a common underlying genetic 
defect [6]. We hypothesized that claudin 3 and claudin 4, both involved in 
paracellular calcium absorption and located within the hemizygously deleted 
WBS region, might be responsible for the hypercalcaemia state of these patients. 
Unfortunately, we were not able to confirm this hypothesis in patients suffering 
from isolated infantile hypercalcaemia [6].  Letavernier et al have suggested 
that hypercalcaemia in WBS patients is the result of TRPC3 overexpression due to 
haploinsufficiency of the transcriptions factor TFII-I, which is located in the 
genomic region that is deleted in WBS patients [7]. Evidence that TRPC3 is involved 
in transepithelial calcium transport in the intestine however is lacking. Despite 
the earlier negative findings, our hypothesis remains valid. The similarities with 
regards to the transient hypercalcaemic phenotype of IIH and WBS patients 
suggest a common underlying genetic defect. Interestingly, the genetic defect 
causing IIH has recently been elucidated, shedding more light on the molecular 
mechanism underlying hypercalcaemia in these patients. Two independent 
studies have found that homozygous or compound heterozygous mutations and 
deletions in the CYP24A1 gene are responsible for the phenotype of patients 
suffering from idiopathic infantile hypercalcaemia. CYP24A1 encodes 25-di hydroxy-
vitamin D 24-hydroxylase, which is the key enzyme in 1,25-dihydroxyvitamin D3 
degradation [8, 9]. Patients display hypercalcaemia, hypercalciuria, and 
suppressed PTH levels, whereas levels of 25-hydroxyvitamin D3 and 1,25-dihydrox-
yvitamin D3 were within normal range. A third study describes patients with a 
heterozygous mutation in CYP24A1 that have a less severe clinical phenotype 
compared to the compound heterozygous patients, indicative of a haploinsufficiency 
or a dominant negative effect [10]. This study also shows that patients with 
CYP24A1 mutations have reduced levels of circulating 24,25-dihydroxyvitamin D3 
in line with a nonfunctional Cyp24a1 enzyme. Together, these studies indicate 
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that in IIH patients, intestinal hyperabsorption of calcium is the result of altered 
vitamin D catabolism.
Interestingly, a gene named Williams Syndrome Transcription Factor (WSTF) is 
located within the WBS deletion region. WSTF is a subunit of the ATP-dependent 
chromatin remodelling complex WINAC, whose activity facilitates ligand-de-
pendent activation of CYP24A1 and repression of 25-hydroxyvitamin D3-1-alpha 
hydroxylase (CYP27B1) by the vitamin D receptor (VDR) [11]. 
 It has previously been hypothesized that hypercalcaemia in WBS is the result 
of loss of WINAC function, leading to reduced transcription of CYP24A1 and 
increased transcription of CYP27B1, theoretically resulting in increased 1,25-dihy-
droxyvitamin D3 [12]. Lack of a clear increase in 1,25-dihydroxyvitamin D3 levels in 
WBS patients seems to contradict this hypothesis. However, the phenotype of 
patients with CYP24A1 mutations clearly demonstrates that a lack of 25-dihydrox-
yvitamin D 24-hydroxylase may indeed lead to a hypercalcaemic phenotype 
without a clear increase in circulating 1,25-dihydroxyvitamin D3 levels, only the 
patients receiving large doses of Vitamin D prophylaxis display elevated levels of 
circulating 1,25-dihydroxyvitamin D3 [9]. As our patient was admitted for failure 
to thrive, it is safe to assume that her vitamin D intake was low. Similar 
observations have been made in Cyp24a1 knockout (KO) mice, which have normal 
1,25-dihydroxyvitamin D3 levels at baseline, but show an impaired clearance of 
administered 1,25-dihydroxyvitamin D3 [13]. The exact explanation for this finding 
remains to be determined, but it strengthens the hypothesis that the hemizygous 
deletion of WSTF could be responsible for the transient hypercalcaemia in WBS, 
despite a lack of clear alterations in 1,25-dihydroxyvitamin D3. These data are in 
line with our hypothesis that deletion of WSTF in WBS patients leads to a reduced 
CYP24A1 activity, therefore a reduced catabolism of 1,25-dihydroxyvitamin D3, 
which results in increased intestinal calcium absorption with subsequent 
hypercalcaemia.
In conclusion, our patient illustrates the potential severity of hypercalcaemia in 
WBS, and demonstrates that both the cause and the solution of this problem may 
be found in the intestinal absorption of calcium. Key to treatment of severe 
hypercalcaemia in WBS is subtotal restriction of calcium and vitamin D intake. 
Follow-up should include careful monitoring of serum and urinary calcium levels, 
to navigate between hypercalcaemia and calcium depletion.
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Introduction
Calcium (Ca2+) and magnesium (Mg2+) play an important role in many of our 
bodily functions, including bone formation, muscle contraction and relaxation, 
and enzymatic activity. It is, therefore, essential that plasma Ca2+ and Mg2+ 
concentrations are maintained within a narrow range. To this end, the plasma 
levels of both minerals are regulated by the concerted action of the intestine, 
bones and kidneys. Since dietary intake is the only source of Ca2+ and Mg2+ for our 
body, intestinal absorption is crucial for the maintenance of normal homeostatic 
levels. In the intestine, but also in the kidney, Ca2+ and Mg2+ are (re)absorbed via 
transcellular and paracellular pathways. Transcellular transport generally 
requires three consecutive steps, in which ions enter the cell via the apical 
membrane, diffuse through the cytoplasm, and exit the cell via the basolateral 
membrane. Two channels, transient receptor potential vanilloid type 6 (TRPV6) 
and transient receptor potential melastatin type 6 (TRPM6), facilitate the entry of 
these cations from the intestinal lumen into the cell, which is considered to be the 
rate-limiting factor in the transcellular transport pathway [4]. When transported 
via the paracellular pathway, ions do not cross the plasma membrane, but 
permeate the epithelium via the tight-junctions that are localized between the 
epithelial cells. The family of claudin proteins plays an important role in 
paracellular transport of Ca2+ and Mg2+ by determining the size- and charge 
selectivity of the paracellular route [5]. Hormones and other regulatory factors 
control transport via both the transcellular and the paracellular pathways. The 
studies described in this thesis were directed at further elucidating the molecular 
mechanisms involved in intestinal absorption of Ca2+ as well as Mg2+. This chapter 
summarizes and discusses the major findings of this thesis. 
The importance of TRPV6 in intestinal Ca2+absorption
For both Ca2+ and Mg2+ the first step of transcellular transport, in which ions enter 
the cell by crossing the apical membrane, is facilitated by proteins from the 
transient receptor potential (TRP) family [6]. TRP proteins contain six mem-
brane-spanning domains (S1–S6), a pore loop between domains S5 and S6, and 
intracellularly located carboxy- and amino termini [6]. Four TRP monomers are 
known to form a cation channel by assembling into homo- or heterotetramers 
(Figure 1). The epithelial Ca2+ channel TRPV6 is considered the primary protein 
responsible for transcellular intestinal Ca2+ absorption [7]. The pore region of each 
TRPV6 monomer contains a crucial aspartic residue at position 542 (position 541 in 
mouse). In the tetrameric channel, these negatively charged residues form a ring 
that facilitates Ca2+ conductance [8, 9]. Indeed, replacement of this aspartic acid 
by an alanine residue abrogated Ca2+ permeation in both human and mouse 
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TRPV6, suggesting that D542/D541 is critical for channel activity [9-11]. To address 
the specific role of TRPV6 in transepithelial Ca2+ permeation in vivo, a mouse 
model with a mutation in the pore region (the TRPV6D541A/D541A knock-in mouse) 
was used in the studies described in Chapter 2 [12, 13]. This mouse model is unique 
since the mutation creates a non-functional TRPV6 channel while the general 
structure of the protein remains unchanged. In contrast, the conventional 
complete knockdown of the channel, such as in TRPV6 knockout (KO) mice, might 
also affect other proteins that would normally interact with the channel [14]. 
Under normal dietary Ca2+ conditions, no differences in Ca2+ homeostasis and 
mRNA expression levels of genes involved in Ca2+ homeostasis were observed 
between wild-type and TRPV6D541A/D541A mice. Presumably, under these conditions 
paracellular Ca2+ absorption prevailed, explaining the lack of differences between 
both genotypes. Importantly, when challenged with a Ca2+ deficient diet, 
TRPV6D541A/D541A mice showed decreased duodenal transcellular Ca2+ absorption 
compared to wild-type mice. This further substantiates that transcellular 
absorption becomes more important during dietary Ca2+ restriction.
Interestingly, Ca2+ absorption was not completely absent in TRPV6D541A/D541A mice, 
implying that other mechanisms are critically involved in transcellular Ca2+ 
absorption. Similar observations have been made in TRPV6 KO mice, in which it 
Figure 1  Structure of transient receptor potential (TRP) proteins. A Schematic 
representation of the six membrane-spanning domains (S1–S6) of a TRP protein, 
with the intracellular amino (N) and carboxy (C) termini. The pore loop (P) is 
located between domain 5 and 6. B Four TRP monomers assemble into a homo- or 
heterotetramer forming a functional cation channel.
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was shown that in the absence of TRPV6, there is still a considerable amount of 
transcellular Ca2+ transport [14, 15]. These findings could indicate that other 
transport mechanisms can, under these specific circumstances, partially 
compensate for the loss of TRPV6. Indeed, during dietary Ca2+ restriction, the 
duodenal expression of TRPV5 was increased significantly in TRPV6D541A/D541A in our 
study. A smaller, albeit non-significant, increase of TRPV5 expression was also 
observed in wild-type mice. Since the expression of TRPV5 in the duodenum is low 
compared to that of TRPV6 (approximately 25 times lower under normal conditions 
and up to 150 times lower during dietary Ca2+ restriction), the physiological 
relevance of this increase in TRPV5 expression remains questionable. Another 
explanation for the remaining Ca2+ transport in absence of TRPV6 would be that 
an additional, potentially yet-unidentified, transporter plays an important role in 
transcellular Ca2+ transport. A potential candidate could be Cav1.3, an L-type 
calcium channel, which has been suggested to play a role in glucose-mediated 
transcellular Ca2+ absorption [16]. Cav1.3 is expressed in the duodenum but its 
presence is most prominent in the jejunum and ileum [17]. Although Cav1.3 KO 
mice have been generated, so far nothing has been reported concerning the 
maintenance Ca2+ homeostasis in these mice [18-20]. One study, however, did 
show that Cav1.3 KO mice have a smaller skeleton, lower body weight and lower 
bone mineral content compared to their wild-type littermates, which could be 
indicative of disturbed Ca2+ homeostasis [21]. To determine whether Cav1.3 indeed 
plays an important role in intestinal Ca2+ absorption in vivo, it would be interesting 
to study Ca2+ homeostasis in Cav1.3 KO mice. In addition, it could be useful to 
analyze the expression levels of Cav1.3 in the various KO models of calciotropic 
genes (such as TRPV6, calbindin-D9K, and 1aOHase, vitamin D receptor, CaSR) 
under normal dietary circumstances as well as during Ca2+ deficiency. This would 
allow determining whether Cav1.3 can play a compensatory role, maintaining 
adequate levels of intestinal Ca2+ absorption in periods of low Ca2+ availability or 
in the absence of TRPV6. In order to get a complete picture of all the major players 
in transcellular intestinal Ca2+ absorption, it is important to determine whether 
Cav1.3 is indeed the “missing link” which is responsible for the remaining Ca2+ 
absorption seen in TRPV6 KO mice.
Understanding proton-pump inhibitor-induced hypomagnesemia
Proton-pump inhibitors (PPIs), a group of powerful suppressors of gastric acid 
secretion, have been on the market for more than two decades and are generally 
considered to have a good safety profile. In 2006, however, two cases of PPI-induced 
hypomagnesemia (PPIH) were reported in the New England Journal of Medicine 
[22]. This first report created awareness amongst physicians with regard to this 
potentially serious side effect, and in the following years more cases of PPIH were 
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described [22]. Subsequently, the United States Food and Drug Administration 
issued a warning, informing the general public that PPI’s may cause 
hypomagnesemia if taken for a prolonged period of time [23]. As patients show no 
evidence of a renal Mg2+ leak, PPIH was hypothesized to result from intestinal 
malabsorption of Mg2+ [24, 25]. However, the exact mechanism underlying this 
defect in intestinal Mg2+ absorption remains unknown. In Chapter 3, we aimed to 
develop a mouse model of PPIH to study the underlying molecular mechanisms of 
this type of drug-induced hypomagnesemia. Although treatment with the PPI 
omeprazole did not cause hypomagnesemia in mice, it increased mRNA expression 
of TRPM6 in the colon. In addition, the mRNA expression of the colonic H+,K+-ATPase 
(cHK-α), a homologue of the gastic H+,K+-ATPase which is the primary target of 
PPI’s, was also upregulated. We speculate that PPI’s inhibit cHK-α, resulting in a 
diminished extrusion of protons into the lumen of the colon (Figure 2). 
Interestingly, an acidic environment is known to stimulate Mg2+ influx via TRPM6 
[26]. Thus, reduced H+ excretion via cHK-α as a consequence of its inhibition by 
omeprazole could, therefore, result in declined Mg2+ transport via TRPM6. 
In the situation that reduced intestinal Mg2+ absorption resulting from PPI use is 
indeed caused by local pH changes in the colon, PPIH might be easily prevented by 
acidifying the colonic milieu. Coudray et al. have published a review describing 
Figure 2  Schematic model of the hypothesized model for PPIH. A. Under normal 
circumstances, Mg2+ transport via TRPM6 is stimulated by protons. B. Omeprazole 
inhibits the colonic H+,K+-ATPase (cHK-α), resulting in reduced proton secretion 
into the intestinal lumen. When cHK-α is inhibited by omeprazole, the stimulatory 
effect on TRPM6 is diminished, resulting in a decrease of colonic Mg2+ absorption 
via TRPM6.
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the effects of different types of fermentable carbohydrates on intestinal Mg2+ 
absorption [27]. Fermentation of carbohydrates by bacteria acidified the caecum 
and colon, and was shown to increase intestinal Mg2+ absorption in various 
animal models as well as in humans. These findings strengthen our hypothesis 
that local changes in pH can affect Mg2+ absorption in the colon. Interestingly, this 
simple dietary intervention could prevent the development of PPIH.
Despite the large number of PPI users worldwide, less than 100 cases have been 
reported to date. This does, however, not necessarily mean that the incidence is 
low. Hypomagnesemia often remains asymptomatic for a long period of time and 
many physicians are still unaware of this side effect of PPI’s. In 2012, a retrospective 
study by Gau et al. showed that in a group of hospitalized patients, PPI use is 
associated with subclinically reduced serum Mg2+ levels [28]. Their study, however, 
did not take into account confounding factors commonly associated with 
hypomagnesemia including gastrointestinal illness, diarrhea, vomiting, chronic 
alcohol use, and chronic use of laxatives, diuretics or other drugs causing Mg2+ 
deficiency. The incidence of lower gastrointestinal illness was significantly higher 
in the PPI group compared to the control group, which may explain the increased 
incidence of hypomagnesemia since lower gastrointestinal disease may lead to 
reduced intestinal Mg2+ absorption and increased intestinal Mg2+ losses [29]. 
Other studies failed to find an association between PPI use and hypomagnesemia 
in their cohorts [30, 31]. This difference is most likely the result of the stricter 
exclusion criteria and correction for confounding factors in the latter studies 
compared to the study by Gau et al. [28]. The key to the correlation between PPI use 
and hypomagnesemia may indeed be found in these confounding factors, as was 
recently demonstrated by Danziger et al. who showed that the use of PPIs only 
correlated with lower serum Mg2+ levels in patients that also used diuretics. 
Among patients concurrently using diuretics, PPI use was associated with a 
significant higher incidence of hypomagnesemia (odds ratio 1.54). In addition, 
serum Mg2+ concentrations were slightly lower in diuretic users with PPI-treatment 
compared with diuretic users not taking PPI’s. Interestingly, the association was 
strongest in those patients taking loop diuretics, followed by patients taking 
thiazides, both of which are known to reduce renal Mg2+ reabsorption [32]. 
Mobilization of Mg2+ from bone stores may maintain plasma concentrations, 
despite a net negative balance as a result of impaired intestinal absorption. This is 
in line with the fact that PPIH patients are often severely Mg2+ depleted upon 
presentation after long-term PPI use (>1 year). 
Due to the, seemingly, low incidence of PPIH, authors of the case-reports often 
speculate on the potential involvement of mutations or SNP’s in TRPM6 in the 
Chapter 8
148
development of PPIH. It is indeed possible that rare genetic variants of 
magnesiotropic genes, or of other genes such as cHK-α, contribute to PPIH. 
However, it is also possible that chronic PPI use slightly decreases intestinal Mg2+ 
absorption in all patients. The development of PPIH could, in that case, depend on 
a patient’s Mg2+ intake, as well as on how well the patient is able to compensate for 
the reduced levels of intestinal absorption via, for example, increased renal Mg2+ 
reabsorption. Carefully designed balance studies are needed to address via which 
mechanisms PPIs negatively affect Mg2+ homeostasis. Meanwhile, physicians 
should be aware of this potentially serious side effect, particularly in “high-risk” 
patients, i.e. long-term PPI users who also take diuretics or other drugs that can 
contribute to the development of hypomagnesemia. By monitoring both serum 
and urinary Mg2+ levels in PPI users, susceptible patients can be identified in an 
early stage of PPIH development. In these patients, serious Mg2+ depletion can be 
prevented by dietary interventions or by the prescription of oral Mg2+ supplements.
Stable Mg2+ isotopes, applicability in absorption studies 
As described in chapter 3, TRPV6 and TRPM6 are expressed at different segments 
of the gastrointestinal tract, indicating that transcellular absorption of Ca2+ and 
Mg2+ are spatially separated. In humans, TRPV6 is expressed predominantly in the 
stomach and duodenum, whereas TRPM6 is mainly expressed in the ileum and 
colon. In mice, TRPV6 was also expressed in caecum and distal segments of the 
colon, while TRPM6 was in addition to ileum and colon also abundantly detected 
in caecum (Figure 3). Mice are non-ruminant herbivores that have a large caecum 
compared to humans, which houses many types of microorganisms that play an 
important role in digestion of plant material by contributing to the enzymatic 
breakdown of cellulose [33, 34]. Since the digestion of cellulose in the caecum of 
mice takes place relatively far along the intestine, the animal would miss a lot of 
nutrients if it only can absorbed its nutrients in the proximal segment. This 
difference could explain the discrepancy between the expression pattern of 
TRPV6 in humans, which do not have a caecum aiding to the digestion of cellulose, 
and mice. The high expression levels of TRPV6 in the stomach are interesting, 
since the stomach is not generally considered to play a role in Ca2+ absorption. It 
has, therefore, been suggested that TRPV6 plays a role in maintaining intracellular 
Ca2+ balance in gastric cells after mucus secretion to refill the depleted Ca2+ stores 
[35]. In addition, TRPV6 has been shown to mediate capsaicin-induced apoptosis 
in gastric cells, the physiological relevance of this finding remains to be 
determined [36].  
One of the reasons that knowledge with regard to intestinal absorption of Mg2+ is 
limited is the lack of proper tools to investigate the absorption processes. In 
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contrast to Ca2+, Mg2+ does not have a radioactive isotope that is suitable for 
research. There are, however, two stable Mg2+ isotopes (25Mg2+ and 26Mg2+) that can 
be distinguished from “normal” 24Mg2+ by inductively coupled plasma mass 
spectrometry (ICPMS). These stable isotopes can be used as tracers in absorption 
studies [37, 38]. In a human setting, these isotopes have been applied to study Mg2+ 
Figure 3  Schematic overview of paracellular and transcellular absorption of Ca2+ 
and Mg2+ along the gastrointestinal tract. In the duodenum, Ca2+ and Mg2+ are 
absorbed via the paracellular pathway involving claudins. In addition, 
transcellular Ca2+ absorption mediated via TRPV6, calbindin-D9K and PMCA1b 
takes place in this segment. Transport of Ca2+ and Mg2+ in the jejunum and ileum 
are not yet clearly defined. In mice, the caecum and distal colon play an important 
role in transcellular absorption of Ca2+ and Mg2+ via TRPV6 and TRPM6. The 
basolateral extrusion mechanism for Mg2+ (?) remains to be defined. Despite the 
tight epithelium, paracellular transport can occur in these segments at high 
luminal concentrations. In the human colon, TRPV6 is not expressed, indicating 
that only Mg2+ is absorbed at this location via the transcellular pathway involving 
TRPM6.
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absorption via faecal monitoring [39]. Similar methods have been applied in 
rodents [40]. However, extensive time-dependent studies following the actual 
absorption of Mg2+ from the intestinal lumen in time have not been published so 
far. 
 In chapter 3, a method to assess in vivo absorption of Mg2+ using the 25Mg2+ 
isotope was developed. With this assay, it is possible to determine time-dependent 
absorption of Mg2+ from the intestine into the circulation. In addition, it was 
shown that intestinal Mg2+ absorption is regulated by bodily needs, exemplified 
by an increase in intestinal absorption when mice were placed on an Mg2+ 
deficient diet. These studies showed that Mg2+ depletion elicits a robust response 
in the kidneys, where the reabsorption of Mg2+ is increased to such extent that 
urinary Mg2+ excretion is virtually diminished. Intestinal absorption of Mg2+ 
changes in response to depletion, however the changes are relatively small. In 
sharp contrast, Ca2+ depletion leads to strong adaptations in intestinal absorption 
of Ca2+, whereas the renal excretion of Ca2+ is much less affected [13].
Interestingly, Mg2+ depletion did not only decrease the urinary excretion of Mg2+, 
but also that of Ca2+. The debate concerning the molecular mechanism underlying 
this observation dates back to the early 20th century [41]. Recently, Bonny et al. 
have addressed this phenomenon in an elegant series of experiments [42]. These 
investigators showed that intravenous Mg2+ infusion significantly increases 
urinary Ca2+ excretion, indicating a renal effect. The outcome was not influenced 
by parathyroidectomy, nor by administration of furosemide, suggesting that the 
process is PTH independent and does not take place in the TAL. The authors 
postulate that Mg2+ directly inhibits the Ca2+ uptake by TRPV5 [42]. Ca2+ currents 
through TRPV5 are largely inhibited in the presence of 1mM extracellular Mg2+, 
which is in line with luminal Mg2+ concentrations in the DCT/CNT [43, 44]. 
Alternatively, other studies using micropuncture have shown that the regulation 
of Ca2+ excretion by Mg2+ takes place in the TAL, where high luminal Mg2+ would 
compete with Ca2+ for paracellular reabsorption [45, 46]. A recent study by Quinn 
et al. has also addressed this issue by comparing the effect of Mg2+ loading and/or 
Ca2+ loading in wild-type mice, PTH KO mice and double KO mice lacking both 
PTH as well as the CaSR [47]. By measuring changes in the levels of both Mg2+ and 
Ca2+ in serum and urine, as well as the levels of hormones potentially participating 
in Mg2+ homeostasis, it was demonstrated that the altered regulation of both Mg2+ 
as well as Ca2+ during Mg2+ loading involves both PTH and the CaSR. Their results 
indicate that PTH as well as the CaSR, are important in the defence against oral 
Mg2+ loading. In their model, the concurring changes in Ca2+ metabolism seem to 
result, at least in part, from phosphate depletion, presumably due to the chelation 
of phosphate by Mg2+ in the gut. 
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 Pi depletion will result in increased production of 1,25-dihydroxy-vitamin D3 
through a direct effect of Pi depletion on 1α-hydroxylase in the renal proximal 
tubule or via a decline in fibroblast growth factor 23 (FGF23)-mediated inhibition 
of 1α-hydroxylase activity. The increase in 1,25-dihydroxy-vitamin D3 levels in 
turn result in increased intestinal Ca2+ absorption [47]. All in all, the results of the 
various studies are conflicting on several points, including the role the intestines 
and kidney in this phenomenon, as well as the involvement of hormones and the 
CaSR. Further research is required, as these findings may have important 
implications in, for example, the methods of supplementation of Ca2+ and Mg2+ 
during deficiencies.
Since TRPM6 is mainly expressed in the distal intestinal segments, normal 
absorption studies in which the isotopes are administered via oral gavage into 
the stomach are not suitable to study TRPM6 mediated intestinal absorption of 
Mg2+ in vivo. Therefore, we developed a surgical procedure to implant intestinal 
cannulas, which allows isotopes to be directly administered in the caecum. 
Combining these cannulas and the stable isotopes it was shown that transcellular 
and paracellular absorption of Ca2+ mainly takes place in the proximal regions of 
the intestine. For Mg2+, paracellular transport is predominant in the proximal 
intestine whereas transcellular absorption mainly occurs in the colon. This 
absorption pattern of Ca2+ and Mg2+ is in line with the observed segmental 
expression of TRPV6 and TRPM6 indicating that transcellular Ca2+ and Mg2+ 
absorption take place at different locations along the intestine.
With the newly developed techniques, we can now address several unanswered 
questions concerning intestinal absorption of Mg2+. For example, it would be 
interesting to investigate the action recently discovered magnesiotropic hormones 
like epidermal growth factor (EGF) and insulin [48, 49]. Both the EGF receptor and 
the insulin receptor are expressed in the intestine, however, due to a lack of 
histological information on the exact expression of TRPM6 it is unclear whether 
the receptors and TRPM6 are co-expressed within the same cells [50, 51]. In 
addition to the hormonal regulation, the intestinal effects of several drugs already 
known to influence renal Mg2+ handling can now be studied [52]. Their effect on 
intestinal Mg2+ absorption is rarely investigated, but could contribute significantly 
to development of hypomagnesemia. The interference of Mg2+ with Ca2+ 
reabsorption in the kidney also triggers questions with regard to the intestinal 
absorption of both cations. It is now timely to adequately address these issues, as 
well as many others. 
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Current views and future perspectives on claudins
Over the last decade, a paradigm shift has taken place concerning our scientific 
view of paracellular transport. With the identification of the family of claudin 
proteins, it became clear that paracellular transport is subject to regulation and 
much more specific and selective than scientists originally recognized. Tight 
junctions share biophysical properties with conventional ion channels, including 
size and charge selectivity, dependency of permeability on electrochemical 
gradients, competition between permeant molecules, anomalous mole-fraction 
behavior, and sensitivity to pH [53]. The current notion is that claudins form 
paracellular channels, making them a new class of channels that join two 
extracellular compartments and determine epithelial tightness by controlling 
paracellular transport between compartments. 
Table 1  Putative ion permeability characteristics of claudin isoforms
Claudin
Cation selective Anion Selective
Predominantly cation pore-forming Predominantly anion pore-forming
Claudin 2 Claudin 7
Claudin 10 Claudin 10
Claudin 16 Claudin 17
Predominantly anion barrier-forming Predominantly cation barrier-forming
Claudin 7 Claudin 1
Claudin 19 Claudin 3
Claudin 4
Claudin 5
Claudin 6
Claudin 9
Claudin 14
Claudin 18
Potential to form cation pore or anion barrier Potential to form anion pore or cation barrier
Claudin 15 Claudin 4
Claudin 8
Claudin 11
Adapted from [2, 54]
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By studying the functional consequences of mutations in CLDN16 and CLDN19, 
considerable progress has been made in our understanding of paracellular 
reabsorption of Ca2+ and Mg2+ in the kidney [55]. With regard to intestinal 
absorption of Ca2+ and Mg2+ via the paracellular pathway, however, little is known 
so far. In chapter 5, the expression of several claudin isoforms along the gastroin-
testinal tract was determined in a panel of human intestinal biopsy samples. 
Claudins were shown to have distinct expression patterns throughout the gastro-
intestinal tract. In addition, analysis of expression levels of claudins in patients 
with Crohn’s disease, active, and inactive ulcerative colitis disclosed that changes 
in claudin expression in inflammatory bowel disease are confined to specific 
intestinal segments, and strongly depend on the inflammatory activity.
The intestine as well as the nephron display an overall decrease in paracellular 
permeability towards their distal end. However, individual segments also show 
major differences with respect to their specific physiological function. This is 
achieved at the molecular level by segment-specific expression of different 
claudins [56]. For the nephron, claudin expression patterns have been relatively 
well defined [57]. For example, segments that reabsorb large quantities of solutes 
and water such as the proximal tubule (PT) and thin descending limb (tDL), 
predominantly express pore-forming claudins, whereas tightening claudins are 
present in the water-impermeable thin ascending limb (tAL) [57]. Studying 
expression pattern of claudins can thus learn us important lessons about their 
function. This also applies to the intestine. CLDN18, for example, which is solely 
expressed in the stomach, has been shown to prevent paracellular H+ leakage, 
which is essential for maintaining the low gastric pH [58]. Figure 4 presents an 
overview of the expression patterns of various claudins along the nephron and 
the gastrointestinal tract. Based on the expression patterns described in our study, 
CLDN2 and CLDN15 are interesting candidates that could play a role in intestinal 
absorption of Ca2+ and Mg2+, as they are mainly expressed in the proximal 
intestinal segments, which are known to be responsible for the bulk of paracellular 
mineral absorption.
CLDN2 is known to function as a high-conductance, cation-permeable paracellular 
pore, which is permeable to, and inhibited by, Ca2+ [59, 60]. In the kidney, CLDN2 
is highly expressed in the leaky PT, where up to 60% of the filtered Ca2+ load is 
reabsorbed from the pro-urine via the paracellular pathway. Interestingly, CLDN2 
KO mice exhibit decreased proximal reabsorption of Na+, Cl- and water. In 
addition, CLDN2 KO mice display hypercalciuria, indicating that claudin-2 plays a 
role in paracellular Ca2+ transport in the PT [61]. In the intestine, CLDN2 expression 
was highest in the various segments of small intestine, which are relatively leaky 
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and the main site of paracellular Ca2+ and Mg2+ absorption. In contrast, CLDN2 is 
virtually absent in the colon, where the epithelium is generally considered to be 
tight [56, 62]. In vitamin D receptor KO mice, intestinal expression of CLDN2 and 
Figure 4  Expression patterns of claudin isoforms along the nephron and 
 gastrointestinal tract. A. Overview of the expression patterns of claudins along 
the nephron based on literature review. dTL, thin descending limb; aTL, thin 
ascending limb; TAL, thick ascending limb; DCT, distal convoluted tubule; CNT, 
connecting tubule. Adapted from [1-3]. B. Overview of the expression patterns of 
claudins along the gastrointestinal tract based on the studies described in chapter 5. 
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CLDN12 was significantly reduced compared to wild-type mice [63]. The expression 
of both genes was increased by 1,25-dihydroxyvitamin D3 in an intestinal 
epithelial cell line, Caco2 cells, coinciding with an increase in paracellular Ca2+ 
transport and a reduction of the transepithelial electrical resistance (TEER) [63]. 
These findings strongly suggest that tight junctions consisting of claudin 2 and/
or claudin 12 form paracellular Ca2+ channels in intestinal as well as in renal 
epithelia. Importantly, they highlight a novel, vitamin D sensitive, mechanism 
participating Ca2+ homeostasis. Of note, the function of claudin 12 is not yet 
entirely clear. On one hand it has been proposed to increase paracellular 
permeability, potentially facilitating paracellular transport of Ca2+, and on the 
other hand a role in epithelial tightening may be deduced from its expression 
within the blood vessels of the brain and the urinary bladder [64, 65]. The function 
of claudin 12 may be affected by the presence of other claudins, which would 
explain the distinct function in different tissues.
Several studies suggested that CLDN15 is responsible for prolactin-stimulated 
paracellular intestinal Ca2+ absorption [19, 66]. In NHE3 KO mice, which display 
various abnormalities in their Ca2+ homeostasis including reduced intestinal Ca2+ 
absorption, both CLDN2 and CLDN15 expression in jejunum is reduced, again 
linking CLDN15 to Ca2+ homeostasis [67]. Other studies, however, showed that the 
overexpression of CLDN15 does not increase paracellular Ca2+ transport in Caco-2 
cells [63]. The phenotype of the CLDN15 KO mice is in this respect informative [68, 
69]. Most strikingly, these mice have an enlargement of their small intestine [68]. 
Furthermore, the luminal Na+ concentration in their small intestine was 
abnormally low, and glucose absorption was impaired [69]. It has, therefore, been 
suggested that CLDN15 could serve as a leaky Na+ channel [69]. At the cellular 
level, claudin-15 is localized in close proximity to the sodium–glucose symporter 
SGLT1 and may contribute to the recirculation of Na+ [69]. In line with the observed 
impairment of glucose absorption, the observed decrease in luminal Na+ directly 
diminishes the activity of SGLT1 in the small intestine, particularly in the jejunum, 
which is the major site of glucose absorption [69]. Interestingly, this is also the site 
where Cav1.3 has been suggested to participate in transcellular Ca2+ absorption. 
CLDN15 is, therefore, not likely to be directly involved in paracellular Ca2+ transport. 
Instead, it probably facilitates the backleak of Na+, which is important for SGLT1 
and NHE3 function. The transport of Na+ across the apical plasma membrane, 
facilitated by these proteins, most likely plays a role in Ca2+ transport, potentially 
by changing the transmembrane electrical potential. This change in potential 
could in turn affect Ca2+ transport via, for example, Cav1.3. Alternatively, 
transcellular Na+ transport may contribute to the maintenance of a transepithelial 
electrochemical gradient facilitating paracellular Ca2+ transport (Figure 3).
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Other interesting candidates in intestinal mineral transport would be CLDN10 
and CLDN14. CLDN10 KO mice have been shown to suffer from hypermagnesemia 
and hypocalcemia, opposing the phenotype of CLDN16 KO mice, which display 
hypomagnesemia and hypercalciuria [70, 71]. Similarly, CLDN14 KO animals 
developed hypermagnesemia and hypocalciuria [72]. CLDN14 has been shown to 
regulate Ca2+ and Mg2+ absorption via an interesting mechanism, involving the 
CaSR and miRNA’s. The expression of miR-9 and miR-374 is regulated by serum 
Ca2+ levels, which are sensed by the CaSR. MiR-9 and miR-374 determine the 
expression level of CLDN14, which in turn can block the paracellular cation 
channel formed by claudin 16 and 19, thereby reducing Ca2+ reabsorption in the 
TAL [73]. Extensive bioinformatical analysis with regard to miRNA target sites in 
claudins could reveal new players in renal, but most importantly, intestinal Ca2+ 
and Mg2+ absorption.
New perspectives of idiopathic infantile hypercalcemia
Idiopathic infantile hypercalcemia (IIH) is a potentially life-threatening disease. 
Interestingly, it is of a transient nature since symptoms usually resolve between 
the ages of 1 to 3 years. IIH was originally described in the United Kingdom in the 
1950s by Lightwood and Fanconi [74, 75] who subdivided their cases into a “mild” 
and a “severe” type, to distinguish between patients suffering solely from 
hypercalcemia and patients who also displayed additional abnormalities such as 
distinctive facial features [76]. The “mild” form, also known as the Lightwood-type 
IIH, has become rare since many European countries forbade vitamin D 
fortification of dairy and food products after an outbreak of vitamin D intoxication 
in neonates. “Severe” IIH, also known as Fanconi-type hypercalcemia, is nowadays 
considered to be one of many symptoms that are part of the Williams-Beuren 
syndrome (WBS) phenotype. WBS is caused by a hemizygous microdeletion at 
7q11.23, encompassing 24 genes [77] [78, 79]. In chapter 4, we hypothesized that the 
similarities in the course of development of hypercalcemia in isolated IIH patients 
and patients suffering from WBS can be explained by a shared underlying genetic 
defect. Figure 5 shows the genes located in the deleted chromosome region in WBS 
patients. A phenotype-genotype correlation has been demonstrated for only a 
few of the genes within this region, such as ELN and LIMK, which are linked to 
supravalvular aortic stenosis and impaired visuospatial constructive cognition 
respectively [79]. Based on this list of candidate genes, we hypothesized that the 
hemizygous deletion of two claudin genes (CLDN3 and CLDN4) can be responsible 
for the hypercalcemia in WBS patients, and could therefore also be responsible for 
the hypercalcemia in our IIH patients [80]. After careful analysis, we concluded 
that in our patients IIH is not caused by mutations in these candidate genes nor by 
deletions or duplications in the genome. 
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Recently, two groups described a new genetic defect in a large cohort of IIH 
patients and patients suspected to suffer from vitamin D intoxification [81, 82]. 
These studies confirm that loss of function of the vitamin D 24-hydroxylase 
enzyme (CYP24A1) can result in IIH. Since CYP24A1 is responsible for breakdown 
of active vitamin D into inactive metabolites, lack of CYP24A1 can result in 
Figure 5  Overview of the genes localized in the WBS deletion region. WBS is 
characterized by the hemizygous microdeletion of the q11.23 region on chromosome 
7. FZD1, frizzled family recoptor 1; BAZ1B, bromodomain adjacent to zinc finger 
domain, 1B; BCL7B, B-cell CLL/lymphoma 7B; TBL2, transducin (beta)-like 2; 
MLXIPL, MLX interacting protein- like; VPS37D, vacuolar protein sorting 37 
homolog D; DNAJC30, DnaJ (Hsp40) homolog, subfamily C, member 30; WBSCR22, 
Williams Beuren syndrome chromosome region 22; STX1A, syntaxin 1A; ABHD11, 
Abhydrolase domain-containing protein 11; CLDN3, claudin 3; CLDN4, claudin 4; 
WBSCR27, Williams Beuren syndrome chromosome region 27; WBSCR28, Williams 
Beuren syndrome chromosome region 28; ELN, elastin; LIMK1, LIM domain kinase 
1; EIF4H, Eukaryotic translation initiation factor 4H; LAT2, linker for activation of 
T cells family, member 2; RFC2, Replication factor C subunit 2; CLIP2, CAP-GLY 
domain containing linker protein 2; GTF2IRDI, general transcription factor 2IRDI; 
WBSCR23, Williams Beuren syndrome chromosome region 28.
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elevated levels of 1,25-dihydroxy-vitamin D3 due to its reduced catabolism. 
Interestingly, serum 25-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 levels 
were only elevated in those patients that were given a high bolus injection of 
1,25-dihydroxy-vitamin D3 (600,000 IU), while patients who received normal 
doses of 1,25-dihydroxy-vitamin D3 prophylaxis (500 IU per day) displayed normal 
vitamin D levels, despite their lack of normal CYP24A1 to catabolize active vitamin D.
The transient nature of IIH remains to be explained. Interestingly, approximately 
half of the homozygous KO Cyp24a1 mice died before weaning due to severe 
hypercalcemia (20, 21). The homozygote mutants that survived past their weaning 
period had lower baseline circulating 1,25-dihydroxy-vitamin D3 levels compared 
to wild-type controls. In addition, the surviving KO mice were found to have a 
decreased ability to clear 1,25-dihydroxy-vitamin D3 from their blood (21). These 
mice also displayed decreased renal expression levels of Cyp27b1, which is 
responsible for the synthesis of active vitamin D (22). This compensatory 
mechanism could explain the lower circulating levels of baseline 1,25-dihy-
droxy-vitamin D3 in the surviving homozygous mice and, if a similar mechanism 
is present in humans, may clarify why the hypercalcemia in IIH appears to 
improve over time (7). Another explanation of the transient nature of 
hypercalcemia in IIH patients can be found in patients suffering from Sotos 
syndrome. A subset of these hypercalcemic patients lack not only NSD1 but also 
SLC43A1 as a result of a microdeletion on chromosome 5q35 [83, 84]. SLC34A1 
encodes NaPi2A, a renal phosphate transporter [85]. An interesting theory has 
been proposed with regard to the transient nature of hypercalcemia in these 
infants: impaired renal phosphate reabsorption leading to hypophosphatemia 
could result in activation of vitamin D and in turn, increased intestinal absorption 
of Ca2+ and phosphate, resulting in hypercalcemia and hypercalciuria [83]. The 
demand on renal phosphate reabsorption is highest during infancy, due to higher 
plasma levels and the phosphate requirement of the growing skeleton [85]. When 
phosphate handling matures, and therefore vitamin D requirement and 
production is diminished, intestinal hyperabsorption of Ca2+ ceases, normalizing 
Ca2+ homeostasis. This could provide an alternative explanation for transient 
hypercalcemia in IIH patients. 
Although the biochemical characteristics of the patients described in chapter 4 
closely resembled those of the patients with a CYP24A1 mutation, they all tested 
negative for mutations in this gene (unpublished results). The mechanism 
underlying IIH in our patients, therefore, remains unresolved to date. Interestingly, 
there is another potential candidate gene within the region that is deleted in the 
WBS patients. BAZ1B, also known as Williams Syndrome Transcription Factor 
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(WSTF), is located within the WBS deletion region and encodes a subunit of the 
ATP-dependent chromatin remodelling complex WINAC, whose activity 
facilitates ligand-dependent activation of CYP24A1 and repression of CYP27B1 by 
the vitamin D receptor (VDR) [86]. Loss of WINAC function will lead to less 
transcription of CYP24A1 and increased transcription of CYP27B1 similar to 
CYP24A1-/- mice and patients with CYP24A1 mutations [87]. Lack of a significant 
increase in 1,25-dihydroxyvitamin D3 levels in WBS patients seems to contradict 
this hypothesis. However, the phenotype of patients with CYP24A1 mutations 
demonstrates that a lack of 25-dihydroxyvitamin D 24-hydroxylase indeed leads 
to a hypercalcemic phenotype without a concomitant increase in circulating 
1,25-dihydroxyvitamin D3 levels [88]. Further investigations measuring vitamin 
D metabolism and catabolism in WBS patients will shed more light on the 
involvement of BAZ1B/WSTF and vitamin D metabolism in hypercalcemia in this 
group of patients. Furthermore, BAZ1B could be an interesting candidate for 
genetic screening in IIH patients negative for CYP24A1 mutations.
Conclusion and future perspectives
The general aim of this thesis was to generate more insight in the physiological, 
pathophysiological and pharmacological regulation of intestinal Ca2+ and Mg2+ 
transport. The studies presented in this thesis illustrate the importance of TRPV6 
and TRPM6 in intestinal absorption of Ca2+ and Mg2+, respectively. A new method 
was developed enabling the direct measurement of intestinal Mg2+ absorption 
using intestinal cannulas and stable Mg2+ isotopes. With this method, it is now 
possible to perform time-dependent, segment specific absorption studies in an in 
vivo setting. We applied this technique, showing the spatial separation of active 
Ca2+ and Mg2+ transport in the intestine. In order to gain more insight in the role of 
claudins in intestinal ion transport, the expression patterns of several claudins 
along the intestinal tract was determined. Three patients with IIH, were described, 
and using a candidate-based approach we tried to unravel the mechanisms 
underlying this phenotype. A case of a patient with WBS coinciding with 
hypercalcemia is described and a hypothesis with regard to the underlying 
molecular defect is discussed in the light of recent genetic findings in children 
suffering from IIH.
Recent studies have identified EGF and insulin as novel magnesiotropic hormones, 
while their effect on intestinal absorption remains unknown. These, and many 
other questions can now be addressed with the aid of the Mg2+ absorption 
technique established in this thesis. Although the importance of claudins in 
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paracellular Ca2+ and Mg2+ reabsorption in the kidney is now well defined, their 
role in intestinal transport remains largely unknown. Based on the intestinal 
expression pattern several candidates were selected and their relevance with 
respect to Ca2+ and Mg2+ absorption was discussed. More research is necessary to 
identify which claudin isoforms play a role in paracellular intestinal absorption 
of Ca2+ and Mg2+ and how they are regulated. Although our understanding of Ca2+ 
homeostasis is relatively well developed, especially when compared to our 
understanding of Mg2+ homeostasis, many questions remain to be answered. 
Recent findings have shed more light on the aetiology of IIH in some patients, 
however, the molecular mechanisms underlying other cases, like the ones 
described in this thesis, remain unclear. 
Future research could provide insight in the missing pieces in our knowledge 
concerning intestinal Ca2+ and Mg2+ homeostasis. To this end, researchers should 
take advantage of recent developments in the field of genetics, which makes 
extensive screening of patients as well as large populations more accessible and 
cost efficient. This type of studies may lead to the identification of new genes 
involved in Ca2+ and Mg2+ homeostasis. Using the stable Mg2+ isotopes, it is now 
also feasible to directly measure Mg2+ absorption in cell and animal models. This 
will allow assessing the function of these newly indentified transport proteins. 
Ultimately, this will help the development of new therapeutic strategies to 
regulate the intestinal absorption of minerals. New therapies should aim to 
correct disturbances in intestinal absorption, and potentially compensate for 
pathological renal losses, both of an inherited or acquired nature. 
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Hoofdstuk 1: Introductie
Calcium (Ca2+) en magnesium (Mg2+) spelen een belangrijke rol bij veel processen 
die essentieel zijn voor het functioneren van ons lichaam, zoals spiercontractie, 
botvorming en enzymactiviteit. Het is daarom van groot belang dat hun 
concentratie in het lichaam goed wordt gereguleerd. Er zijn diverse overeenkomsten 
tussen de Ca2+ en de Mg2+ huishouding in het lichaam. Zo is er veel overlap in de 
organen die betrokken zijn bij hun opname en uitscheiding, de hormonen die hun 
transport reguleren, en de biologische sensoren die de concentratie van deze 
divalente kationen in het bloed waarnemen. De concentratie van Ca2+ en Mg2+ in 
ons bloed wordt nauwkeurig gereguleerd door i) de darmen, waar deze divalente 
kationen worden opgenomen; ii) het bot, waarin mineralen kunnen worden 
opgeslagen en waar vanuit ze kunnen worden afgegeven aan het bloed; iii) de 
nieren, die de uitscheiding van Ca2+ en Mg2+ via de urine faciliteren. Omdat ons 
voedsel de enige bron van mineralen voor ons lichaam is, is opname via de 
darmen essentieel voor de handhaving van een normale Ca2+ en Mg2+ huishouding. 
Er zijn 2 routes waarlangs Ca2+ en Mg2+ geabsorbeerd kunnen worden. Bij transport 
via de paracellulaire route passeren Ca2+ en Mg2+ het epitheel via kleine ruimtes 
tussen de cellen, de zogenaamde “tight junctions”. Eiwitten uit de familie van 
claudines vormen een belangrijk onderdeel van deze tight junctions, omdat ze 
onder andere bepalen welke elektrolyten worden doorgelaten via deze 
paracellulaire route. Bij transport via de transcellulair route gaan de kationen 
door het apicale en basolaterale plasmamembraan van de cel heen, hetgeen 
mogelijk wordt gemaakt door specifieke ionkanalen en transporteurs. In de darm 
spelen de ionkanalen TRPV6 (Ca2+) en TRPM6 (Mg2+) bij dit proces een essentiële 
rol; ze faciliteren de opname van Ca2+ en Mg2+ zodat deze vanuit het lumen van de 
darm via de plasmamembraan de cel binnenkomen. Vanuit de cel kunnen deze 
ionen vervolgens via de basolaterale plasmamembraan naar het bloed worden 
getransporteerd. Het doel van het onderzoek beschreven in dit proefschrift, was 
om meer inzicht te krijgen in de fysiologische, pathofysiologische en farmacolo-
gische regulatie van Ca2+ en Mg2+ transport in de darm. Deze samenvatting geeft 
een kort overzicht van dit onderzoek en beschrijft op welke wijze het heeft 
bijgedragen aan ons begrip rondom de opname van deze twee divalente kationen 
in de darm en de processen die daarbij betrokken zijn.
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Hoofdstuk 2: TRPV6 kanalen zijn essentieel voor de transcellulaire 
absorptie van Ca2+
Het epitheliale Ca2+ kanaal TRPV6 bestaat uit 4 monomeren die samen als 
homotetrameer het transcellulaire transport van Ca2+ in de darm faciliteren. 
Iedere monomeer heeft 6 transmembraan domeinen, waarvan de hydrofobe 
regio tussen transmembraan domein 5 en 6 betrokken is bij de vorming van een 
porie waardoor Ca2+ via de apicale membraan de cel in kan diffunderen. Binnen 
deze regio bevinden zich negatief geladen aminozuren die er mede voor zorgen 
dat TRPV6 het positief geladen Ca2+ kan doorlaten. Wanneer één van deze 
aminozuren, namelijk een aspartaat op positie 541, wordt vervangen door een 
neutraal alanine residu is het ionkanaal niet meer functioneel. In hoofdstuk 2 
werd onderzocht wat de rol is van dit aminozuur van TRPV6 in de Ca2+ huishouding 
door gebruik te maken van muizen met en zonder deze aminozuurverandering 
(respectievelijk TRPV6D541A/D541A en wild-type muizen). Wanneer de muizen via het 
voer een normale hoeveelheid Ca2+ binnenkregen waren er geen verschillen 
tussen de twee soorten muizen waarneembaar; zowel serum Ca2+ concentraties, 
renale Ca2+ uitscheiding als de expressie van genen betrokken bij Ca2+ huishouding 
waren onder deze omstandigheden gelijk. Wanneer de muizen echter op een dieet 
werden geplaatst waarin slechts zeer weinig Ca2+ aanwezig was, bleek de 
hoeveelheid Ca2+ die opgenomen werd vanuit de darm in TRPV6D541A/D541A muizen 
lager dan in wild-type muizen. Op basis van deze resultaten kon geconcludeerd 
worden dat TRPV6 kanalen essentieel zijn voor de opname van Ca2+ in de darm via 
de transcellulaire route.
Hoofdstuk 3: Omeprazol stimuleert de expressie van TRPM6 in het 
colon
Protonpomp remmers, zoals omeprazol, reduceren de secretie van maagzuur sterk 
en worden daarom veelvuldig voorgeschreven aan patiënten met maagzuur-ger-
elateerde klachten. Hoewel het gebruik van omeprazol over het algemeen als 
veilig wordt beschouwd, zijn er de afgelopen jaren bijna 100 casussen gepubliceerd 
over patiënten met een protonpompremmer-geïnduceerde hypomagnesiëmie. 
Aangezien er bij deze patiënten geen aanwijzingen zijn dat de hypomagnesiëmie 
wordt veroorzaakt door een renaal Mg2+ verlies, is de momenteel gangbare 
hypothese dat deze bijwerking het gevolg is van een verminderde intestinale 
opname van Mg2+. In hoofdstuk 3 is het effect van omeprazol op de Mg2+ 
huishouding in de muis bestudeerd. Er werden geen verschillen in serum Mg2+ 
concentraties gemeten tussen muizen die waren behandeld met omeprazol en 
muizen die een placebobehandeling kregen. Ook de renale en fecale uitscheiding 
van Mg2+ was gelijk in beide groepen. Behandeling van muizen met omeprazol 
had echter wel een effect op de expressie van specifieke genen. In het colon van de 
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muizen die waren behandeld met omeprazol was de expressie van een waterstof/
kalium pomp (cHK-α) sterk verhoogd ten opzichte van muizen die behandeld 
waren met placebo. cHK-α is een homoloog van de waterstof/kalium pomp in de 
maag die het primaire aangrijpingspunt van omeprazol is. Ook de expressie van 
TRPM6 nam toe in het colon van de met omeprazol behandelde muizen. Op basis 
van deze bevindingen is de hypothese geformuleerd dat omeprazol de werking 
van cHK-α in het colon remt, waardoor er minder protonen worden uitgescheiden 
in het lumen van de darm. Aangezien TRPM6 wordt gestimuleerd door extra-
cellulaire protonen kan dit leiden tot een vermindering van het transport van 
Mg2+ via TRPM6. De toename van TRPM6 expressie kan potentieel compenseren 
voor het verminderde transport, waardoor de intestinale absorptie op peil blijft. 
Dit zou verklaren waarom de behandeling van muizen met omeprazol niet leidt 
tot veranderingen in serum Mg2+ concentraties, of tot een verandering in de 
uitscheiding van Mg2+ via de urine en feces. 
Hoofdstuk 4: Segmentale absorptie van Ca2+ en Mg2+
TRPV6 en TRPM6 hebben verschillende expressiepatronen in de humane darm. 
TRPV6 komt voornamelijk tot expressie in de proximale segmenten, zoals het 
duodenum, terwijl TRPM6 vooral in het colon voorkomt. Deze bevinding 
suggereert dat de transcellulaire absorptie van Ca2+ en Mg2+ op verschillende 
locaties in de darm plaatsvindt. Met behulp van stabiele Mg2+ isotopen werd 
aangetoond dat de intestinale Mg2+ absorptie afhankelijk is van de mate waarin 
het lichaam behoefte heeft aan Mg2+. Zo neemt de opname van Mg2+ in de darm 
bijvoorbeeld toe wanneer er langere tijd weinig Mg2+ in het voedsel aanwezig is. 
Met behulp van canules, geplaatst in verschillende segmenten van de darm van 
muizen, werd aangetoond dat Ca2+ transport zowel bij lage als bij hoge luminale 
Ca2+ concentraties voornamelijk plaatsvindt in de dunne darm. Mg2+ transport 
daarentegen vindt bij hoge luminale Mg2+ concentraties vooral plaats in het 
duodenum, terwijl het bij lagere concentraties meer in het caecum en colon wordt 
opgenomen. Deze bevindingen sluiten aan bij eerder beschreven expressiepa-
tronen van TRPV6 en TRPM6. Er is weinig bekend over de hormonale regulatie van 
de Mg2+ absorptie in de darm. Er wordt gesuggereerd dat vitamine D niet alleen 
een effect op de Ca2+ absorptie, maar ook op de Mg2+ opname heeft. Op basis van 
de studies in dit proefschrift lijkt er echter geen effect te zijn van vitamine D op de 
intestinale absorptie van Mg2+ of de expressie van de daarbij betrokken genen. 
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Hoofdstuk 5: Expressiepatronen van claudines in het humane 
gastro-intestinale stelsel 
Als onderdeel van de tight junctions bepalen claudines voor een groot deel de 
permeabiliteit van het epitheel in onder andere de darmen en de nieren. Ze spelen 
daarom een belangrijke rol in het paracellulaire transport in deze organen. In 
hoofdstuk 5 zijn de mRNA expressiepatronen van diverse claudines binnen de 
verschillende segmenten van het gastro-intestinale stelsel van de mens 
onderzocht. Daarnaast is het effect van inflammatoire darmziekten zoals de 
ziekte van Crohn en Colitis Ulcerosa op de expressie van deze claudines bestudeerd. 
De verschillende claudines hebben ieder een specifiek expressiepatroon, veelal 
samenhangend met de functie van de desbetreffende transporteur en het 
intestinale segment. Zo komen de claudines die het epitheel permeabel maken 
voor water en elektrolyten veelal tot expressie in de dunne darm, terwijl de 
claudines die het epitheel minder doorlaatbaar maken juist meer voorkomen in 
de distale segmenten van de darm. Daarnaast werd aangetoond dat veranderingen 
in de expressie van claudines in patiënten met inflammatoire darmziekten 
afhankelijk is van het intestinale segment dat onderzocht wordt en van de lokale 
ontstekingsgraad. 
Hoofdstuk 6: De rol van claudines in idiopathische infantiele 
hypercalciëmie
Idiopathische infantiele hypercalciëmie (IIH) is het gevolg van intestinale 
hyperabsorptie van Ca2+. Het is een zeldzame ziekte die meestal voor het eind van 
het derde levensjaar vanzelf verdwijnt. Een vergelijkbaar beeld van tijdelijke 
hypercalciëmie komt voor bij patiënten die lijden aan het Williams-Beuren 
syndroom (WBS), waarbij een heterozygote microdeletie op chromosoom 7 heeft 
plaatsgevonden. Op basis van het Ca2+ fenotype in IIH en WBS patiënten werd 
verondersteld dat er een overeenkomstig onderliggend genetisch defect zou 
kunnen zijn. WBS-patiënten missen een gebied dat codeert voor meer dan 25 
genen, waaronder CLDN3 en CLDN4. Deze 2 genen, die coderen voor claudine 3 en 
4, zijn belangrijk bij het paracellulaire transport van ionen en komen tot expressie 
in de darm. Op basis van een grondige genetische analyse, uitgevoerd aan de 
hand van drie goed gekarakteriseerde IIH patiënten, werd aangetoond dat IIH 
niet veroorzaakt wordt door mutaties in CLDN3, CLDN4 of TRPV6, noch door 
deleties of duplicaties in het genoom.
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Hoofdstuk 7: Het belang van een Ca2+ en vitamine D beperkt dieet  
in WBS
Een patiënt met ernstige hypercalciëmie in combinatie met WBS illustreert hoe 
belangrijk de beperking van zowel Ca2+ als vitamine D kan zijn wanneer de 
gebruikelijke behandeling met bijvoorbeeld bifosfonaten onvoldoende resultaat 
heeft. Overeenkomsten met betrekking tot de Ca2+ huishouding in WBS en IIH 
patiënten suggereren dat er een gezamenlijk onderliggend defect in deze patiënten 
aanwezig is. In een groot aantal patiënten is recentelijk aangetoond dat mutaties 
in CYP24A1, een belangrijk enzym in de degradatie van 1,25-dihydroxyvitamin D3, 
kunnen leiden tot IIH. Opmerkelijk is dat een van de genen die ontbreekt in de 
aangedane chromosomale regio bij WBS-patiënten codeert voor Williams 
Syndrome Transcription Factor (WSTF). Het corresponderende eiwit is betrokken 
bij de transcriptie van twee enzymen (CYP24A1 en CYP27B1) die een essentiële rol 
vervullen in het vitamine D metabolisme. De heterozygote deletie van WSTF in 
WBS patiënten zou mogelijk het Ca2+ fenotype in deze patiënten en de 
overeenkomsten met IIH patiënten kunnen verklaren.  
Hoofdstuk 8: Algemene discussie
De studies beschreven in dit proefschrift hebben inzicht gegeven in de 
fysiologische, pathofysiologische en farmacologische regulatie van Ca2+ en Mg2+ 
transport in de darm. In de diverse studies is het belang van het transcellulaire en 
paracellulaire transport, en de hierbij betrokken spelers zoals TRP-kanalen en 
claudines, op de absorptie van Ca2+ en Mg2+ in de darm onderzocht. Daarnaast 
werd een techniek ontwikkeld om met behulp van stabiele Mg2+ isotopen op een 
tijdsafhankelijke manier te bepalen hoeveel Mg2+ vanuit de darm wordt 
opgenomen. Door middel van canules, die in verschillende segmenten van de 
darm kunnen worden geplaatst, kan bovendien de absorptie in een specifiek deel 
van de darm bestudeerd worden. 
Er zijn nog vele onbeantwoorde vragen omtrent de opname van Mg2+ in de darm. 
Zo is de rol van twee recentelijk geïdentificeerde magnesiotrope hormonen, 
namelijk de epidermale groei factor (EGF) en insuline, op de intestinale absorptie 
van Mg2+ nog onduidelijk. Ook zijn er veel medicijnen (zoals protonpompremmers, 
remmers van de EGF receptor, en diverse antimicrobiële middelen, calcineurine 
remmers en cytostatica) waarvan bekend is dat ze Mg2+ tekorten kunnen 
veroorzaken. De rol die Mg2+ absorptie, en de mogelijke verstoring hiervan door 
medicijnen, in de darm speelt bij het ontstaan van deze tekorten is tot op heden 
onderbelicht gebleven. De in dit proefschrift beschreven techniek voor het meten 
van intestinale Mg2+ absorptie zal in de toekomst bij kunnen dragen aan het 
beantwoorden en verder uitdiepen van deze en andere vraagstukken. 
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Door middel van technieken zoals exome sequencing is het mogelijk om nieuwe 
genen, betrokken bij Ca2+ en Mg2+ homeostase, te identificeren in patiënten met 
erfelijke afwijkingen in de mineraalhuishouding. Daarnaast maken genoom 
wijde associatie studies het mogelijk om in een groep patiënten een correlatie 
vast te stellen tussen genetische varianten in bepaalde genen en, bijvoorbeeld, de 
concentraties van mineralen in het bloed. Ook bij het bepalen van de functie van 
de op deze wijze geïdentificeerde genen of genetische varianten, is het gebruik 
van de stabiele Mg2+ isotopen waardevol ter aanvulling van de bestaande 
technieken zoals de patch-clamp techniek. Deze kennis kan uiteindelijk worden 
gebruikt om nieuwe therapieën te ontwikkelen voor de behandeling van zowel 
erfelijke als verworven ziekten die geassocieerd zijn met tekorten in de Ca2+ en 
Mg2+ huishouding als gevolg van een verminderde intestinale absorptie, maar 
ook ter compensatie van tekorten als gevolg van niet goed functionerende nieren.
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List of abbreviations
1α-OHase 25-hydroxyvitamin-D3-1α-hydroxylase
1,25(OH)2D3 1,25-dihydroxy-vitamin-D3 / calcitriol
ANOVA analysis of variance
AQP aquaporin
ATP adenosine 5’triphosphate
AU arbitrary units
BW body weight
45Ca2+ radioactive calcium isotope
Ca calcium atom
Ca2+ calcium ion
CaSR calcium-sensing receptor
Cav1.3 L-type calcium channel
CD collecting duct
CD Crohn’s disease
cDNA complementary deoxyribonucleic acid
cHK-α colonic H+,K+-ATPase 
Cl- chloride ion
CLDN gene encoding claudin
CNNM2 cyclin M2
CNT connecting tubule
CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1
CYP27B1 cytochrome P450, family 27, subfamily B, polypeptide 1
DCT distal convoluted tubule
DM2 type 2 diabetes
ECF extracellular fluid
EGF epidermal growth factor
EGFR epidermal growth factor receptor
ER endoplasmic reticulum
FGF23 fibroblast growth factor 23
FHHNC  familial hypomagnesemia with hypercalciuria and nephrocalcinosis
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GDM gestational diabetes mellitus
gHK-α  gastric H+,K+-ATPase
HNF1B hepatocyte nuclear factor 1 homeobox B
HPRT hypoxanthine-guanine phosphorybosyl transferase
HSH hypomagnesemia with secondary hypocalcemia
IBD inflammatory bowel diseases 
IIH idiopathic infantile hypercalcemia
IRH isolated autosomal recessive hypomagnesmia
K+ potassium ion
Kv1.1 K+ voltage gated channel subfamily A, member 1
KO knockout
Mg magnesium atom
Mg2+ magnesium ion
miR microRNA
mRNA messenger ribonucleic acid
Na+ sodium ion
NCX1 Na+/Ca2+ exchanger 
NHE3 Na+/H+ exchanger 3
NKCC2 Na+-K+-2Cl- co-transporter
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OMIM online mendelian inheritance in man
PCR polymerase chain reaction
PMCA1b plasma membrane Ca2+-ATPase
PPI proton pump inhibitor
PPIH PPI-induced hypomagnesemia
PT proximal tubule
PTH parathyroid hormone
PTHrp parathyroid hormone-related peptide
RDA recommended daily allowance
ROMK inward rectifying ATP-sensitive K+ channel
RT-PCR  reverse-transcriptase polymerase chain reaction
SEM standard error of the mean
SNPs single nucleotide polymorphisms
TAL thick ascending loop of Henle
TRPV transient receptor potential channel, subfamily vanilloid
TRPM  transient receptor potential channel, subfamily melastatin
UC ulcerative colitis
VDR  vitamin D receptor
VDRE  vitamin D responsive elements
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Curriculum Vitae
Anke Lameris werd geboren op 25 december 1984 te Grubbenvorst. Zij behaalde in 
2002 haar VWO diploma aan het Blariacum college in Venlo. Vervolgens studeerde 
zij Medische Biologie aan de Radboud Universiteit Nijmegen. Tijdens deze 
opleiding doorliep zij een Bachelor stage van 3 maanden op de afdeling Psycho-
neurofarmacologie (onder leiding van Dr. B. Ellenbroek en Prof. Dr. L. Cools). 
Gedurende haar Master opleiding Medische Biologie bracht ze 9 maanden door bij 
de afdeling Maag-, Darm- en Leverziekten voor een stageonderzoek, waarin ze 
onder begeleiding van Dr. E. Waanders en Prof. Dr. J. Drenth onderzoek verrichtte 
naar de samenstelling van cystevocht van patiënten die lijden aan polycysteuze 
leverziekte. Vervolgens liep ze gedurende 6 maanden stage bij de afdeling 
Fysiologie, waar ze zich onder leiding van Dr. T. de Groot en Prof. Dr. J. Hoenderop 
verdiepte in de celbiologie van het calciumkanaal TRPV5. 
 In augustus 2009 behaalde zij haar doctoraal examen met de toevoeging 
bene meritum. Ze startte reeds in januari 2009 als PhD student op de afdeling 
Fysiologie op een door ZonMW gesubsidieerd project, hetgeen heeft geleid tot het 
in dit proefschrift beschreven onderzoek. Ze werkte gedurende haar pro-
motieonderzoek samen met diverse groepen in binnen- en buitenland, wat onder 
andere heeft geleid tot publicaties met collega’s uit Duitsland, Finland en 
Australië. Tijdens haar promotie begeleidde ze diverse Bachelor- en Masterstu-
denten van de studies Moleculaire levenswetenschappen, Geneeskunde en 
Biomedische Wetenschappen. Daarnaast leverde ze, in de vorm van practica en 
werkgroepen, een bijdrage aan het onderwijs voor studenten Biomedische 
Wetenschappen en Geneeskunde. Vanaf oktober 2012 was ze bovendien actief als 
stagecoördinator, waarbij ze onder andere verantwoordelijk was voor de organi-
satorische zaken rondom de werving en begeleiding van studenten binnen de 
afdeling Fysiologie.
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Dankwoord
Zoals velen van jullie weten is het promoveren me niet altijd even makkelijk 
afgegaan. In januari 2009 begon ik, nog voordat ik goed en wel afgestudeerd was, 
aan dit promotie traject. Jong, naïef, en vol enthousiasme stortte ik me op de 
wetenschap. Nu, 5 jaar later en voor mijn gevoel 10 jaar ouder, is het dan eindelijk 
zover. Promoveren doe je niet alleen en er zijn dan ook heel veel mensen die ik in 
deze laatste pagina’s van dit proefschrift graag wil bedanken.
Allereerst  gaat mijn dank uit aan mijn promotoren Prof. Dr. Hoenderop en Prof. Dr. 
Bindels. Bedankt dat jullie me de kans hebben gegeven om binnen de afdeling 
Fysiologie mijn promotieonderzoek te doen. Joost, je deur staat altijd open voor 
een snel overleg, een peptalk of gewoon een grapje in het voorbijgaan. Het 
enthousiasme en de ongelofelijke hoeveelheid energie waarmee jij je in de 
wetenschap stort werken aanstekelijk en zijn een grote stimulans voor mij en vele 
andere jonge onderzoekers. Bedankt dat je steeds weer voor me klaarstond op de 
momenten dat ik het nodig had. René, ik heb veel van je geleerd. Ik heb enorm veel 
respect voor de manier waarop je je taken als scientific director van het NCMLS en 
als hoofd van onze afdeling weet te combineren. Je gestructureerde, georganiseerde 
manier van werken en je oog voor detail zijn ongeëvenaard en vormen het 
fundament voor het succes van onze afdeling. 
Ook wil ik Prof. Dr. Monnens graag bedanken. Toen ik als PhD-studente begon bij 
de afdeling fysiologie werd mij door Joost en René verteld dat er een gepensioneerde 
kindernefroloog was die het leuk vond om nog wat bij de wetenschap betrokken 
te blijven. Onervaren als ik was, had ik geen flauw idee dat het een van de pioniers 
binnen het Nijmeegse onderzoek naar water- en zouttransport betrof. Leo, je 
enorme kennis, bevlogenheid, enthousiasme, betrokkenheid en goede neus voor 
interessante patiënten bewonder ik zeer. Graag wil ik je bedanken voor alles wat 
je voor me hebt gedaan de afgelopen jaren, ik had het niet beter kunnen treffen en 
kijk met veel plezier terug op onze overlegmomenten op je “kantoor”.
Tijdens je PhD breng je veelal meer tijd op het lab door dan je lief is. Een goede sfeer 
en leuke, kundige collega’s zijn dan ook onontbeerlijk voor het voltooien van een 
PhD-traject. Dankzij alle leuke collega’s heb ik ontzettend veel goede herinneringen 
aan de afgelopen jaren. 
Theun, onder jouw leiding startte ik mijn loopbaan bij Fysiologie als student, ik 
heb veel van je geleerd en denk nog steeds met heel veel plezier terug aan die tijd! 
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Titia, altijd stond je voor me klaar met goed advies en wijze raad. Wat heb ik je 
gemist toen terug naar Groningen ging! Ik ben blij dat ik de kans kreeg om je te 
helpen de V6-paper af te ronden, nu kunnen we toch nog zeggen dat we samen 
aan een project hebben gewerkt. Dankjewel voor al je hulp en lieve mailtjes de 
afgelopen jaren. 
Mijn partners in crime voor verkleedpartijtjes: Jenny en Leonie. Wat hebben we 
een hoop lol gehad bij de diverse feestjes en etentjes. Dankjewel voor alle mooie 
herinneringen meiden! Leonie, we zijn zo verschillend maar soms ook zo gelijk. Ik 
ben blij dat we na je vertrek bij fysiologie contact hebben gehouden. Niets is zo 
goed voor het moraal als een avondje stAnneke: na het delen van lief, leed en 
broodjes met aioli ziet het leven er altijd ineens weer een stuk zonniger uit.
Bobby, meer dan eens heb ik me de afgelopen jaren afgevraagd of ik niet toch 
beter naar je had moeten luisteren. Gelukkig bel/mail je altijd op de momenten 
dat ik je peptalks het hardst nodig heb. Ik weet nog steeds niet of dat toeval is of 
dat je misschien een uiterst discrete spion op het lab hebt rondlopen? Het is in 
ieder geval altijd leuk om samen de nieuwste roddels en ontwikkelingen binnen 
ons veld te bespreken. 
Silvia, good things come in small packages. Our trip to Milano where we stayed 
with your great family was an amazing experience. Over the years you taught me 
a lot about science, good food and cocktails ;) I hope that, after a bit of rest, you will 
“really really like magnesium” and science again. Wherever life may take you, I 
whish you all the best.
Sjoerd, Jeroen and Paco, the three musketiers from Unit 10. Never a dull moment 
when you are around! I will always cherish the memories of our fantastic trip to 
Cadiz! Sjoerd, altijd sta je klaar voor iedereen. Bij gebrek aan inspiratie heb je 
goede ideeën, bij problemen heb je wijze raad, bij verdriet heb je een opbeurend 
woordje en bij honger? Een boterhammetje cervelaat natuurlijk ;). Dankjewel voor 
al je hulp en de gezelligheid in de afgelopen jaren. Je bent altijd welkom in Gennep 
voor een middagje Ajax-PSV. Paco, it’s always fun fighting the “kidney-people” in 
the lab together, one day we’ll convince them that the kidney is not the only organ 
of importance in physiology/fishiology. Thanks for the many times we spent 
discussing science and all kind of other things, you are a great colleague and 
friend! Jeroen, de petit-prince, mijn favoriete golden-boy, mijn evil-twin, mijn 
vriendje! Je bent een van de weinigen die mijn ietwat sarcastische gevoel voor 
humor niet alleen weet te waarderen maar regelmatig zelfs weet te overtreffen! 
Je “politieke” talent is ongeëvenaard en ik heb de afgelopen jaren veel van je 
10
Dankwoord
185
mogen leren op dit vlak. Ik heb enorm veel bewondering voor de manier waarop 
jij je doelen nastreeft en waarmaakt. Het is mooi om te zien hoe je met volle 
overgave en een duidelijke visie werkt aan je wetenschappelijke carrière. Ik heb er 
het volste vertrouwen in dat al het harde werk van de afgelopen jaren zijn 
vruchten af gaat werpen in de toekomst. Dankjewel voor alle momenten dat je er 
de afgelopen jaren voor me was, en ik ben blij dat je op de dag van mijn verdediging 
aan mijn zij zal staan als paranimf.
Eline, ondanks alle tegenslagen ben je blijven vechten, nog even volhouden meid, 
je bent er bijna! Vergeet vooral niet in jezelf te geloven. Ik mis je op het lab, maar 
gelukkig is Arnhem dichtbij.
Liz en Ellen/Evil (in combinatie ook wel bekend als “het kippenhok”) jullie hebben 
me zeer vakkundig door de laatste 1,5 jaar van mijn promotie heengesleept. 
Muffins, thee, gekke briefjes, horoscopen, ijsjes, PeterJan Rens en dansende bloemen: 
alles werd in de strijd gegooid wanneer het even tegenzat en ik opgebeurd moest 
worden. Thanks meiden! Nog even en dan zijn jullie aan de beurt, heel veel succes 
met jullie onderzoek, jullie komen er wel!
Mark H. Onze samenwerking verliep niet altijd even soepel, maar heeft uiteindelijk 
toch tot een prima publicatie geleid. Het is mooi om te zien hoe je inmiddels grote 
vorderingen maakt bij de verdere ontrafeling van PPIH in je patiëntenstudies, en 
ik waardeer het enorm dat je me nog steeds op de hoogte houdt van je nieuwste 
bevindingen. Succes met het afronden van je PhD.
Irene, wanneer je ziek of op vakantie bent blijkt altijd onmiddellijk weer hoe 
belangrijk je bent. Je bent de stille kracht die ons lab draaiende houdt. Bedankt 
voor het uitzoeken en bestellen van al mijn “exotische” producten.
AnneMiete, ik kan nog steeds niet helemaal geloven dat je echt met pensioen 
bent, het fysiologie-lab zonder jou is niet compleet! Bedankt voor al je hulp de 
afgelopen jaren.
Sjoeli, in no-time wist je jezelf onmisbaar te maken op de afdeling. Niet alleen 
vanwege je organisatorische talenten, maar vooral vanwege je vrolijke en gezellige 
persoonlijkheid. Femke, ook jij brengt het nodige leven in de brouwerij op het 
secretariaat fysiologie. Bedankt voor jullie hulp bij alle organisatorische zaken de 
afgelopen jaren, maar vooral voor alle leuke en gezellige momenten. 
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Joris, toen ik als student op het fysiologie lab rondliep kwam jij net terug uit 
Schotland. Met je baard, vreemde schotse accent en enorme hoeveelheid weten-
schappelijke kennis vond ik je destijds een beetje eng. Een paar jaar, vele peptalks, 
knuffels, en een bekerglas vol chocotofs vermomd als muizenvoer later is dat wel 
over. Ik hoop dat je het naar je zin hebt in Groningen, hier in Nijmegen missen we 
je nog steeds. 
Anne, de manier waarop jij, ondanks de vele wetenschappelijke tegenslagen, 
altijd positief bleef is bewonderenswaardig. Stiekem ben je daarin altijd een 
beetje een voorbeeld voor me geweest. 
Erik, een vrolijke persoonlijkheid en een keiharde werker, je bent de Bom ;). Ook 
voor jou geldt: vergeet niet in jezelf te geloven!
Mijn studenten Ila, Ellen, en Daisy, ik hoop dat jullie net zo veel van mij hebben 
geleerd als ik van jullie, dank jullie wel voor alle hulp! 
Mark de Graaf, Henrik, Marla, Laurianne, Maxime, Femke, Hans, Annelies, Ramon, 
Rick, Kuki, Sandor, Miyuki, Sabina, Ganesh, Johan, Christiane, Melissa, Marcel, 
Dennis, en alle andere mensen die ik hier waarschijnlijk nog vergeet: Bedankt 
voor jullie hulp, gezelschap en alle goede herinneringen die ik dankzij jullie heb 
aan mijn tijd op het lab!
Ook buiten de afdeling hebben vele mensen bijgedragen aan het tot stand komen 
van dit proefschrift.
Dr. Pasi Nevalainen; the unique set of biopsy samples you provided us with 
formed the basis for two of the papers in this thesis. Over the years, we’ve 
exchanged countless emails, discussed ideas and manuscripts via Skype, and 
even managed to meet once for a face-to-face discussion, thank you for all your 
help.
Dr. Michiel Schreuder; ook aan jou dank ik een van de hoofdstukken in dit 
proefschrift. Door de lange dagen in het lab vergeet je als onderzoeker soms waar 
je het allemaal voor doet, de verhalen en casussen uit de kliniek zetten dit allemaal 
echter meteen weer in perspectief. Ik vond het erg leuk om samen te brainstormen 
en te pogen om alle stukjes informatie die we hadden aan elkaar te puzzelen, 
bedankt!
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Jelle Eygensteijn, alweer een aantal jaar geleden besloot ik dat het hoog tijd werd 
dat er binnen de afdeling fysiologie een nieuwe methode kwam om magnesium 
transport te bestuderen. Met veel geduld legde je mij de basis-principes van de 
ICPMS uit, en bekeken we samen de resultaten van mijn eerste experimenten. Ik 
hoop en verwacht dat er met behulp van deze techniek in de toekomst nog veel 
mooie functionele studies gedaan zullen worden op de afdeling fysiologie. 
Bedankt voor je hulp bij het opzetten en voor het analyseren van al mijn samples. 
Wanneer je niet alleen dit dankwoord maar ook de rest van dit proefschrift hebt 
bekeken zul je gezien hebben dat ik nogal wat onderzoek met dieren heb gedaan. 
Dit was allemaal onmogelijk geweest zonder de hulp van de geweldige mensen 
van het CDL: Henk en Jeroen M.; toen ik net begon met mijn PhD stonden jullie 
altijd klaar om me met veel geduld de fijne kneepjes van het vak te leren. Janneke, 
Thea, Wilma, Alex, Jeroen de B, en Denise: dankzij jullie hulp verliepen niet 
alleen mijn experimenten goed maar was het bovendien altijd fijn om op de VGD 
te werken en even te ontsnappen aan het lab. Bianca, op de PRIME was ik af en toe 
te vinden voor het werk met radioactief calcium, het is een genot om te werken op 
je mooie en super soepel lopende afdeling. Maikel, een speciaal woordje voor jou: 
ondanks de lange  drukke dagen en een naar muizen stinkende OK klaagde je 
nooit wanneer je me moest helpen...O wacht, dat deed je wel, en daarna zeurde je 
om taart ;)  dankjewel voor alle hulp!
Daphne, dit proefschrift zou niet zijn wat het is zonder jou en je “gouden handjes”. 
Onze samenwerking begon met een, wetenschappelijk gezien, teleurstellende 
trip naar Amsterdam. Bij gebrek aan een goed voorbeeld besloten we daarna met 
vereende krachten zelf de methode voor het aanleggen van de darmcanules op te 
zetten. Je zwangerschap dreigde even roet in het eten te gooien m.b.t. de planning 
van mijn experimenten, maar als jij iets in je hoofd hebt houdt niets je tegen. 
Nauwelijks meer achter de microscoop passend en tussen de harde buiken door 
opereerde je nog even 2 enorme series muizen zodat ik verder kon met mijn 
onderzoek tijdens je verlof. Ik ben je ongelofelijk dankbaar voor al je hulp, en kijk 
met plezier terug naar alle uren die we doorbrachten op het microscopen-labje, 
waar we tijdens de ok’s kletsten over  huizen, trouwen, babies, big fat gypsie 
weddings en de laatste roddels van zowel het CDL als het NCMLS ;)
En dan is er ook nog het leven buiten het lab, waar zoveel vrienden en familie 
onbewust hebben bijgedragen aan het tot stand komen van dit boekje.
Lieve San, meer dan eens gedurende de afgelopen jaren heb ik mezelf gaande 
gehouden onder het motto “niet zeuren Anke, Sandra heeft het nog veel zwaarder 
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en die leeft ook nog steeds”. Onze telefoongesprekken vanuit de auto op weg naar 
huis om te klagen over bazen, collega’s, patiënten, semi-artsen, reviewers en 
vriendjes hebben op wonderbaarlijke wijze nooit tot ongelukken geleid. Met dank 
aan de drukke agenda’s is het niet altijd makkelijk om een gaatje te vinden om 
met z’n tweetjes of samen met Arjan en Sjoerd een avondje bij te kletsen, maar als 
het lukt is het altijd gezellig. Ik hoop dat je voor altijd jezelf en mijn vriendinnetje 
blijft! Dankjewel dat je me op de dag van mijn verdediging bij wilt staan als 
paranimf.
Fien, je hebt een geweldige zoon op de wereld gezet, dankjewel voor alle goede 
zorgen de afgelopen jaren. Debby en Cliff, het is altijd weer heerlijk om onder het 
genot van een glaasje wijn bij te kletsen en ondertussen te genieten van mijn 
liefste nichtje en neefje Marit en Julian. Bedankt dat jullie al die jaren steeds weer 
interesse hebben getoond in mijn saaie wetenschapsverhalen!
Miriam en Joerie, ook jullie verdienen hier een plekje. Lieve zus, het was altijd 
lekker om even aan de hectiek van het promoveren te ontsnappen door een 
middagje te helpen met het versieren van de klas of met het maken van nieuwe 
knutselwerkjes. Dankjulliewel voor de correcties van de Nederlandse gedeeltes 
van dit proefschrift en het aanhoren van de eerste versies van mijn leken-praatje! 
Lieve Opa, ik vind het geweldig dat ik na al dat lange wachten nu eindelijk mijn 
boekje aan je kan overhandigen. Vaak vertelde je me hoe trots je op me bent en 
hoe je naar deze dag uitkeek. Maar ik ben ook trots; trots op mijn lieve, sterke en 
zorgzame en ontzettend eigenwijze Opa, van wie ik leerde om ondanks alles altijd 
door te zetten!
Lieve Pappa en Mamma, jullie staan altijd voor me klaar met een luisterend oor, 
een helpende hand, wijze raad of gewoon een hele dikke knuffel. Het is voor jullie 
niet altijd even gemakkelijk geweest om van een afstandje toe te moeten kijken 
en niet te kunnen (lees: mogen) helpen. Dankjewel voor jullie onvoorwaardelijke 
steun en liefde, zonder jullie was ik nooit zo ver gekomen.
Arjan, lieve sies, lang heb ik gezocht naar de juiste woorden en vele malen heb ik 
dit stuk herschreven om uiteindelijk tot de conclusie te komen dat woorden 
simpelweg tekort schieten. Ik ben de laatste jaren (en eigenlijk ook alle jaren 
daarvoor) niet de makkelijkste geweest. Desondanks sta je al 11 jaar altijd voor me 
klaar, maak je me steeds weer aan het lachen, en weet je me keer op keer weer te 
verassen. Dankjewel sies, ik kijk uit naar alles wat de komende jaren ons nog gaan 
brengen! 
Anke Lameris




